PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast: Recent Episodes
PVI, PeerView Institute for Medical Education
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable remissions, the challenges of multiple relapses, and symptoms such as fatigue and anxiety over bleeding; Cite the mechanistic rationale, efficacy, and safety evidence supporting the use of BTK inhibitors in patients with previously treated ITP; Integrate newer therapeutics, including BTK inhibitor-based options, into the management of adults and adolescents with persistent and chronic ITP; and Address practical aspects related to the use of innovative therapeutics in ITP, including management of unique dosing and safety considerations; attention to patient quality of life; and provision of education to patients requiring therapy for relapsed disease.
Go online to PeerView.com/UTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care. Upon completion of this activity, participants should be better able to: Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance; Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions; Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors; and Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies.
Go online to PeerView.com/MVQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials. Upon completion of this activity, participants should be better able to: Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors; Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs; and Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK fusion–positive NSCLC or other solid tumors in the context of clinical practice or clinical trial participation.
Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.
Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.
Go online to PeerView.com/HZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding use of CD38 antibodies, CAR-T, and BCMA and non-BCMA treatment options has quickly changed the clinical conversation for modern multiple myeloma (MM) management. Are you prepared for the new “ABCs” of myeloma care? Find out by accessing this PeerView MasterClass and Case Forum event developed in collaboration with the HealthTree Foundation for Multiple Myeloma and recorded at the 2023 ASCO Annual Meeting. During this activity, our experts provide insights and case-based guidance on therapy selection, dosing, scheduling, and management of treatment-related AEs with CD38 antibodies and BCMA platforms in MM. Learn the real-world “ABCs” of treatment innovation in MM, and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize the unique MOA and safety/efficacy evidence supporting the use of CD38 and BCMA-targeting antibodies, CAR-T therapy, and other innovative compounds across multiple myeloma treatment settings; Develop personalized upfront and sequential treatment plans with innovative antibody and immunotherapy platforms, based on relevant prognostic information and safety considerations; and Address practical aspects of multiple myeloma care when using antibody and immunotherapy platforms, including dosing, scheduling, patient referral to specialized care, education, counseling, and unique treatment-related toxicities
Go online to PeerView.com/WEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you aware of the evidence supporting the use of innovative EHL FVIII therapies for the prophylactic management of hemophilia A? Find out in this activity based on a “MasterClass” event recorded at the 2023 Congress of the International Society on Thrombosis and Haemostasis. Hear what hemophilia experts are saying about the latest clinical evidence that supports the use of innovative EHL FVIII therapy in hemophilia as they link the data directly to case-based decisions in real-world settings—with a goal of clearly illustrating the practicalities of safely using novel and emerging factor products. The experts also provide guidance on implementing evidence-based protocols and preventing and managing complications in the context of EHL FVIII therapy. Upon completion of this activity, participants should be better able to: Assess the latest safety, efficacy, and pharmacokinetic data among currently approved and emerging EHL FVIII products for prophylaxis of hemophilia A; Develop personalized prophylactic regimens with novel and emerging EHL FVIII products based on patient- and disease-specific factors; and Manage practical aspects of care, such as patient education, adherence counseling, monitoring, and AE management, when using novel and emerging EHL FVIII products for prophylaxis of hemophilia A
Go online to PeerView.com/AYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging and animated activity, an expert on EGFR exon 20 insertion–positive NSCLC discusses the role of biomarker testing and examines the evidence for new and emerging therapies to offer patient-centered guidance on individualizing care and improving outcomes. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of EGFR mutations in NSCLC, frequency and characteristics of EGFR exon 20 insertion mutations, latest evidence and guidelines on targeted therapies in this setting, and importance of biomarker testing to identify patients for these therapies in clinical practice; Apply multidisciplinary strategies for biomarker testing and targeted treatment selection and sequencing to optimize therapeutic outcomes in patients with NSCLC harboring EGFR exon 20 insertion mutations; and Engage patients with EGFR exon 20 insertion–positive NSCLC in shared decision-making regarding available targeted therapy options to ensure individualized treatment selection that aligns with their needs, values, and preferences
Go online to PeerView.com/RMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative intensive therapy, often consisting of potent induction/consolidation protocols followed by hematopoietic stem cell transplant (HCT), has been shown to extend survival in challenging acute myeloid leukemia (AML) settings where conventional chemotherapy options are suboptimal. In this “Clinical Consults” activity, a panel of experts provide guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes and discuss how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. The panelists use serial case vignettes inspired by real-world scenarios, debate the selection and use of novel cytotoxic platforms and targeted agents, and examine emerging approaches in a range of difficult-to-treat patient populations. Upon completion of this activity, participants should be better able to: Review the diagnostic, prognostic, and therapeutic implications of baseline factors such as age, genetic/molecular features, and functional status for challenging AML subtypes such as secondary AML or mutation-defined disease; Review updated clinical data surrounding novel upfront induction/consolidation regimens in diverse AML settings, including for patients with higher-risk or mutation-defined disease; Select evidence-based, personalized upfront treatment platforms for patients with challenging AML subtypes, including patients eligible for HCT; andDevelop a management plan for the unique safety considerations associated with novel upfront treatment platforms, including innovative cytotoxic and targeted regimens
Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management
Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life
Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don’t miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events
Go online to PeerView.com/UUY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approaches to managing patients with hepatocellular carcinoma (HCC) are undergoing renovation! A recent wave of improved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including immune checkpoint inhibitors (eg, pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib and regorafenib). Emerging data on other up-and-coming targeted platforms are forthcoming, including evidence for perioperative applications in earlier disease settings. With all of these developments, how should we update our clinical rulebooks for treating HCC? This activity, based on a recent live symposium, uncovers innovative treatment strategies in early and intermediate HCC and presents validated and emerging strategies in advanced HCC. The unique Tumor Board format uses case-based scenarios to facilitate an interactive discussion covering practical guidance you can use to renovate your own clinical rulebook. Upon completion of this activity, participants should be better able to: Examine the latest clinical evidence supporting the use of immunotherapy, targeted therapy, and combination regimens for the management of HCC; Integrate individualized treatment plans for patients with HCC based on the latest clinical evidence, expert recommendations, and patient-specific factors; and Employ team-based strategies and practical considerations when integrating novel HCC regimens, including monitoring, patient consultation, and adverse event management
Go online to PeerView.com/PYA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Newer treatment modalities for acute myeloid leukemia (AML) have rapidly eclipsed the decades-long cytarabine-based standard of care and helped clinicians adopt more personalized management using innovative cytotoxic platforms, targeted agents (including FLT3, BCL2, and IDH inhibitors), and other unique management strategies. Clinicians can now improve patient outcomes across all AML treatment settings, while at the same time selecting the most potent, personalized option that can be designed to address a given patient’s needs. This “Seminars and Tumor Board” activity, adapted from our recent live event held at the 2023 ASCO Annual Meeting and developed in collaboration with the HealthTree Foundation for Acute Myeloid Leukemia, reveals how modern baseline assessment paired with cutting-edge prognostication has pushed patient management to new heights of innovation and changed the management of patients with AML with therapeutically relevant features (such as FLT3 or IDH mutations), patients presenting without driver mutations, or individuals with comorbid illnesses or higher-risk features. Join the AML experts for a real-world “Tumor Board”–style discussion of how the latest evidence can inform your practice. Upon completion of this activity, participants should be better able to: Summarize baseline patient-related and disease-related factors, including age, comorbidities, functional status, and cytogenetic/mutational findings, that can influence prognostication and treatment selection in AML; Cite current evidence supporting the personalized use of novel treatment modalities, including new cytotoxic platforms, targeted agents, immunotherapy, and epigenetic strategies, for the management of newly diagnosed or relapsed/refractory AML; Integrate novel therapeutics into the personalized team-based management of AML according to the results of baseline assessment, presence or absence of targetable mutations, functional status, or AML subtype; and Address care delivery considerations, including optimized dosing and safety management, when caring for patients with AML
Go online to PeerView.com/DGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovation in renal cell carcinoma (RCC) has brought new opportunities to improve patient outcomes through personalized medicine. With multiple FDA approvals and promising agents being explored in a variety of settings, multitargeted TKIs and immune checkpoint inhibitors have earned their place in cancer care plans either as guideline-recommended therapy or through clinical trial enrollment. In this activity, which was based on a recent live event, a panel of expert oncologists combines a concise overview of essential research on approved and emerging RCC treatments with discussion of real-life patient cases to provide guidance on integrating validated strategies into everyday patient care. Learn how patient-, disease-, and treatment-specific factors affect therapeutic selection and sequencing—including when to consider adjuvant therapy, which patients may benefit from immunotherapy-based combination regimens in the frontline setting, and how to determine which strategies to recommend for patients with relapsed disease. Hear guidance on collaborative approaches to managing adverse events, insights on the use of emerging agents, and updates on clinical trials underway. Upon completion of this activity, participants should be better able to: Evaluate treatment efficacy and safety of approved and emerging therapeutic regimens for patients with RCC; Select personalized therapeutic strategies based on current evidence and patient-, disease-, and treatment-specific factors for patients with RCC; and Integrate strategies to anticipate, mitigate, and manage various adverse events associated with treatments for patients with RCC
Go online to PeerView.com/UDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While recurrent or advanced endometrial cancer (EC) has traditionally been associated with a poor prognosis, the use of immune checkpoint inhibition (ICI) in both monotherapy and combination approaches has led to improved outcomes. These gains have been well established in the second-line setting with multiple regulatory approvals, and ICIs have recently been shown to have an impact in the frontline setting, further altering the standard of care. In this activity, based on a recent live symposium, a panel of experts provides participants with foundational knowledge on the mechanistic rationale and up-to-date evidence supporting the use of ICIs in patients with advanced EC. Through discussion of real-life patient cases, the faculty provides practical guidance on incorporating approved and emerging approaches into clinical practice. Featured topics include biomarker testing, clinical trial enrollment, patient/provider education, and management of immune-related adverse events. Upon completion of this activity, participants should be better able to: Cite the rationales, therapeutic roles, and key efficacy/safety evidence supporting the use of immuno-oncology treatments and emerging approaches for patients with recurrent or advanced endometrial cancer; Select personalized treatment options for patients with recurrent or advanced endometrial cancer, taking into consideration the latest evidence, guideline recommendations, and biomarker testing results; and Implement proactive, collaborative strategies to mitigate and manage immune-related adverse events associated with immunotherapy-based treatment
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
Go online to PeerView.com/GUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings. Upon completion of this activity, participants should be better able to: Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease; Craft team-based treatment plans that include immunotherapy for resectable and unresectable melanoma, including BRAF-mutant or BRAF wild-type disease, based on updated evidence and guideline recommendations; and Develop management strategies for the unique adverse events associated with immunotherapy for patients with melanoma across the spectrum of disease.
Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.
Go online to PeerView.com/JQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have transformed the frontline management of recurrent/metastatic head and neck cancer (HNC)—but how can oncology professionals build on that foundation to expand the therapeutic applications of immunotherapy in HNC? This “MasterClass & Case Forum” activity, taken from a recent live event, features a panel of leading HNC experts sharing case-based insights on clinical decision-making with immunotherapy in recurrent/metastatic disease and beyond. Developed in collaboration with the Head and Neck Cancer Alliance (HNCA), each case-centric session also features the latest evidence on established and emerging immune-based treatments, combinational and sequential approaches, and the potential of checkpoint blockade in resectable and locally advanced disease. Upon completion of this activity, participants should be better able to: Cite the latest clinical evidence and guideline recommendations supporting the use of checkpoint inhibitors and other immunotherapy options for the management of HNC; Develop individualized treatment plans that incorporate checkpoint inhibitors and other immune modalities, including innovative combinational platforms, for the management of resectable, locally advanced, or recurrent/metastatic HNC; and Address practical aspects of care when using immunotherapy options, including provision of patient education and management of symptoms and immune-related AEs.
Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular testing, including HER2 expression, and its role in treatment selection for patients with HER2-positive GI cancers; Implement personalized treatment strategies based on molecular findings, current evidence and recommendations, and patient-specific factors when managing HER2-expressing GI cancers; and Apply practical strategies to manage and mitigate treatment-related AEs associated with HER2-targeting agents when managing BTC and GEA.
Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation, and asparaginase discontinuation, and get their perspectives on optimized asparaginase dosing and toxicity mitigation approaches. Learn how you can utilize modern asparaginase strategies to improve outcomes in ALL by watching today! Upon completion of this activity, participants should be better able to: Discuss current efficacy evidence and unmet needs related to the optimized use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds; Devise strategies to address therapeutically relevant considerations related to asparaginase use for pediatric ALL such as appropriate dosing, pre-empting truncation/discontinuation, and drug-related toxicity; Identify the emergence of asparaginase hypersensitivity, silent inactivation, or toxicity through the use of evidence-based monitoring plans in pediatric ALL; and Select treatment strategies to avoid asparaginase discontinuation and ensure adequate exposure to therapy, including switching to Erwinia asparaginase options after confirming hypersensitivity.
Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.
Go online to PeerView.com/XZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique video-based activity will offer learners a window into practice by featuring a series of expert-led lectures that will seamlessly link the latest scientific evidence on CAR-T therapy across a range of hematologic malignancies with panel-based insights on clinical decision-making. Each session will include a Tumor Board segment designed to reflect real-world clinical experiences and decision challenges, from identifying patient candidates to appropriate follow-up and the management of a unique spectrum of adverse events. Upon completion of this CE activity, participants will be able to: Evaluate the latest clinical evidence on the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies in patients with hematological malignancies across existing and potential future indications; Adopt best practices for integrating CAR-T therapy into the care of patients with hematologic malignancies, including appropriate patient selection, referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care; and Develop appropriate adverse event management strategies for patients with hematological malignancies who are experiencing toxicity (eg, cytokine release syndrome or neurotoxicity) while receiving CAR-T therapy.
Go online to PeerView.com/ZYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care. Upon completion of this activity, participants should be better able to: Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes; Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors; and Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT.
Go online to PeerView.com/DSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For over a century, surgery, radiotherapy, and systemic therapy have served as the mainstays of cancer treatment. An opportunity to further improve survival and quality of life for patients with aggressive solid tumors has emerged with novel locoregional therapies (LRTs)—in particular, tumor treating fields (TTFields)—a state-of-the-art, noninvasive modality associated with clear efficacy benefits and minimal toxicity. Currently, TTFields is approved for newly diagnosed and recurrent glioblastoma (GBM) and resectable, previously untreated malignant pleural mesothelioma (MPM) and is being further examined across a range of solid tumors with poor prognoses. In a new activity from PeerView, expert panelists use a mix of case-based instruction and high-level presentations of evidence and guidelines to illustrate the effective use of TTFields in the treatment of patients with GBM and MPM. Throughout, the expert panelists share insights on engaging, real-world patient cases and perspectives on using TTFields as a component of multimodal therapy. Key topics include patient selection for therapy, safety management, provision of patient and caregiver education, and the potential future of TTFields as a unique LRT option in liver, pancreatic, ovarian, and gastric cancers. Upon completion of this activity, participants should be better able to: Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM); Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers; Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors; and Employ evidence- and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors.
Go online to PeerView.com/XGS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Two experts highlight how a prostate cancer care team can use the latest clinical evidence, treatment guidelines, and consensus recommendations to improve outcomes for patients with prostate cancer and will give practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Review current guideline recommendations related to germline and somatic tumor testing in patients with prostate cancer; Select patients with advanced prostate cancer who are likely to benefit from novel systemic therapies and combination strategies based on recent clinical evidence, regulatory updates, genetic/molecular status, and current practice guidelines; and Implement personalized treatment plans for patients with advanced prostate cancer that incorporate new agents and combinations, expert recommendations, shared decision- making, and multidisciplinary team-based care.
Go online to PeerView.com/CDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Research and clinical practice continue to build on the success achieved to date with cancer immunotherapy and to refine rational strategies to expand its benefits to more patients, including in curative-intent settings. Immunotherapy has started to radically transform the multimodal approach to treatment of resectable stage I-III NSCLC. Recently, highly positive data have emerged from the first few phase 3 trials evaluating neoadjuvant and adjuvant immunotherapies in resectable lung cancer, leading to regulatory approvals and new standards of care in these settings. What do these advances mean for thoracic surgeons, medical oncologists, pulmonologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to discuss new, practice-changing evidence, the implications and applicability of the latest data to practice, and how to achieve better partnerships across disciplines to facilitate the incorporation of immunotherapies into new standards of care to improve outcomes and quality of life for patients with stage I-III NSCLC. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings; Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy; Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions; and Collaborate with the multidisciplinary team to integrate immunotherapy into individualized, multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.
Go online to PeerView.com/MVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies that target the classical complement pathway and individualizing treatment plans for patients living with CAD. Upon completion of this activity, participants should be better able to: Describe the consequences of inhibiting complement C1s as long-term therapy for CAD, particularly on symptoms influenced predominantly by activation of the classical complement pathway (eg, chronic hemolysis, anemia, and fatigue); and Integrate classical complement pathway–targeted therapies into individualized treatment plans for CAD based on consideration of efficacy and safety data, patient-specific characteristics, and other potential prescribing considerations.
Go online to PeerView.com/RJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed both in biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. A growing number of new agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon, requiring a precision approach. Watch PeerView’s latest educational video, based on a recent live symposium, and learn to better navigate biomarker-driven, individualized therapy for patients with EGFR-mutated NSCLC. Experts analyze the expanding evidence base and provide actionable, case-based guidance for improving testing, interpretation of results, and therapeutic decision-making for patients with NSCLC across a variety of EGFR mutations. Upon completion of this activity, participants should be better able to: Review the different types of EGFR mutations and their role as therapeutic targets in NSCLC, including in earlier disease stages; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; Apply current evidence and guidelines to individualize targeted therapy for patients with EGFR-mutated NSCLC based on EGFR mutation type and patient needs, values, and preferences; and Communicate with the multidisciplinary team and with patients to promote rapid detection and management of treatment-related adverse events in patients receiving EGFR-targeted therapies for NSCLC.
Go online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit! Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease; Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others; Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others
Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches
Go online to PeerView.com/AHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to care for your patients with multiple myeloma (MM) who are experiencing ocular complications associated with the latest myeloma treatments? Ophthalmologists play an important in the care of myeloma, and in this PeerView MasterClass & Ophthalmology Case Forum an ophthalmologist and an oncologist highlight the importance of the ophthalmology and oncology connection in myeloma care. Tune in to get practical guidance on the challenges of accurately recognizing and characterizing ocular toxicity in MM patients receiving novel therapy and case-based guidance on collaborating within a modern MM management team, and see how addressing ocular toxicity can contribute to the delivery of highly effective treatment. Upon completion of this activity, participants should be better able to: Recognize the range of novel, therapy-associated ocular complications in the multiple myeloma treatment setting; Integrate proven techniques, including scheduled and routine eye examinations, dry eye prophylaxis, and therapeutic dose adjustment to address ocular toxicity in patients with multiple myeloma; Work collaboratively within oncology-ophthalmology teams to effectively monitor and manage treatment-emergent ocular toxicity in multiple myeloma patients
Go online to PeerView.com/VRE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver’s perspective on their first-hand experience with the treatment strategies and his journey. These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants should be better able to: Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations; Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care; Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination
Go online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't miss this opportunity to learn why these customizable and convenient agents are part of the revolution in care for MM. Upon completion of this activity, participants should be better able to: State the rationale for and current evidence supporting the use of BCMA-targeting options in RRMM, including triple-class–refractory disease; Create sequential, evidence-based treatment plans that integrate novel antibody options for management of patients with RRMM; Utilize proven tools and cross-disciplinary teamwork to manage the unique safety considerations associated with BCMA-directed antibodies, including ocular toxicity, CRS, and neurotoxicity, among others
Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC
Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Go online to PeerView.com/WRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approximately 40% of patients with early-stage lung cancer experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Management of patients with NSCLC should be individualized based on a number of factors, including the molecular profile of the patient’s tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have prompted strong interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. Early findings from studies in the neoadjuvant setting are beginning to emerge now as well, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. As part of the multidisciplinary team, thoracic surgeons play an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational video, based on a recent live symposium, provides an essential overview of the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings, as well as practical advice for optimal integration of targeted therapies in practice or as part of a clinical trial. Multidisciplinary discussions on the new practice-changing data highlight important implications for the surgeon–oncologist partnership, utilizing EGFR-targeted therapy as part of multimodal management of patients with resectable NSCLC with the goal of improving outcomes and quality of life. Upon completion of this activity, participants should be better able to: Review the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and importance of identifying patients who might benefit from these therapies in perioperative settings; Apply the latest evidence and guidelines to identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches; Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC
Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView’s latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life
Go online to PeerView.com/FGB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-targeting therapies have led to remarkable improvements in patients with HER2-positive early and advanced breast cancer. Recently, novel antibody–drug conjugates (ADCs) and other HER2-targeting therapies have also demonstrated impressive activity in patients with HER2-low breast cancer, who account for approximately 40%-50% of patients with breast cancer and are a population with a high unmet medical need. The concepts of how to best define and test for HER2-low breast cancer are evolving, but the modern HER2-targeting agents offer new hope for dramatically improved outcomes in patients who currently have limited options. This PeerView educational video, based on a recent live symposium, explores the biology and foundational concepts of HER2-low breast cancer, highlights the rationale for and data supporting the use of HER2-targeted therapies in HER2-low breast cancer, assesses emerging approaches for identifying patients with HER2-low breast cancer who could benefit from HER2-targeted therapies, and clarifies how to best incorporate these therapies into practice in real-world settings. Clinical case scenarios are also used to provide useful guidance for testing and treatment of patients with HER2-low breast cancer. Upon completion of this activity, participants should be better able to: Explain the biologic rationale and clinical evidence on the growing role of HER2-targeting therapies in the treatment of patients with HER2-low breast cancer; Apply standard and emerging testing approaches to identify patients with HER2-low breast cancer to determine their eligibility for novel HER2-targeted therapies; Integrate individualized management plans that incorporate a collaborative and coordinated multidisciplinary team-based approach to care in accordance with the latest treatment guidelines and recommendations for patients with lower spectrum HER2-expressing breast cancer in the context of clinical practice or clinical trials
Go online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events. Upon completion of this activity, participants should be better able to: Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer; Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration; Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs); Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence
Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS
Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy
Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.
Go online to PeerView.com/QKA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this inExchange from PeerView, a multidisciplinary team of experts from oncology, endocrinology, and pathology discuss the advantages of a team-based approach to NTRK fusion testing and TRK inhibition in thyroid cancer. In this 30-minute learning opportunity, you’ll hear how endocrinologists can lead the interprofessional charge to enhance outcomes by optimizing NTRK fusion testing and TRK-targeted therapy. This presentation covers the rationale, science, and evidence, and presents actionable strategies for putting the data into practice for patients with fusion-positive thyroid cancer. Upon completion of this activity, participants should be better able to: Explain the rationale for testing for NTRK fusions in patients with thyroid cancer, including their role in disease development and progression and impact on prognosis and treatment algorithms; Cite current efficacy and safety evidence on TRK-targeted therapies in patients with NTRK fusion–positive thyroid cancers; Implement practical strategies to ensure patients with thyroid cancer receive timely and appropriate NTRK fusion testing in order to inform optimal therapeutic decision-making; and Apply best practices for collaboration and coordination of care with multidisciplinary colleagues for patients with NTRK fusion–positive thyroid cancer, including appropriate integration of TRK-targeted therapies into treatment plans and recognition/management of treatment-related adverse events.
Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.
Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences.
Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.
Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individualized management plans for patients with breast cancer that incorporate TROP2-targeting therapies using the latest clinical evidence and current practice guidelines to inform daily practice; and Apply a team-based approach to care that incorporates shared decision-making and patient counseling/education and leverages effective interprofessional collaboration and care coordination.
Go online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies. In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations. Upon completion of this activity, participants should be better able to: Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations; and Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.
Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.
Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don’t miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.
Go online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patient advocate explore these themes through a case-based discussion of novel antibody platforms in a range of MM treatment settings. Learners can expect insights on the safety and efficacy evidence supporting the use of antibody-based therapies in newly diagnosed and relapsed MM, along with practical guidance for safe delivery of care, and strategies for engaging with patients when developing treatment plans that include antibody components. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging antibody options, including monoclonal and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; Address practical aspects of antibody therapy in MM, including unique safety considerations and effective sequential treatment; and Counsel patients with MM on dosing, safety, drug delivery, and therapeutic expectations with novel antibodies when engaging in shared decision-making discussions.
Go online to PeerView.com/JFN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimized use of asparaginase is a cornerstone of successful administration of multiagent chemotherapy in acute lymphoblastic leukemia (ALL) and has implications for patient outcomes across populations—are you prepared for the emergence of novel asparaginase formulations and the use of strategies that can help avoid treatment discontinuation? This MasterClass & Case Forum video presents an opportunity to understand and surmount the challenges associated with delivering effective ALL care with the asparaginase component of modern therapy. In this activity, an expert panel addresses topics ranging from current guidance on first- and second-line asparaginase options, monitoring and management of barriers such as asparaginase hypersensitivity, and therapeutic planning using available tools to maintain asparaginase exposure. Upon completion of this activity, participants should be better able to: Summarize comprehensive management recommendations for pediatric, AYA, and adult patients with ALL, including chemotherapy and asparaginase protocols, immunotherapy, and tyrosine kinase inhibitors; Cite the clinical impact of E coli asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations; Develop evidence-based treatment plans for asparaginase sequencing with E coli and Erwinia asparaginase, including recombinant formulations; and Manage E coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.
Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.
Go online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy. Upon completion of this activity, participants should be better able to: Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM); Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM; and Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting.
Go online to PeerView.com/NTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice. Upon completion of this activity, participants should be better able to: Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence; Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy; and Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers.
Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma; Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma; and Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.
Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.
Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and can have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity, based on a recent PeerView Live event held during the 2022 ASCO Annual Meeting, focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials will also be highlighted to continue to push for progress in better understanding the biology and expanding the treatment options for SCLC. Upon completion of this activity, participants should be better able to: Describe available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other treatment strategies, as well as emerging prospects in biomarker testing and subtyping that may help guide patient selection for different therapies; Apply the latest evidence and guidelines to incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or through clinical trial enrollment; Implement best practices for diagnosing and managing treatment-related toxicity in patients with SCLC; and Integrate multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC.
Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView’s “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don’t miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.
Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.
Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.
Go online to PeerView.com/NUC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to keep up with changes to the treatment landscape of hepatocellular carcinoma (HCC) as the choice of regimens for patients with intermediate- to advanced-stage disease continues to expand and innovative locoregional and multimodal strategies move closer to entering mainstream clinical practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on both disease stage and a variety of patient- and treatment-specific factors. Participate in this PeerView activity for an in-depth examination of how interventional radiologists can collaborate with the HCC management team to offer the best possible care for their patients! Upon completion of this activity, participants should be better able to: Evaluate the current and emerging therapeutic roles of and key clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immune checkpoint inhibitors, and combinations, for patients with intermediate- to advanced-stage HCC; Recommend clinical trials assessing innovative strategies, including tumor treating fields, Y-90 glass and resin microspheres, and combinations of locoregional and systemic therapies, to patients with HCC across the disease spectrum; and In collaboration with multidisciplinary colleagues, develop evidence-based management plans that incorporate novel therapeutic approaches, patient-specific factors such as underlying liver disease severity and biomarker status, and expert recommendations on timely transitions from locoregional to systemic therapy for patients with intermediate- and advanced-stage HCC.
Go online to PeerView.com/SDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The arrival of immunotherapy in basal cell carcinoma (BCC) increases the potential for successful treatment outcomes—are you prepared to address several practical questions related to selection and sequencing of immunotherapy, safety management, and patient monitoring? In this activity, based on a recent PeerView Live Seminars & Tumor Board educational event held at the 2022 American Society of Clinical Oncology Annual Meeting, our expert panel links the evidence supporting the use of immunotherapy in locally advanced and metastatic BCC with case-based teaching designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards, ultimately illustrating how checkpoint inhibitors can be integrated into the care of patients with BCC. Leverage the power of immunotherapy to improve clinical outcomes for your patients with advanced BCC! Upon completion of this activity, participants should be better able to: Cite the rationale, therapeutic role, and current evidence and guidelines supporting the use of immune checkpoint inhibitors (ICIs) in the management of advanced BCC; Integrate novel immunotherapy options into the management of appropriate patients with advanced BCC in consultation with the wider management team; and Employ proactive, team-based approaches to recognize, mitigate, and manage potential immune-related adverse events in patients receiving ICI therapy for advanced BCC.
Go online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more patients achieving cure. The number of available ICIs is expected to grow, as many new agents and combinations are in the final stages of testing, and novel checkpoints such as TIGIT and LAG-3 are showing promise in clinical trials. Consequently, predictive biomarker testing to refine treatment selection is paramount, and there is increasing focus on new surrogate endpoints to assess ICI efficacy, especially in early-stage settings where pathologic complete response, major pathologic response, and disease-free survival are helping to move the field forward faster. However, these exceptional advances are not without challenges. Not all patients with lung cancer benefit from ICIs, while others who could benefit do not have access to these therapies due to persistent disparities in biomarker testing, clinical care, and research. Determining the best immunotherapy option for each individual patient at the right time and in alignment with the particular needs and preferences of each patient is not simple and requires multidisciplinary collaboration and patient-centric shared decision-making. In addition, astute vigilance is required to mitigate potential immune-related adverse events (irAEs) to keep more patients benefiting from these therapies. This activity, based on a PeerView Live Seminars & Practicum educational event held at the 2022 ASCO Annual Meeting, provides guidance for navigating the evidence supporting the use of current and emerging immunotherapies throughout the NSCLC disease continuum and translating evidence to practice with the goal of improving patient outcomes in both advanced/metastatic and early-stage settings. Produced in partnership with LUNGevity Foundation, patient perspectives are also emphasized to improve team-based collaboration, patient engagement, shared decision-making, and health equity in clinical care and research. Upon completion of this activity, participants should be better able to: Describe the latest evidence supporting the use of current and emerging immune checkpoint inhibitors (ICIs) and combinations in locally advanced or metastatic and early-stage non–small cell lung cancer (NSCLC); Select the most appropriate ICI-based treatment for eligible patients with locally advanced/metastatic and early-stage NSCLC, considering the disease presentation, tumor characteristics, biomarker results, patient needs and preferences, current evidence and guidelines, multidisciplinary perspectives, and other relevant factors; Implement multidisciplinary and patient-centric approaches to ensure optimal and equitable use of immunotherapies in the care of all eligible patients with NSCLC; and Apply current guidelines and best practices for monitoring and management of immune-related adverse events (irAEs) in patients with NSCLC who are receiving or have received immunotherapy.
Go online to PeerView.com/KVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. CDK4 and 6 inhibitors and endocrine therapy have significantly improved outcomes in ER+/HER2- advanced breast cancer, and recently, the first CDK4 and 6 inhibitor was approved in combination with endocrine therapy in the adjuvant setting for patients with HR+/HER2-, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of ≥20%. However, pretreated ER+/HER2- breast cancer remains a challenging area with limited treatment options. A number of novel ER-targeting therapies are being investigated in this setting and are showing great promise, including oral selective estrogen receptor degraders (SERDs), selective estrogen receptor modifiers (SERMs), SERD/SERM hybrids, selective estrogen receptor covalent antagonists (SERCAs), and proteolysis-targeting chimeras (PROTACs). This activity, based on a PeerView Live Seminars & Practicum educational web broadcast held in conjunction with the 2022 ASCO Annual Meeting, provides the multidisciplinary breast cancer care team with the latest research and evidence on current and emerging targeted and endocrine therapy options and the implications of these therapeutic advances for practice to ensure that more patients benefit and have improved outcomes. The patient perspective is highlighted as well, and advice for overcoming persistent disparities in breast cancer clinical care are shared. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including CDK4 and 6 inhibitors, SERDs, and SERCAs, and their evolving role in clinical practice; Develop personalized treatment plans for patients with ER+/HER2- breast cancer that take into account recent approvals and safety and efficacy findings from emerging therapies in the context of clinical practice or clinical trials, particularly in areas of high unmet need; and Integrate a team-based, collaborative, and coordinated approach to care, educate patients about new and emerging treatment options for which they may be eligible, and engage patients in shared decision-making to ensure that their unique needs and preferences are taken into account when making treatment decisions.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instruction on the use of next-generation triplets and quadruplets, maintenance strategies, and effective therapeutics in early relapse and treatment-refractory disease. Link cutting-edge evidence in MM to clinical decisions in your own practice—watch today! Upon completion of this activity, participants should be better able to: Cite current practice recommendations and clinical evidence surrounding the efficacy of novel proteasome inhibitor and IMiD options, novel antibody platforms, targeted agents, and cellular therapy across MM treatment settings; Select personalized, evidence-based regimens with novel components for the management of patients with newly diagnosed MM according to baseline comorbidities, functional status, and patient preferences, among other factors; Select evidence-based treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options into patient care; and Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome.
Go online to PeerView.com/HVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What is your sense of the “next steps” with practice-changing immunotherapy options for head and neck cancer (HNC)? Future advances will likely be driven by longer-term evidence in recurrent/metastatic disease, the use of immunotherapy in conjunction with surgery and radiotherapy, the potential of novel combinatorial regimens, and the emergence of newer PD-1–targeting therapies or innovative immune-based treatments. In this “Clinical Consult” activity, based on a live symposium held at the 2022 ASCO Annual Meeting and developed in collaboration with the Head and Neck Cancer Alliance (HNCA), a panel of experts will use case-based conversations to illustrate the present and future of immunotherapy across lines of care in HNC and provide guidance on the next wave of innovation emerging from clinical trials. Upon completion of this activity, participants should be better able to: Summarize updated clinical evidence and guideline recommendations regarding the use of checkpoint inhibitors and other immunotherapy options to treat the spectrum of head and neck cancer; Incorporate checkpoint inhibitors into treatment plans for resectable, locally advanced, and recurrent/metastatic head and neck cancer based on current evidence, guideline recommendations, patient preferences, and availability of clinical trials; and Develop a management plan for immune-related adverse events associated with checkpoint inhibitors used as monotherapy or in conjunction with other modalities.
Go online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC as well. Designed to bridge the gap between theory and practice, this CME/MOC-certified educational activity, in partnership with KCCure, features expert guidance on how oncologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Upon completion of this activity, participants should be better able to: Assess the therapeutic roles of and key efficacy and safety evidence on novel and emerging systemic therapy strategies for patients with localized or advanced/metastatic RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, guideline recommendations, and patient-, disease- and treatment-specific factors; Integrate evidence-based strategies and best practices to recognize, mitigate and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC.
Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/GBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS)—a serious complication arising in the aftermath of hematopoietic stem cell transplantation? In addition to life-threatening organ dysfunction in serious cases, VOD presents additional diagnostic and assessment challenges based on its varied onset time and symptomatology. PeerView’s Clinical Consults CME video will help you meet these challenges head-on through a series of case-centric lectures illustrating how modern VOD management techniques can improve outcomes in adult and pediatric patients at risk for this post-transplant complication. Throughout, our expert panelists will highlight the modern tools and evidence that can help capture VOD cases, determine the presence of organ dysfunction, and support the initiation of timely supportive care and pharmacologic treatment. Upon completion of this activity, participants should be better able to: Describe risk factors for VOD/SOS, updated diagnostic criteria, and clinical markers of disease severity/multiorgan failure, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including for individuals presenting with or without organ dysfunction, Use modern severity grading models to determine the presence of organ dysfunction in patients with a VOD/SOS diagnosis, Incorporate novel therapies into treatment plans for VOD/SOS, including in the setting of multiorgan dysfunction, based on clinical assessment and current evidence.
Go online to PeerView.com/KQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The use of asparaginase, including E coli- and Erwinia-derived compounds, remains an important component of pediatric acute lymphoblastic leukemia (ALL) care, and its use has consistently improved survival outcomes—are you up to the challenge of developing modern regimens that ensure appropriate exposure to asparaginase? In this PeerView CME activity, based on a live “Clinical Consults” symposium at the 2022 ASPHO conference, Drs. Stuart S. Winter and Reuven Schore address the challenges of clinical decision-making with asparaginase compounds as part of pediatric ALL therapy, focusing on topics such as the management of E coli-derived asparaginase hypersensitivity or silent inactivation, preventing discontinuation/truncation, and the integration of novel Erwinia formulations when E coli-derived asparaginase discontinuation occurs. Tune in to learn how to adapt your practice to reflect the innovative science supporting the use of modern asparaginase compounds in pediatric ALL. Upon completion of this activity, participants should be better able to: Describe the clinical ramifications of Escherichia coli asparaginase hypersensitivity and asparaginase discontinuation in pediatric acute lymphoblastic leukemia (ALL), Cite efficacy and safety evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of multi-agent chemotherapy for pediatric ALL, Implement strategies to overcome barriers to the effective use of asparaginase in pediatric ALL, including the use of appropriate monitoring and management for hypersensitivity, mitigation for infusion reactions, and the integration of novel Erwinia asparaginase compounds into treatment plans.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/AFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pharmacists have a central role in the management of chronic lymphocytic leukemia (CLL) and the delivery of potent targeted agents. How will new evidence influence the core tenets of pharmacy practice? In this activity, a leukemia clinical pharmacy specialist provides answers through a precise review of the newest targeted therapy standards for CLL. This program includes insights on the latest efficacy evidence and regulatory status of targeted agents in CLL, while addressing drug interactions, treatment adherence, safety considerations, dosing, and care coordination. Upon completion of this activity, participants should be better able to: Summarize the current treatment role, efficacy and safety evidence, and regulatory status of targeted therapy in CLL, including BTK, BCL-2, and PI3K inhibitors, Educate patients and clinical staff about potential drug–drug interactions, and appropriate dosing, safety, and drug delivery considerations related to the use of targeted agents for CLL, Apply team-based approaches to integrate novel therapies into customized CLL management while addressing drug interactions, adherence, safety, dosing, and care coordination.
Go online to PeerView.com/GUR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gain the skills you need to adapt your current management protocols to reflect the new treatment reality in chronic lymphocytic leukemia (CLL), utilize novel combinatorial and sequential strategies, and map out the role of emerging cell-based therapies! In this activity, expert hematologist-oncologists provide expert guidance on the transformed nature of modern CLL management, the practice-changing evidence that validated targeted therapy platforms, and the science that is redefining the roles of hematopoietic stem cell transplantation and cellular therapy, including in challenging pretreated CLL settings. Upon completion of this activity, participants should be better able to: Cite current guidelines and evidence on the treatment roles of hematopoietic stem cell transplantation; BTK, PI3K, and BCL-2 inhibitors; monoclonal antibodies; and CAR-T cell therapy in the CLL setting, Discuss evidence surrounding the efficacy and safety of novel therapeutics across the spectrum of CLL, including in higher-risk disease settings or in patients relapsing after multiple prior treatments, Recommend regimens with novel components for patients presenting with treatment-naïve, high-risk, or relapsed/refractory CLL.
Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon completion of this activity, participants should be better able to: Discuss current evidence supporting the use of novel therapeutics as prophylactic or treatment options for acute or chronic graft-versus-host disease (GVHD) in the post-transplant setting, including JAK and BTK inhibitors, T-cell blocking agents, α1-antitrypsin, and ROCK inhibitors, among others, Develop management plans informed by evidence and practice guidelines that incorporate novel therapeutics into the management of acute GVHD, Integrate novel and emerging therapies into management plans for the management of chronic GVHD, including novel combinatorial strategies and/or options for second-line management.
Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer types for which novel targeted therapies are being developed, and targeting TROP2 is showing promise as well. Given these treatment advances, biomarker testing to identify patients who may benefit the most from HER2-, HER3-, and TROP2-targeted therapies has never been more important. This activity, based on a recent live web broadcast, will provide essential updates and practical guidance regarding biomarker testing and individualized treatment of patients with HER2-altered cancers, and novel targets such as HER3 and TROP2 will be explored as well. Upon completion of this activity, participants should be better able to: Identify patients with solid tumors with HER2, HER3, and TROP2 alterations using established and emerging testing approaches, Incorporate therapies directed at HER2, HER3, and TROP2 into the treatment of patients with tumors with targetable alterations based on the characteristics, mechanisms of action, and latest clinical evidence on approved and emerging therapies, Develop individualized management plans that leverage predictive testing, the most recent clinical findings, and multidisciplinary team-based care in accordance with the latest treatment guidelines and recommendations for patients with solid tumors with HER2, HER3, and TROP2 alterations, either in the context of clinical practice or clinical trials.
Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin’s lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.
Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.
Go online to PeerView.com/UDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly in recent years, and research endeavors continue to expand treatment options with significant implications for patients. In addition to the approval of multiple second-generation androgen deprivation therapies (ADTs), current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. Furthermore, when managing patients with mCSPC, clinicians must consider established, newly approved, and emerging therapies, as well as individual patient-, tumor-, and treatment-related factors. Given the wealth of new options, how do clinicians determine the best treatment course for each patient? Answers to this and other thought-provoking queries are provided in this educational activity based on a recent live symposium, as a panel of prostate cancer experts examine the latest clinical data for novel and emerging therapeutic approaches and discuss evidence-based strategies for individualizing treatment for each patient with mCSPC. Upon completion of this activity, participants should be better able to: Assess the rationale and clinical evidence for novel therapeutic approaches for patients with mCSPC, such as the addition of novel androgen axis inhibitors or docetaxel to ADT, Develop optimal, individualized treatment plans for patients with mCSPC that incorporate novel therapeutics as appropriate, taking into consideration individual patient-, disease-, and treatment-related factors, Apply evidence- and team-based strategies to proactively mitigate and manage treatment-related adverse events that may occur in patients with mCSPC who are receiving novel therapeutics as part of their care, Employ effective strategies to engage patients with mCSPC in shared decision-making, with the goal of maximizing patient satisfaction, clinical outcomes, and treatment adherence.
Go online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Summarize the current roles, mechanisms of action, and key evidence pertaining to novel systemic therapies for patients with localized or metastatic bladder cancer, such as immunotherapies, small molecule targeted therapies, and antibody-drug conjugates, among others, Plan personalized treatment algorithms for patients with localized or metastatic urothelial cancer that incorporate novel and emerging therapies, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Implement evidence-based strategies and expert recommendations to prevent, mitigate and/or manage treatment-related adverse events that may occur among patients receiving novel systemic therapies for bladder cancer.
Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.
Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.
Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.
Go online to PeerView.com/GWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. Remarkable data have emerged from several immunotherapy trials in perioperative settings and FDA has granted new regulatory approvals for both neoadjuvant and adjuvant immunotherapy regimens, effectively establishing new standards of care in early-stage NSCLC. Still, many questions remain on how to transition these exciting advances to practice and improved patient outcomes in real-world setting. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? These and other essential topics are addressed by two leading experts in thoracic surgery in this PeerView educational activity based on a recent live event. Watch this stimulating discussion of practice-changing data on perioperative immunotherapy, surgical implications and applicability to practice, and how to make the most of ICIs as part of multimodal management of resectable NSCLC. Watch intriguing debates framed by real cases and discussion points selected to highlight the practicalities and challenges of integrating perioperative immunotherapy into practice. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings, Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy, Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions, Integrate best practices for multidisciplinary communication and collaboration to enhance appropriate incorporation of immunotherapies into multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.
Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView’s expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.
Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.
Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it’s on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what’s to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.
Go online to PeerView.com/WFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the last two decades, there have been very limited advancements in the treatment of HR+, HER2- early breast cancer, and a particularly marked unmet need has existed for patients at the highest risk of recurrence. Fortunately, there is new hope of improved outcomes for these patients following the recent FDA approval of the first CDK4 and 6 inhibitor for the adjuvant treatment of patients with HR+, HER2-, node+ early breast cancer at high risk of recurrence and a Ki-67 score ≥20%. Shortly thereafter, guideline updates were released that recommended adjuvant CDK4 and 6 inhibitor therapy combined with endocrine therapy to a broader population of patients at high risk of recurrence. The emergence of this new therapeutic option along with varied indications and recommendations has resulted in much uncertainty about which patients should and should not receive adjuvant CDK4 and 6 inhibitor therapy, and how to best integrate it into clinical practice to meaningfully impact outcomes in this challenging patient population. In this educational activity, two leading experts deliver pertinent updates and use patient cases to provide practical guidance for the multidisciplinary team on how to navigate the changing standards of care in HR+, HER2- early breast cancer. Learn how to identify the most appropriate patients who can achieve the highest absolute benefit from adjuvant CDK4 and 6 inhibition, and ensure that those with a particularly poor prognosis are not excluded from this therapy. Additionally, receive guidance on how to recognize and manage treatment-related adverse events so that patients continue to adhere to CDK4 and 6 inhibitor therapy and derive maximum benefit from it in the adjuvant setting. Upon completion of this activity, participants should be better able to: Discuss the evidence, tools, and strategies for risk assessment and stratification in HR+, HER2- early breast cancer to guide treatment selection, including identification of candidates for adjuvant CDK4 and 6 inhibitor therapy, Integrate the latest safety and efficacy data on adjuvant CDK4 and 6 inhibitor therapy into clinical decisions for patients with high-risk, HR+, HER2- early breast cancer, Incorporate modern risk assessment approaches, supporting evidence, regulatory and guideline recommendations, adverse event prevention/management strategies, and shared decision-making into the establishment of individualized treatment plans for patients with HR+, HER2- early breast cancer to improve outcomes in this patient population, including reducing the risk of recurrence in patients with poor prognosis.
Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.
Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.
Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection. This PeerView educational activity, based on a recent live event, provides essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy. Upon completion of this activity, participants should be better able to: Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer, Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing, Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials, Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/YDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It is estimated that there are about 1 million adults in the United States who identify as transgender, and this number may be higher depending on the surveys used, the questions asked, and the diversity of subcultures within the transgender community. Although being transgender is not in itself a medical condition, transgender individuals have unique healthcare needs and face barriers to screening and preventive care, particularly with cancer screening. Consequently, these patients may receive lower quality medical care than the general population as a result of stigma, discrimination, and providers’ lack of knowledge about gender identity. Additionally, transgender patients may only seek medical care as part of gender affirmation and avoid primary care health concerns, including screenings. This activity, based on a recent live web broadcast, will focus on improving cancer prevention and early detection strategies in the transgender community, as well as enhancing the knowledge and competence of interdisciplinary and interprofessional healthcare providers to appropriately deliver culturally competent care. An interdisciplinary panel of recognized clinical experts will offer learners tactics to improve disease prevention in transgender patients, while the patient advocate will provide the transgender patient perspective throughout the program. Upon completion of this activity, participants should be better able to: Recognize that transgender individuals may be disproportionately at increased risk for contracting HIV and those living with HIV have an increased risk of several types of cancers, Properly screen for and identify cancer in a timely manner to prevent advanced disease in the transgender community, Develop individualized preventive care plans for transgender patients consistent with the patient's current anatomical structure, Provide affirming, inclusive, and culturally humble care to transgender patients to facilitate adherence to clinical recommendations and engagement in care.
Go online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Implement appropriate strategies for biomarker testing and integration of novel immunotherapy options into personalized management plans for patients with recurrent or advanced endometrial cancer, in alignment with the latest clinical evidence, approved indications, and guideline recommendations, Employ proactive, collaborative strategies to mitigate and manage immune-related adverse events in patients receiving immune-based therapies for recurrent and advanced endometrial cancers, Apply multidisciplinary, interprofessional, and patient-centric practices and tools that can realistically serve to mitigate disparities in healthcare service delivery and cancer-related outcomes for patients with endometrial cancer.
Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.
Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.
Go online to PeerView.com/TRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to bring the new standard of care for advanced renal cell carcinoma (RCC) into your clinical practice? Join PeerView and KCCure to learn what the latest research on multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) means for your patients with advanced disease. Our panel of experts will discuss how highly efficacious therapeutic strategies are changing outcomes in earlier lines of treatment and the potential for approved agents to be used in new settings. With illustrative patient cases guiding the discussion, this engaging activity will provide participants with the information they need to navigate important clinical decisions, including how to sequence available therapies; which systemic therapies to use in patients with metastatic, locally advanced, or high-risk localized disease; what steps should be taken to manage AEs associated with newer treatment strategies; and which patients could benefit from clinical trial enrollment. Don’t miss this opportunity to learn more about providing guideline-recommended individualized care for your patients with RCC. Upon completion of this CE activity, participants will be able to: Incorporate novel therapeutic approaches, latest clinical evidence, expert recommendations, and patient-, disease-, and treatment-specific factors in the development of contemporary, personalized management plans for patients with RCC, Recommend clinical trials evaluating novel agents and/or combination approaches as standard treatment options for eligible patients with RCC across the disease spectrum, Apply evidence-based strategies and best practices to diagnose, mitigate, and manage AEs related to novel systemic therapies, including combination regimens, for patients with RCC.
Go online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an interprofessional manner to identify patients in primary care at risk for VTE, Compare the efficacy and safety profile and dosing regimens of available treatment options for VTE, Implement the most up-to-date evidence-based guidelines in the management of VTE to determine an individually appropriate treatment strategy for each patient, Explain the indications and rationale for standard vs extended treatment for the secondary prevention of VTE, Educate patients on the heightened risk of VTE recurrence, and the importance of treatment adherence.
Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
Go online to PeerView.com/DRJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to bring modern approaches to the treatment of patients with biliary cancers to your clinical practice? Learn how the treatment paradigm is shifting from conventional chemotherapy to biomarker-guided treatments and immunotherapy in a new event from PeerView and the Cholangiocarcinoma Foundation. Our experts will offer learners a deep dive into the latest science on the biologic rationale for targeting prevalent genetic aberrations in biliary cancers and review key safety and efficacy data from recent pivotal clinical trials of novel strategies. Through discussions of relevant patient scenarios, our panel will offer insight on how to integrate biomarker-guided treatments into clinical practice and practical guidance on identifying patients with advanced biliary cancers who are eligible for targeted treatment. Upon completion of this CE activity, participants will be able to: Summarize the rationale for use and recent efficacy and safety data on newly available and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Identify patients with advanced biliary cancers who are eligible for treatments with available and emerging therapies targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 alterations, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Integrate the latest clinical evidence into the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics in the context of clinical practice or a clinical trial.
Go online to PeerView.com/GAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management. Upon completion of this CE activity, participants will be able to: Discuss current challenges, unmet needs, and newer developments in ITP including the importance of differential diagnosis, testing, and guideline recommendations in treatment decision-making, Analyze safety, efficacy, evidence, and mechanism of action of BTKis and other emerging agents to improve quality of life and invoke long-term, off-treatment remissions, Develop personalized treatment plans for front-line and second-line therapies based on patient- and disease-specific factors to improve patient outcomes in ITP.
Go online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts will pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity highlights strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this CE activity, participants will be able to: Incorporate the latest clinical evidence, describe the current therapeutic roles and mechanistic rationales of novel systemic therapies, including immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates, across bladder cancer settings and patient populations (eg, localized or metastatic), Develop personalized treatment plans for patients with localized or metastatic bladder cancer that incorporate novel agents, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Employ evidence-based, collaborative strategies to mitigate and manage treatment-related AEs in patients receiving novel systemic therapies for bladder cancer.
Go online to PeerView.com/CRA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. While remarkable data have emerged from several trials assessing ICIs and rational combinations in neoadjuvant and/or adjuvant settings, many questions remain. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? These and other essential topics are addressed by two leading experts in thoracic surgery in this PeerView Live Seminar and Case Forum. Watch this stimulating discussion of practice-changing data on perioperative immunotherapy, surgical implications and applicability to practice, and how to make the most of ICIs as part of multimodal management of resectable NSCLC to reduce the risk of recurrence and improve cure rates. You will also be able to watch an intriguing debate of real cases selected to highlight the practicalities and challenges of integrating perioperative immunotherapy into practice. Upon completion of this CE activity, participants will be able to: Review the mechanistic aspects of immune checkpoint inhibition, rationale for their use as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapies in these settings, Describe the latest evidence on surrogate endpoints, such as pathologic response criteria, to assess treatment response and gain perspective on the prognosis of patients with resectable lung cancer receiving immunotherapy, Select appropriate resectable NSCLC patients for perioperative immunotherapy, weighing the benefits/limitations and surgical implications based on critical analysis of clinical trial findings and persisting misperceptions, Implement best practices for multidisciplinary communication and collaboration to ensure integration of immunotherapies into multimodal treatment plans for appropriate patients with stage I-III resectable NSCLC.
Go online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The panelists will tackle topics such as the use of checkpoint inhibitors as standard adjuvant therapy in stage III/IV melanoma; the potential of adjuvant immunotherapy in stage II disease; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging novel immune-based treatments in resectable melanoma (eg, LAG-3 inhibitors). This program will help inform the identification of optimal candidates for immunotherapy, address treatment selection and dosing considerations, and support effective management of immune-related events. Upon completion of this CE activity, participants will be able to: Summarize updated evidence and guideline recommendations supporting the use of adjuvant and neoadjuvant immunotherapy in resectable or potentially resectable melanoma, including in stage II, III, and IV settings, Select appropriate adjuvant immunotherapy options for patients with resected melanoma requiring additional treatment, including those with BRAF-mutant and wild-type disease, Integrate neoadjuvant immunotherapy into the management of patients with melanoma who may benefit from presurgical treatment, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.
Go online to PeerView.com/BNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the expanding role of macrocyclic TKIs in the treatment of fusion-positive NSCLC and other solid tumors. Upon completion of this activity, participants should be better able to: Discuss the structure and mechanisms of action of macrocyclic tyrosine kinase inhibitors (TKIs) and their role in the treatment of fusion-positive non–small cell lung cancer (NSCLC) and other solid tumors, Compare the characteristics, efficacy, and safety of macrocyclic TKIs with those of standard TKIs in the treatment fusion-positive NSCLC and other solid tumors, including in treatment-naïve and pretreated populations, Implement best practices for identifying patients with fusion-positive NSCLC or other solid tumors who might benefit from the use of macrocyclic TKIs in the context of clinical practice or clinical trials.
Go online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion of treatment options has also presented dilemmas for those trying to choose the right treatment for the right patient. For instance, next-generation anti-androgen agents have proven efficacious in early stages of prostate cancer, while approvals of poly (ADP-ribose) polymerase (PARP) inhibitors are available in later-line metastatic castration-resistant prostate cancer (mCRPC). Combination approaches, under investigation across various stages of prostate cancer, further highlight the expansive opportunities for treatment personalization across the disease continuum. Given this new wealth of options, how do clinicians determine the best treatment course for each patient? Join PeerView and the Prostate Conditions Education Council for an expert-led event designed to answer important questions on prostate cancer treatment in the modern era. Combining insight on relevant data from important trials with practical guidance on using guideline-recommended strategies in clinical practice, this event will help clinicians provide optimal personalized care informed by relevant patient-, tumor-, and treatment-related factors and address AEs related to newer therapies and combinations. Upon completion of this CE activity, participants will be able to: Apply current guideline recommendations for germline and tumor testing for clinically relevant biomarkers in patients with prostate cancer, Integrate novel treatment regimens into the management of patients with advanced prostate cancer, based on recent evidence, genetic/molecular features, current guideline recommendations, and individual patient needs and preferences, Employ evidence- and team-based approaches to proactively mitigate and manage treatment-related AEs that may arise in patients receiving novel therapies and combinations for advanced prostate cancer.
Go online to PeerView.com/KAP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.In this expert-led activity, you will learn to leverage S1PR modulators to provide patient-centered MS care Upon completion of this activity, participants should be better able to: Identify the mechanisms of action for S1PR modulators approved for the treatment of multiple sclerosis in the context of disease pathophysiology. Assess the benefits and risks associated with S1PR modulators based on the most recent clinical data,Apply the latest clinical data on S1PR modulators to individualized MS treatment plans
Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]
Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.
Go online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance. Throughout, the panelists will share insights on evidence-based and effective sequential therapy (including with second-generation covalent BTK inhibitors, noncovalent BTK options, and non–BTK inhibitor agent classes) and use case-based discussion to illustrate how therapeutic challenges associated with BTK inhibitor therapy can be overcome. Upon completion of this CE activity, participants will be able to: Develop plans to capture therapeutic intolerance or BTK resistance mutations before or at disease progression in patients receiving treatment with covalent BTK inhibitors, Select evidence-based sequential therapy for patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations, Recommend appropriate sequential options for patients with B-cell cancers who exhibit therapeutic intolerance to BTK inhibitors in order to maximize safety, ensure continued efficacy, and augment patient quality of life.
Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.
Go online to PeerView.com/CPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While TKIs have been a mainstay in the first three lines of treatment for patients with gastrointestinal stromal tumors (GISTs), new discoveries and emerging science have led to the development of newer agents that address treatment resistance. Known as modern TKIs, these agents have a confirmed role in the treatment of patients with specific mutations or in later-line settings and are now being tested in earlier-stage disease. While oncologists, oncology nurses, and other members of the interdisciplinary cancer care team have new opportunities for increasing survival and improving QOL in their patients with unresectable/metastatic GIST, they are also faced with more complex treatment paradigms that must account for mutation profiling, treatment selection/sequencing, symptom and AE management, psychological support, and nutritional considerations. Join our experts to hear how all members of the cancer care team can work together to effectively incorporate these modern TKIs into clinical practice. Upon completion of this CE activity, participants will be able to: Summarize current clinical evidence on established (ie, standard and newly available) and emerging TKI strategies (ie, modern TKIs in early-line settings) for unresectable/metastatic GIST, Sequence appropriate targeted therapy over multiple lines of treatment for patients with unresectable/metastatic GIST, Develop personalized treatment plans that address effective safety, dosing, and QOL strategies associated with the use of TKIs with an interprofessional team of clinicians who care for patients with unresectable/metastatic GIST.
Go online to PeerView.com/RVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Improving outcomes for patients with advanced urothelial carcinoma (UC) has been challenging, with many patients experiencing only short periods of progression-free survival after treatment with first-line chemotherapy. A game changer in many cancers, immunotherapy has provided new avenues for the cancer care team to help their patients with advanced UC live longer. In particular, new data on the use of immunotherapy in the first-line maintenance setting has shown that using immunotherapy before patients’ progress to the second-line setting increases survival without a negative impact on quality of life. In this activity, a panel of experts discusses strategies for incorporating these important data into individualized patient care. Upon completion of this CE activity, participants will be able to: Cite the available clinical evidence on the use of immune checkpoint inhibitors as first-line (1L) maintenance vs. delayed (2L) therapy in patients with advanced UC after response to 1L platinum chemotherapy, Select patients with advanced UC who may be eligible for 1L maintenance therapy with an immune checkpoint inhibitor based on response to initial chemotherapy, PD-L1 status, and other patient- and disease-related factors, Incorporate new clinical evidence and updated guideline recommendations on 1L immunotherapy maintenance regimens into current treatment algorithms for patients with advanced UC.
Go online to PeerView.com/HYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibodies have allowed clinicians to bring their “A” game when managing multiple myeloma (MM). To see how this happened, watch this activity, developed in collaboration with HealthTree Foundation, to view how experts have rapidly integrated CD38, SLAMF7, and BCMA antibodies into the management of newly diagnosed and relapsed/refractory disease. Each case-based lecture also includes a video testimonial from a patient with MM on how treatment with novel antibodies has made a difference in their lives. Upon completion of this CE activity, participants will be able to: Cite updated evidence on the use of novel antibody platforms targeting CD38, SLAMF7, and BCMA in NDMM and RRMM, Integrate antibody-based therapies, including triplet and quadruplet regimens, into the management of patients with NDMM, Recommend appropriate antibody options for the management of RRMM, including for patients with early relapse or heavily pretreated disease, Develop strategies addressing practical aspects of antibody therapy in MM, including issues related to dosing/scheduling and unique safety considerations, such as neutropenia, infection, and ocular toxicity.
Go online to PeerView.com/YQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology-oncology provides an overview of paroxysmal nocturnal hemoglobinuria (PNH) and discusses current and emerging treatment options for managing PNH. Upon completion of this CE activity, participants will be able to: Discuss the complement pathway and its mechanistic relationship to paroxysmal nocturnal hemoglobinuria (PNH), Summarize efficacy and safety data surrounding complement pathway inhibitors, including factor B inhibitors, to treat PNH, Manage the unique adverse events associated with complement pathway inhibitors for PNH.
Go online to PeerView.com/GWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The transformation of patient care in diffuse large b-cell lymphoma (DLBCL), driven by advances with antibodies and cellular therapy, continues—what will this mean for your practice? Find out in PeerView’s “Clinical Consults” video activity where a panel of DLBCL will focus on the applications of these dual innovations in the management of DLBCL. Using a series of alternating case-based discussions and mini-lectures, the panelists use recent science to explore the practice of novel antibodies and CAR-T cell therapy, including: the identification of candidates for treatment with novel antibodies or cellular therapy; the principles of therapeutic sequencing; appropriate safety management and monitoring strategies; and the emergence of novel immunotherapy options in the form of bispecific antibodies. Upon completion of this CE activity, participants will be able to: Summarize the treatment role of novel antibodies and CAR-T options in the management of relapsed diffuse large b-cell lymphoma (DLBCL) as supported by current evidence and clinical practice guidelines, Integrate novel antibody and cellular therapy options, including as sequential therapy, in the management of patients with relapsed/refractory DLBCL, Manage practical considerations associated with antibody and cellular therapy in DLBCL, including confirmation of patient eligibility for treatment, referral to specialized care centers when appropriate, and strategies for mitigating or managing adverse events in patients receiving therapy.
Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.
Go online to PeerView.com/CMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in sickle cell disease discuss current and future disease management strategies, including recent safety, efficacy, and tolerability data for currently approved and emerging therapies. Upon completion of this CE activity, participants will be able to: Discuss the disease burden, etiopathogenesis, complications, and unmet needs associated with SCD, Appraise recent safety, efficacy, and tolerability data associated with currently approved and emerging therapies for SCD including anti-adhesion agents, antisickling agents, and pyruvate kinase-R (PKR) activators among others, Develop treatment plans to prevent and/or reduce veno-occlusive crises and end-organ damage in patients with SCD, Implement collaborative strategies and shared decision-making practices to ensure patient engagement in treatment decisions and management of therapy-related adverse events.
Go online to PeerView.com/HCA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in breast cancer discuss the latest advances in the management of patients with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) breast cancer, including the rapidly accumulating evidence supporting the use of novel therapies such as selective estrogen receptor degraders (SERDs), selective estrogen receptor modulators (SERMs), selective estrogen receptor covalent antagonists (SERCAs), complete estrogen receptor antagonists (CERANs), and proteolysis-targeting chimeras (PROTACs), among others. In addition to analyzing the recent data from clinical trials with these ER-targeted therapies, patient case scenarios are presented to illustrate their potential role and use, and how to incorporate these novel treatments into the current management paradigm to improve outcomes in patients with ER+ breast cancer. Upon completion of this CE activity, participants will be able to: Cite the rationale for use, mechanism of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Incorporate the most recent efficacy, safety, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations into treatment regimens for eligible patients with HR+ breast cancer in the context of clinical practice or via clinical trial participation.
Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.
Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.
Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.
Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/KKF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with cancer often present to the ED in an acutely ill state with complications from their cancer or treatments used, but a broadening use of a new class of cancer immunotherapies has changed the types of complications experienced by these patients. This spectrum of unique toxicities, termed immune-related adverse events (irAEs), is less well known, and commonly, they are overlooked, misdiagnosed, and not appropriately managed in ED settings. Standard algorithms for diagnosis and treatment no longer apply, as irAEs require a distinct approach. Are you prepared to handle the new category of oncologic emergencies you are likely to increasingly encounter in your ED? This activity will help you get up to date and change your practice. Emergency medicine and oncology experts will join forces to provide practical, case-based guidance for timely and accurate recognition, triage, diagnosis, and management of irAEs associated with novel immunotherapies in patients with cancer who present to the ED. Upon completion of this CE activity, participants will be able to: Review the biologic reasons and mechanisms that drive the development of immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Describe the spectrum of irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency medicine (EM) professionals in the emergency department (ED), Implement latest recommendations for identification, assessment, diagnosis/differential diagnosis, and management of irAEs in ED settings, Integrate team-based approaches to triage, evaluate, diagnose, and manage pertinent irAEs in the ED in collaboration with oncology professionals.
Go online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-2 inhibitors—can improve care across the clinical spectrum of CLL. Upon completion of this activity, participants should be better able to: Cite current efficacy and safety data surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors and novel combinations, Apply evidence on current prognostic factors, genetic/molecular findings, and patient- or disease-related features when making treatment decisions in CLL, Develop an optimal treatment plan with targeted agents, including fixed-duration or continuous therapy, or appropriate combinatorial or sequential options for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.
Go online to PeerView.com/TGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the multidisciplinary relationship between urologic oncologists and advanced practice clinicians in the management of patients with prostate cancer has become increasingly more important in providing the best patient care. During this video, an expert panel highlights how a multidisciplinary team can use the latest clinical evidence, treatment guidelines, and expert consensus recommendations to improve care for patients with prostate cancer and gives practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. The experts also provide meaningful guidance to assist clinicians in optimizing treatment planning based on a modern understanding of prostate cancer biology, best treatment practices, and the expanding opportunities for treatment personalization across the disease continuum. Upon completion of this CE activity, participants will be able to: Implement guideline recommendations related to genetic testing when managing patients with prostate cancer, Apply current evidence about available and emerging anti-androgen and non-hormonal agents when deciding on treatment for prostate cancer, Integrate appropriate anti-androgen and non-hormonal strategies into treatment plans for patients with prostate cancer.
Go online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuvant, or perioperative immunotherapy in early-stage cancers, key trials and relevant endpoints, and evolving evidence supporting ICI use in different early-stage solid tumors, Implement best practices for multidisciplinary/interprofessional patient and tumor evaluation as well as coordination of care when managing patients with early-stage cancers, Integrate immunotherapies into individualized, multimodal treatment plans for appropriate patients with early-stage cancers in clinical practice or through clinical trial participation, Assess the risks and benefits associated with neoadjuvant/adjuvant/perioperative immunotherapy use to ensure safe, optimally selected, and appropriately timed delivery of systemic and local multimodal therapies to patients with early-stage solid tumors.
Go online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include PD-1/PD-L1–targeting immune checkpoint inhibitors, TKIs targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates, into clinical practice. For instance, which factors determine whether a patient will benefit from a particular treatment, and how are the unique AEs associated with these new agents managed? To answer these questions, PeerView’s urologic oncology experts present a new educational event featuring the latest evidence on novel therapeutics for bladder cancer and practical strategies for using these agents in patients with early through advanced bladder cancer. Using patient cases drawn from clinical practice and interactivity that allows participants to see how their treatment choices compare with those of their colleagues, the faculty will address the mechanistic rationale for these new therapies, therapeutic decision-making, and AE mitigation strategies. Upon completion of this CE activity, participants will be able to: Discuss the current therapeutic roles of novel agents across bladder cancer settings and various patient populations (eg, localized or metastatic), Examine updated clinical efficacy and safety evidence surrounding the use of novel therapies, including immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates, across the spectrum of bladder cancer settings, Develop a treatment plan for bladder cancer that includes novel therapies and considers disease- and patient-related features, Manage the unique adverse events associated with novel immune, targeted, and antibody-based treatments for bladder cancer.
Go online to PeerView.com/XZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent validation of novel multitargeted TKIs and immune checkpoint inhibitor therapies in metastatic disease, the treatment horizon of renal cell carcinoma (RCC) has vastly expanded and has continued to broaden with the emergence of long-term data supporting the efficacy of dual checkpoint blockade and combination therapies involving immunotherapy/TKI partners. Despite recent regulatory approvals, guideline updates, and abundant evidence, many medical and urologic oncologists find it challenging to bring these novel immune and targeted strategies into clinical practice. Designed to bridge the gap between theory and practice, this educational activity features expert guidance on how oncologists and urologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Featuring cases drawn from practice, participants will hear how peers resolve clinical issues as the faculty present best practices for individualized RCC treatment. Upon completion of this CE activity, participants will be able to: Choose appropriate, personalized treatment regimens that make use of recent clinical research findings on validated immune and targeted therapies for patients across the disease spectrum, including resectable disease, newly diagnosed metastatic, or previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for patients with RCC in different disease and treatment settings, Incorporate practical strategies to mitigate and manage AEs related to targeted and immune-based therapies for patients with RCC.
Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient’s genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.
Go online to PeerView.com/TKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With new developments in the advanced renal cell carcinoma (RCC) treatment landscape, clinicians have more opportunities for personalizing therapeutic approaches for patients with RCC. Validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents, have led to FDA approvals, and novel approaches synergistically combining checkpoint inhibition with targeted therapy have expanded frontline treatment options for patients with advanced disease. This program features the latest research on the efficacy and safety of these newer treatment approaches and expert guidance on selecting and managing the overlapping and non-overlapping adverse events associated with potent immune-based and targeted therapy treatment options. Upon completion of this activity, participants sould be better able to: Identify the latest efficacy and safety findings on new treatment approaches, such as immune checkpoint inhibitors, targeted tyrosine kinase inhibitors, and novel and emerging combination approaches, for advanced and/or resectable renal cell carcinoma (RCC), Choose appropriate, personalized treatment regimens that make use of immune and targeted therapies for patients with advanced RCC in the first-line setting based on pertinent patient- and disease-related characteristics, Integrate novel components into treatment plans over multiple lines of therapy for patients with previously-treated advanced RCC taking into account patient treatment history and comorbidities, Assess treatment-related adverse events in patients with RCC receiving immunotherapy and targeted agents.
Go online to PeerView.com/ZQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Seminar & Multidisciplinary Tumor Board program will pair insightful commentary on emerging systemic and locoregional options in HCC with clinical insights from different disciplines. Each Tumor Board segment will feature a case-centered discussion on the increasingly important multidisciplinary team-based management of patients across the HCC disease continuum. Hear an in-depth conversation on how the HCC management team can successfully collaborate to offer the best possible care to their patients. Upon completion of this CE activity, participants will be better able to: Assess the latest efficacy and safety evidence on available and emerging systemic treatments, including multikinase inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors (as monotherapy or within a combination strategy) for patients with advanced HCC, Review ongoing clinical trials and recent data for innovative strategies, including tumor treating fields, and locoregional combinations with systemic therapies, across the HCC disease spectrum, Develop personalized treatment plans for patients with early- to advanced-stage HCC, inclusive of clinical trial enrollment when appropriate, that are based on the latest clinical evidence, practice guidelines, treatment history, and other patient- and disease-specific factors, Apply best practices for collaboration and coordination of care among the multidisciplinary HCC care team to optimize patient assessment and treatment and minimize treatment-related toxicities.
Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.
Go online to PeerView.com/TMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC management is finally changing. Additionally, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings are presented, with specific implications for SCLC. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of integrating immunotherapies and immune-based combination approaches into the SCLC treatment arsenal throughout the disease continuum, Review efficacy and safety findings from key clinical trials assessing immunotherapies and combination approaches across different treatment settings of SCLC, as well as data on potential biomarkers, Incorporate immunotherapies into treatment plans for appropriate patients with SCLC in managed care settings.
Go online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestations. These experts provide practical guidance on strategies and techniques for diagnosing, staging, and managing patients who present with various cardiac irAEs. This virtual session will engage participants with opportunities to participate in consultative assessments of real-world patient cases, including contributing to key aspects of diagnostic decision-making and deliberation of optimal strategies for collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Summarize the prevalence, biologic mechanisms, burden, and consequences of the development of cardiac immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Utilize algorithms and practical tools based on the latest clinical evidence and recommendations for identification, diagnosis/differential diagnosis, treatment, and management of cardiac irAEs, Integrate shared decision-making, team-based approaches, and telemedicine to facilitate multidisciplinary and interprofessional collaboration and care coordination and improve clinician-patient communication and patient outcomes.
Go online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimitotic therapy with a unique mode of delivery continues to be combined with conventional cancer therapies, including surgery, systemic therapy, and radiation therapy, the oncology community will benefit from understanding the practical implications in the multidisciplinary management of cancer. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the expert panel will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GI and gynecologic tumors. Upon completion of this activity, participants should be better able to: Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM, Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings, Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials.
Go online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Orally bioavailable CDK4 and 6 inhibitors have become established standard-of-care options in HR+/HER2- metastatic breast cancer, and these agents are now expected to have a major impact in early breast cancer (EBC). CDK4 and 6 inhibition has recently shown significant benefit as adjuvant therapy in patients at high risk of early recurrence, but other studies in the adjuvant and neoadjuvant settings are under way as well. How should these advances be transitioned to the clinic based on the accumulating supportive evidence? How can surgeons and oncologists work together to ensure proper risk assessment and treatment planning to improve outcomes in patients with HR+/HER2- EBC? This PeerView Virtual Workshop provides pertinent updates on the most recent research and available evidence on CDK4 and 6 inhibition in HR+/HER2- EBC, as well as practical, case-based guidance on the application of these agents using individualized treatment plans and effective multidisciplinary collaboration. Upon completion of this CE activity, participants will be able to: Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence, Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 & 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease, Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.
Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon’s role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.
Go online to PeerView.com/DCQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Esophageal cancer has a poor prognosis with 5-year survival rates below 35% in the non-metastatic setting. Despite the use of trimodality approaches with chemotherapy, radiation, and surgery, survival benefits remain suboptimal. Promisingly, recent phase 3 evidence suggests that adjuvant immunotherapy can significantly improve disease-free survival in patients with esophageal or gastroesophageal junction (GEJ) cancer. Moreover, a number of other trials are underway studying approaches that harness the patient’s own immune system with immunotherapy in different settings of locally advanced and earlier stage, indicating the expanding role of immunotherapy in the therapeutic management of esophageal or GEJ cancer. Preparing for new treatment strategies that can improve patient outcomes requires the cancer care team of radiation, medical, and surgical oncologists to work in a concerted multidisciplinary approach. This activity will provide a comprehensive and practically-oriented, multidisciplinary overview on the expanding role of immunotherapy in esophageal and GEJ cancer. Radiation and medical oncology experts will offer their insights to optimize the integration and use of immunotherapies in the multimodal management of esophageal and GEJ cancer. Upon completion of this activity, participants should be better able to: Describe the mechanisms by which immunotherapies harness the immune system in the treatment of esophageal and gastroesophageal junction (GEJ) cancers and the rationale for using immune checkpoint inhibition as adjuvant therapy in locally advanced and earlier-stage disease, Evaluate the latest clinical trials and data related to the use of adjuvant immunotherapy in locally advanced and earlier stages of esophageal or GEJ cancer, Develop optimal multidisciplinary treatment plans for patients with locally advanced and earlier-stage esophageal or GEJ cancer, including clinical trial enrollment, based on the available evidence, patient- and disease-related factors, and expert recommendations.
Go online to PeerView.com/AMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance. Upon completion of this CE activity, participants will be able to: Summarize the mechanistic and selectivity differences among covalent and noncovalent BTK inhibitors, including their implications for off-target effects, agent safety profiles, and therapeutic intolerance, Describe the mechanisms of BTK inhibitor resistance, including core mechanisms of acquired resistance to covalent agents and how noncovalent inhibitors can overcome resistance mutations.
Go online to PeerView.com/YBS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in endometrial cancer examines the evidence for current and emerging treatment strategies and shares evidence-based recommendations for maximizing the potential of immunotherapies to improve outcomes for patients with advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for integrating biomarker testing and immunotherapy into the management of endometrial cancer, Review current guidelines and clinical trial evidence on new and emerging immune-based treatment strategies in endometrial cancer, Implement the latest guidelines, evidence, and team-based strategies for biomarker testing, immunotherapy selection, and adverse event management in patients with endometrial cancer.
Go online to PeerView.com/KPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid progress in the treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has practice-changing implications for pathologists, oncologists, and the broader multidisciplinary lung cancer care team. In addition to multiple targeted therapy options available for patients with metastatic NSCLC with more commonly occurring EGFR mutations, new agents have recently been approved by the FDA for those with less common but highly important EGFR exon 20 insertion mutations. Furthermore, EGFR-targeted therapy is now also transitioning from the advanced to early-stage settings of lung cancer, with the first regulatory approval granted for adjuvant therapy so far, and further developments are anticipated. The expansion of the treatment arsenal means that appropriate biomarker testing is increasingly more important, including the selection and use of correct testing methodologies to identify all patients with diverse EGFR mutations who can benefit from novel targeted therapies. Are you prepared for the enhanced precision and granularity in testing and treatment that is now required? This PeerView activity highlights all the recent need-to-know advances in EGFR-targeted therapy, along with the implications for pathology and oncology practice. Top experts will also provide useful, case-based guidance on what, how, and when to test, and how to accurately interpret the complex results of EGFR mutation testing to guide individualized treatment decisions for patients with EGFR-mutated NSCLC. Upon completion of this CE activity, participants will be able to: Describe the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, including in earlier disease stages, Apply the latest recommendations and best practices for biomarker testing to detect common and less common EGFR mutations in NSCLC, Implement multidisciplinary strategies for biomarker testing and individualized treatment selection throughout the NSCLC disease continuum, Integrate established, new, and investigational targeted therapies into the treatment of patients with EGFR-mutated NSCLC according to the latest evidence and guidelines and patient needs, values, and preferences.
Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.
Go online to PeerView.com/AGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable genetic disorder that primarily gives rise to nervous system tumors but can also lead to multisystem involvement. Neurofibromas are a key feature of NF1, and approximately 50% of patients will develop plexiform neurofibromas (PNs), which are associated with substantial morbidity and carry the potential to transform into malignant peripheral nerve sheath tumors. Optimal care of children with NF1 and NF1-related plexiform tumors includes awareness of the disease biology and the most recent clinical data on innovative therapies for managing the disease. Recent therapeutic developments for NF1 have been tumor-directed, often leveraging agents developed for the treatment of a variety of cancers. Notably, inhibitors of the MAPK signaling pathway, such as MEK inhibitors, offer rational therapeutic options for patients with NF1. This web broadcast features an expert review of treatment recommendations, current management paradigms, and challenges in the care of NF1 and NF1-associated tumors in children, as well as insight into the expanding landscape of targeted therapies and guidance on effectively incorporating these strategies into patient care. Upon completion of this activity, participants should be better able to: Describe fundamental aspects of NF1 etiology, pathophysiology, and clinical presentation as they relate to pediatric patients, Summarize current recommendations for NF1 diagnosis and treatment of NF1-associated tumors in pediatric patients, Evaluate recent evidence regarding the role of emerging therapies in the treatment of NF1-associated tumors in pediatric patients, including agents that affect the RAS/MAPK pathway, Assess options for patient-centered treatment of PNs and other NF1-associated tumors in pediatric patients.
Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView’s Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don’t miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.
Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what’s showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.
Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.
Go online to PeerView.com/AEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGCT presentations, and illustrate the nuances of multidisciplinary collaboration when managing patients with TGCT. Throughout, the panelists profile a modern management synthesis that combines surgery, physical therapy, and the use of targeted agents, including for patients for whom surgery alone is unlikely to be beneficial. Upon completion of this CE activity, participants will be able to: Interpret the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Utilize multidisciplinary management strategies for localized and diffuse TGCT that include collaboration between oncologists, orthopedic surgeons, advanced practice clinicians, and other relevant professionals, Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients for whom continued surgery is unlikely to produce clinical benefits, Manage safety and dosing considerations with targeted agents in the setting of TGCT.
Go online to PeerView.com/QRC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss IO biomarkers. Upon completion of this accredited CE activity, participants should be better able to: Discuss the rationale for and practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cut-points, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for multidisciplinary collaboration and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.
Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.
Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/ZZW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in myelofibrosis discuss risk stratification, individualized care, and treatment strategies, including the use of JAK inhibitors and JAK inhibitor–based combinations. Upon completion of this accredited CE activity, participants should be better able to: Review modern risk stratification models, molecular features, cytogenetics, and clinical presentation of myelofibrosis, Evaluate the latest safety, efficacy, and tolerability data supporting the use of JAK inhibitors and other novel strategies, including JAK inhibitor–based combinations or sequencing approaches for managing transplant-eligible and transplant-ineligible patients with myelofibrosis, Address practical aspects of individualized care and risk-adapted therapy in myelofibrosis for managing lower- and higher-risk patients, including those failing prior JAK inhibitor therapy, Educate patients on the treatment strategies, what to expect when undergoing treatment with JAK inhibitor or JAK inhibitor–based combinations, and how they can effectively collaborate with the oncology team to monitor and manage therapy-related adverse events.
Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.
Go online to PeerView.com/ECV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guidelines supporting a treatment role for targeted agents, including BTK and BCL-2 inhibitors, in the management of B-cell malignancies, Identify the unique spectrum of adverse events associated with the use of targeted agents in B-cell malignancies, including hypertension, bleeding, cardiac events, TLS, neutropenia, fatigue, and others, Develop team-based management strategies to address the emergence of adverse events in patients with B-cell malignancies receiving therapy with novel agents, Utilize team-based educational and counseling strategies detailing therapeutic and safety expectations for patients with MCL, CLL, or other B-cell malignancies.
Go online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ultimately improve care for their patients with MM. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence about the use of novel antibody platforms targeting CD38 and BCMA in relapsed/refractory multiple myeloma (RRMM), including in heavily pretreated disease, Integrate antibody-based therapies into team treatment plans for the management of patients with RRMM, Develop team-based strategies addressing practical aspects of antibody therapy in RRMM, including issues related to dosing/scheduling, unique safety considerations such as neutropenia, infection, and ocular toxicity, and patient and staff education on drug safety/delivery.
Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what’s looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn’t rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.
Go online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Appraise recent efficacy and safety data on newly available, guideline-based, and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Summarize ongoing/accruing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, for patients with advanced biliary cancers, Apply practice-changing clinical trial evidence to personalize the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics.
Go online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, and other team members can collaborate to overcome the many challenges of VOD/SOS. Upon completion of this activity, participants should be better able to: Explain the clinical signs, symptoms, and medical burden of VOD/SOS to patients preparing for transplantation, Apply team-based approaches to risk assessment and diagnostic confirmation of VOD/SOS, including interpretation of clinical symptoms/disease onset and use of techniques such as ultrasound imaging or other strategies as appropriate, Use modern adverse event severity grading models to determine the presence and severity of organ dysfunction in patients with a VOD/SOS diagnosis, Recommend appropriate team management options for adult and pediatric patients with VOD/SOS in the post-HCT setting.
Go online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emergence of newer non-covalent BTK options. Throughout, our experts share sound, evidence-based treatment plans designed to address the medical needs of patients progressing on or unable to tolerate BTK covalent inhibitor therapy in the CLL/SLL and MCL settings. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence on the mechanistic properties, safety, and efficacy of covalent and non-covalent BTK inhibitors with therapeutic applications in B-cell malignancies, including in settings where therapeutic intolerance or resistance mutations are present, Develop management models for capturing therapeutic intolerance or BTK resistance mutations at disease progression in patients receiving treatment with covalent BTK inhibitors, Recommend evidence-based management plans addressing the therapeutic and safety needs of patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations or who are unable to continue on therapy due to adverse events.
Go online to PeerView.com/WST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of pharmacy experts in multiple myeloma management discusses the latest evidence on novel antibody and CAR-T options and link key take-homes from the data to core aspects of pharmacy practice, from minimizing adverse events/drug interactions to educating patients and staff while addressing other pharmacy considerations. Upon completion of this accredited CE activity, participants should be better able to: Identify the current treatment role and regulatory status of novel antibodies and cell-based therapy for multiple myeloma, Summarize efficacy and safety evidence related to the use of CD38, SLAMF7, and BCMA-targeting antibodies and BCMA CAR-T therapy in newly diagnosed and relapsed multiple myeloma, Develop educational plans for staff and patients surrounding safety, dosing, and potential drug interactions associated with novel antibodies and cell therapy in multiple myeloma, Apply team-based management strategies for the integration of novel antibodies and cell therapy into existing treatment protocols for multiple myeloma, including addressing formulary concerns or developing intrainstitutional therapeutic algorithms.
Go online to PeerView.com/DDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The broad implications of the expanding role of cancer immunotherapies in lung cancer necessitate multidisciplinary collaboration, especially in the locally advanced setting where appropriate patient evaluation and selection for immune checkpoint inhibitors (ICIs) along with other multimodal therapies requires input from a medical oncologist, a radiation oncologist, as well as a thoracic surgeon, among other specialists. Effective communication and coordination of care are also essential in the management of patients with unresectable stage III non–small cell lung cancer (NSCLC) deemed to be good candidates for consolidation ICI therapy after chemoradiation. How should this be operationalized in real-world settings? Learn useful strategies from this PeerView MasterClass and Tumor Board based on a recent web broadcast, which delivers evidence-based guidance on the best practices related to multidisciplinary patient assessment and treatment planning to help you improve outcomes in your patients with stage III NSCLC. Our panel of experts navigates through the latest evidence, key challenges, and controversies, as well as debates a series of real cases to demonstrate how to individualize patient care in the midst of rapid research and clinical advances. Upon completion of this activity, participants should be better able to: Discuss the latest clinical evidence on cancer immunotherapy in unresectable stage III NSCLC, Collaborate with relevant specialists to stage lung cancer, assess tumor resectability, and develop individualized treatment plans for patients with stage III NSCLC, Integrate cancer immunotherapies into the management of patients with unresectable stage III NSCLC according to the latest evidence and guidelines, multidisciplinary/interprofessional perspectives, and patient treatment and quality of life goals, Apply effective strategies to identify and manage immune-related adverse events in patients receiving cancer immunotherapy for unresectable stage III NSCLC treatment.
Go online to PeerView.com/SFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered. Upon completion of this accredited CE activity, participants should be better able to: Summarize clinical, molecular/genetic, and pathologic features of secondary AML/AML-MRC that can be used to confirm a diagnosis and distinguish this disorder from other subtypes, Describe the testing tools and methods that can be used to capture the morphologic and molecular features of secondary AML/AML-MRC, Cite efficacy and safety evidence surrounding the use of novel therapeutics in patients with secondary AML, Develop a diagnostic and risk-stratification strategy in consultation with treating clinicians once a diagnosis of AML is suspected so a definitive diagnosis of secondary AML can be rendered and appropriate therapies can be selected.
Go online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from these therapies, and thus, broad biomarker testing is essential to identify these patients, as is making the best rational therapies available to them. Many barriers to biomarker testing and appropriate biomarker-driven treatment exist, and there are also significant disparities in lung cancer clinical care and research, but effective steps can be taken to overcome them. An essential component of modern lung cancer management is patient education, which allows patients to become well-informed participants in their care and participate in shared decision-making with their multidisciplinary clinical teams. This PeerView educational activity, based on a recent web broadcast and developed in collaboration with the LUNGevity Foundation, brings together leading experts in lung cancer, patients, and advocates who engage in candid conversations and clinical consultations focused on how to navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer, and provide the best possible care to all patients. Upon completion of this accredited CE activity, participants should be better able to: Describe established, new, and emerging genomic alterations with potential for therapeutic targeting in NSCLC, Discuss the increasing importance of broad biomarker testing for clinical decision-making and the latest methods for identifying genomic alterations in NSCLC, Compare the mechanisms of action, efficacy, and safety of precision therapies targeting established, new, and emerging molecular alterations in NSCLC, Implement best practices, collaborative strategies, and shared decision-making to ensure widespread biomarker testing, precision treatment, and equitable care of diverse populations of patients with NSCLC in the context of clinical practice or clinical trials.
Go online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs and rational combinations are starting to show promising activity as neoadjuvant and adjuvant therapies for patients with resectable stage I-III NSCLC as well. Optimal approaches are still being determined, and many questions and controversies remain, but it is essential for oncologists, thoracic surgeons, and other multidisciplinary specialists to work together to make these therapies available to patients with earlier stages of lung cancer. This PeerView educational activity, based on a recent web broadcast, provides essential updates on the evolving science supporting the use of ICIs in multimodal treatment of unresectable and resectable stage I-III NSCLC. Multidisciplinary perspectives on how to make the most of immunotherapies and rational combinations in curative-intent settings are shared as well. Upon completion of this accredited CE activity, participants should be better able to: Characterize the rationale for using immunotherapy as a component of multimodal therapy in locally advanced or earlier stages of non–small cell lung cancer (NSCLC), Review key clinical trials and available efficacy/safety data on immunotherapies and immune-based combinations in locally advanced and earlier stages of NSCLC, Determine the best assessment and treatment approaches for diverse populations of patients with stage I-III NSCLC as part of clinical practice or clinical trials based on the latest evidence and recommendations, effective multidisciplinary and interprofessional collaboration and care coordination, and patient needs, values, and preferences.
Go online to PeerView.com/XTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of multiple myeloma experts discuss the recent changes in the multiple myeloma (MM) treatment landscape that have occurred at “warp speed” by focusing on the emergence of novel antibodies, cellular therapy, and targeted strategies across the MM treatment continuum. Throughout, the panelists engage in dedicated Tumor Board sessions designed to illustrate how professionals can apply evidence that can lead to improved patient outcomes in diverse MM patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite evidence surrounding the efficacy of regimens with novel proteasome inhibitors, immunomodulatory drugs, antibodies, targeted therapies, and cell therapies across multiple myeloma (MM) treatment settings, including smoldering MM, newly diagnosed MM, and relapsed/refractory MM, Select evidence-based regimens with novel components for the management of patients with newly diagnosed MM, Develop treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options, Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome, among others.
Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an innovative, case-based activity designed to bring participants the latest data on established targeted therapies and emerging combination strategies for patients with gastric and GEJ cancers and expert guidance on incorporating treatment advances into day-to-day clinical practice. With a focus on multidisciplinary care of patients with gastric and GEJ cancers, the faculty panel will address selection and sequencing of treatment regimens along with symptom management, psychological support, nutritional considerations, and a variety of other issues that affect patients’ quality of life and outcomes. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the latest clinical evidence on established targeted therapies (eg, anti-angiogenic agents) and emerging combination strategies (eg, with chemotherapy or immune checkpoint inhibitors) for patients with advanced gastric or GEJ cancer, Discuss the clinical implications of recently approved and emerging first-line treatment strategies in the settings of advanced gastric or GEJ cancer that take into consideration the potential impact of treatment selection and sequencing beyond first-line therapy, Implement a tailored approach to treatment selection and sequencing over multiple lines of therapy, based on the latest clinical evidence, current practice guidelines, and patient-, disease-, and treatment-specific factors, for patients with advanced gastric or GEJ cancer, Integrate multidisciplinary, interprofessional, and holistic care strategies that address nutritional needs, emotional and psychological concerns, treatment-related adverse events, the risk of disease progression, and other issues into the management of patients with advanced gastric or GEJ cancer.
Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.
Go online to PeerView.com/CCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the molecular genetics, cytogenetics, and clinical features of myelofibrosis as well as modern prognostic scoring systems, and their potential impacts on clinical decision-making, Explain the current therapeutic role of JAK inhibitors and emerging novel combination therapies in the management of myelofibrosis, Review the latest clinical evidence supporting the use of first- and second-generation JAK inhibitors and other investigational JAK inhibitor-based combinations in the management of myelofibrosis, Develop individualized, safe, risk-adapted treatment protocols for patients with symptomatic or asymptomatic myelofibrosis, including those with high-risk mutations or who fail prior JAK inhibitor therapy.
Go online to PeerView.com/ESW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon completion of this accredited CE activity, participants should be better able to: Identify the clinical signs of AML, relevant prognostic factors, and patient- or disease-related features that influence treatment selection, Discuss efficacy and safety evidence surrounding novel cytotoxic, targeted, and epigenetic therapies for AML, Develop educational strategies for patients with AML related to therapeutic expectations, adherence, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with AML receiving novel cytotoxic, targeted, and epigenetic therapies.
Go online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the global disease burden, etiopathogenesis, risk factors, and stratification scores for cancer-associated VTE using established diagnostic tools, Review safety & efficacy evidence, clinical trial data, and practice guidelines for currently available treatment options for managing cancer-associated VTE, Employ guideline-concordant, evidence-based care and shared decision-making strategies including multidisciplinary and interprofessional collaboration for prevention and treatment of cancer-associated VTE in routine clinical practice.
Go online to PeerView.com/KKH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses a team-based approach to the management of light chain (AL) amyloidosis. Hear from Suzanne Lentzsch, MD, PhD, Mathew S. Maurer, MD, and Margaret Cuomo, MSN, FNP-C, from the Columbia University Medical Center, as they give insights on diagnostic strategies for AL amyloidosis and as they explore treatment guidelines, evidence, and safety concerns of established and novel approaches to managing AL amyloidosis. Upon completion of this accredited CE activity, participants should be better able to: Summarize the distinct clinical features, symptoms, and clinical course of light chain (AL) amyloidosis, Develop team-based diagnostic and assessment strategies that capture relevant symptoms, differentiate AL amyloidosis from other disease subtypes, and characterize disease-related complications in the heart, kidneys, skin, liver, and other organ systems, Discuss current guidelines and evidence supporting established and novel approaches to managing AL amyloidosis and related cardiac or renal dysfunction, Design team-based management plans that safely incorporate novel therapies into the management of patients with AL amyloidosis.
Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.
Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView’s unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.
Go online to PeerView.com/YFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses new evidence from ASCO 2021 on the continuing integration of immunotherapy, targeted agents, and novel therapeutics across a wide range of renal cell carcinoma settings. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.
Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.
Go online to PeerView.com/FJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and a unique myeloprotective agent has become available that can decrease the incidence of chemotherapy-induced myelosuppression in patients with SCLC. These developments have provided new hope to patients with SCLC, but they have also increased the urgency to diagnose and treat SCLC in a timely manner to ensure patients can derive benefits from these therapies. This activity based on a live web broadcast focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases, to illustrate how to integrate the new therapeutic options into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Describe the challenges, disparities, and latest treatment advances that have led to improvements in outcomes in small cell lung cancer (SCLC), Review the latest efficacy, safety, and biomarker data from clinical trials evaluating immune checkpoint inhibition, transcription inhibition, and other novel treatment approaches and combinations in SCLC, Apply best practices for collaboration and coordination of care among the multidisciplinary lung cancer team to optimize diagnosis, assessment, and rapid initiation of treatment, and minimize treatment-related toxicities in all patients with SCLC, Develop individualized treatment plans for patients with SCLC throughout the disease continuum in the context of clinical practice or clinical trial participation.
Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.
Go online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the use of newer cytotoxic strategies, targeted agents, epigenetic modifiers, and antibody-based treatment. Upon completion of this accredited CE activity, participants should be better able to: Describe factors for prognostic assessment and selection of treatment for patients with AML, including a diagnosis of CBF-AML; secondary AML; or AML with intermediate cytogenetics or TP53, FLT3, and/or IDH mutations, Summarize updated clinical evidence surrounding the use of novel cytotoxic, antibody, epigenetic, or targeted strategies, including novel combination strategies, for a range of AML patient populations and treatment settings, including upfront and post-remission therapy or in the management of relapsed/refractory AML, Design a personalized treatment plan for patients with newly diagnosed or relapsed/refractory AML who present with favorable, intermediate, or poor prognostic factors, Develop management protocols for unique adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.
Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.
Go online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma and unresectable, metastatic disease, Summarize evidence on novel applications of immunotherapy in melanoma, including as neoadjuvant therapy, as an adjuvant option for stage II disease, or as part of novel combinatorial approaches, Integrate immunotherapy into the management of patients with resectable and unresectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy across the spectrum of disease.
Go online to PeerView.com/SYN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView Seminar and Tumor Board activity, CLL experts discuss how BTK inhibitors are changing the treatment landscape for patients with CLL. Find out how these experts make treatment choices for upfront and relapsed disease, factoring safety into the decision to use BTK inhibitors and sequencing strategies. These clinical conversations are supported by scientific seminars designed to reinforce the lessons of recent, relevant evidence and by discussions on the integration of BTK inhibitors in a range of CLL patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite the selectivity and safety profiles of first- and second-generation BTK inhibitors available for use in CLL, Discuss safety and efficacy evidence related to the use of BTK inhibitors as single-agent or combination regimens in treatment-naive and relapsed CLL, and in the setting of BTK inhibitor intolerance, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL based on prognostic features, safety profiles, and therapeutic history, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with CLL.
Go online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, AYA, and adult patients. Our experts give insights on standard asparaginase compounds, monitoring and management of toxicities, hypersensitivity/silent inactivation, and sequential use of alternative asparaginase compounds. Upon completion of this accredited CE activity, participants should be better able to: Cite current, multimodal recommendations for acute lymphoblastic leukemia (ALL) management in pediatric, adolescents and young adult (AYA), and adult populations, including multi-agent chemotherapy and asparaginase compounds, antibody-based approaches, cellular therapy, and tyrosine kinase inhibitors, Discuss the clinical implications of Escherichia coli (E. coli) asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations, Summarize evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of chemotherapy for ALL, Apply updated protocols for the management of E. coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.
Go online to PeerView.com/GHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In a new CME- and ABIM MOC-certified program on RCC from PeerView and the Kidney Cancer Research Alliance (KCCure), an expert faculty panel will share how to optimally select and sequence treatment regimens across multiple lines of therapy for patients with advanced RCC, talk about new options for resectable RCC, and discuss clinical trials involving novel therapies. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.
Go online to PeerView.com/TPR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in basal cell carcinoma (BCC) discusses the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures are linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly illustrate how oncologists can adapt their current practice and offer the power of immune-based treatment to patients with BCC. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanistic rationale and potential clinical role of immune checkpoint inhibitors in the treatment of basal cell carcinoma, Summarize clinical evidence on the use of checkpoint inhibitors in patients with locally advanced or metastatic basal cell carcinoma, including in patients progressing on prior therapy, Integrate immunotherapy into the management of patients with basal cell carcinoma in consultation with the wider management team, Recognize the spectrum of immune-related adverse events associated with the use of immunotherapy in the basal cell carcinoma setting.
Go online to PeerView.com/MHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary oncology discusses new and emerging strategies for the management of patients with bladder cancer. Upon completion of this accredited CE activity, participants should be better able to: Review when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations; Summarize key findings from pivotal clinical trials on newer therapies, including immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates, across the spectrum of bladder cancer settings; Consider patient-related factors and preferences in the selection of novel therapeutics for the management of bladder cancer; Integrate appropriate strategies to mitigate and manage unique adverse events associated with new immune-, targeted-, and antibody-based treatments for bladder cancer.
Go online to PeerView.com/WUP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hemophilia explores the evidence supporting novel, emerging hemophilia therapeutics and provides guidance on the implications of the evidence presented for real-world practice. Upon completion of this accredited CE activity, participants should be better able to: Discuss current challenges and new developments in the management of patients with hemophilia A and B, Review the mechanism of action of RNA interference and the role of novel, investigational nonfactor replacement therapies in hemophilia A and B, Evaluate the safety and efficacy profiles and clinical trial data for emerging nonfactor, nongene therapies for treating patients with hemophilia A and B with or without inhibitors.
Go online to PeerView.com/FNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, leading experts explore the benefits and limitations of newer potassium binders, such as patiromer and sodium zirconium cyclosilicate, and share evidence-based strategies for managing hyperkalemia to improve patient outcomes. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of hyperkalemia in patients with HF and/or CKD, Differentiate current agents for the management of hyperkalemia according to their mechanisms of action, Apply current guidelines and best-available evidence to the management of hyperkalemia in patients with HF and/or CKD, Employ evidence-based strategies for care coordination among the multidisciplinary team members to reduce the risk of readmission for hyperkalemia in patients with HF and/or CKD.
Go online to PeerView.com/EQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS annual meeting, our expert panel discusses tactics on how to maximize clinical outcomes for their lower- and higher-risk patients with myelodysplastic syndromes (MDS), with a focus on current and emerging treatment options. Hear practical insights and real-world case discussions and get informed on key safety and efficacy evidence for the treatment of MDS, and hear how an interprofessional-team approach can improve patient care. Upon completion of this accredited CE activity, participants should be better able to: Review clinical presentation, diagnostic-prognostic workups, risk stratification, and identification of transfusion needs of patients with MDS, Interpret recent clinical evidence on currently approved and innovative emerging treatment strategies for managing low-risk as well as high-risk patients with MDS, Develop educational strategies for patients with MDS related to therapeutic expectations, adherence, safety considerations, and differences among novel agent classes, Employ strategies to manage treatment-related adverse events to enhance quality of life for patients with MDS.
Go online to PeerView.com/FXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, medical oncologists discuss the latest advances in managing patients with HER2-positive breast cancer, including an overview of approved and emerging HER2-targeted therapies, and share perspectives on novel targeted therapies and combinations that may improve outcomes in challenging patient subgroups. In addition, practical guidance is offered to help facilitate the integration of the latest HER2-targeted therapies into individualized treatment plans for patients with breast cancer. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the characteristics, mechanisms of action, efficacy/safety profiles, and potential clinical roles of approved and investigational HER2-targeted therapies for metastatic HER2-positive breast cancer, Review the clinical evidence on novel HER2-targeted therapies and combinations that may offer new treatment options to challenging patient subgroups that are unlikely to benefit from currently available HER2-directed therapies (eg, patients with CNS metastases, low HER2 expression), Integrate the latest HER2-targeted therapies into individualized treatment plans for appropriate patients with metastatic HER2-positive breast cancer either in the context of clinical practice or through clinical trial participation.
Go online to PeerView.com/PSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As key members of the interdisciplinary care team, thoracic surgeons play an essential role in collaborating and coordinating with their colleagues from other specialties to assess and manage patients with esophageal/GEJ cancer and determine the most appropriate treatment plans based on new evidence inclusive of local and systemic treatment modalities. Thoracic surgeons must also engage patients in shared decision-making to select appropriate treatment according to stage, tumor characteristics, and patient values and preferences, among other key factors. This activity will provide a comprehensive, practically oriented, multidisciplinary overview on the expanding role of immunotherapy in esophageal and GEJ cancer. The experts discuss essential evidence supporting clinical decisions and offer practical guidance on key clinical issues concerning the continued integration of immunotherapy into individualized management plans for patients with esophageal/GEJ cancer. Upon completion of this accredited CE activity, participants should be better able to: Summarize the biologic rationale for the use of immune checkpoint inhibitors in the multimodal treatment of locally advanced and early-stage esophageal/GEJ cancer, Appraise the latest safety and efficacy evidence and guideline recommendations on the use of immune checkpoint inhibitors in patients with locally advanced or early-stage esophageal/GEJ cancer, Implement a collaborative care model among surgical, medical, and radiation oncology specialists and the greater multidisciplinary team to integrate immunotherapy into multimodal treatment plans for eligible patients with locally advanced or early-stage esophageal/GEJ cancer based on recent evidence, patient- and disease-related factors, and guideline recommendations.
Go online to PeerView.com/RYZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Practicum will provide oncology professionals involved in the care of patients with RCC with a strong understanding of how newer therapeutic regimens, such as immune checkpoint inhibitors and new TKIs, fit within the current management paradigm. They will also be offered tools to help them master practical aspects tied to their use—from management of unique dosing and safety considerations to the development of updated educational and counseling protocols for patients, including education on clinical trial opportunities, which in many cases may represent the best available option for treatment. By adapting their practice to reflect the evidence that supports the use of innovative therapeutic strategies in RCC, oncology professionals can deliver enhanced, more effective care, provide up-to-date education, and effectively address supportive care and safety issues—ultimately culminating in improved patient outcomes. Upon completion of this accredited CE activity, participants should be better able to: Review the latest clinical evidence on recently approved and emerging regimens for the management of renal cell carcinoma (RCC), including immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination approaches, Apply acquired knowledge to provide appropriate patient education and guidance on newer targeted- and immune-therapeutic and novel options in different RCC disease settings, Implement practical strategies and team-based care, including patient education, to monitor for and manage treatment-related toxicities in patients with RCC receiving immune checkpoint and/or tyrosine kinase inhibitors or novel agents.
Go online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inhibitors as neoadjuvant and adjuvant systemic therapies in earlier stages of NSCLC, and promising data have started to emerge, including from the first few phase 3 studies. With the continual expansion of immunotherapy into earlier disease settings, multidisciplinary collaboration among thoracic surgeons, medical oncologists, radiation oncologists, and the greater lung cancer care team is paramount. This PeerView Live Seminar and Practicum based on a recent live web broadcast explores the latest advances and clinical trial findings with immunotherapies, analyzes implications for surgical management of patients, and provides case-based, practical guidance for integrating immunotherapies into multimodal management of stage I-III NSCLC in the context of multidisciplinary care. Upon completion of this accredited CE activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/ZBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert faculty panel focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric acute lymphoblastic leukemia (ALL) therapy by pairing a sample case scenario with a short lecture designed to illustrate the tactics and techniques for addressing hypersensitivity and effectively utilizing available asparaginase options. Upon completion of this accredited CE activity, participants should be better able to: Describe the clinical implications of Escherichia coli asparaginase hypersensitivity and asparaginase discontinuation in pediatric acute lymphoblastic leukemia (ALL), Summarize evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations, as a component of multiagent chemotherapy for pediatric ALL, Develop protocols for the management of E coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/EQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary malignancies discusses novel therapies for bladder cancer. Upon completion of this activity, participants should be better able to: Cite the regulatory status and treatment roles of novel therapeutic classes in the management of urothelial cancer, Summarize updated evidence on the use of novel therapies, including immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates, across the spectrum of bladder cancer settings, Integrate novel therapeutics into management protocols for bladder cancer, including in the context of a clinical trial, Manage unique adverse events associated with novel immune-, targeted, and antibody-based treatments for bladder cancer.
Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView’s experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.
Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.
Go online to PeerView.com/WNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML. Upon completion of this accredited CE activity, participants should be better able to: Identify the diagnostic, prognostic, and therapeutic implications of TP53-mutant AML, Recommend appropriate molecular/pathology testing to establish diagnosis of TP53-mutant AML in order to inform the evidence-based selection of treatment, Summarize evidence on the use of novel antibody and targeted options for the management of TP53-mutant AML.
Go online to PeerView.com/VHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of improved understanding of the genetic mechanisms underlying solid tumors, PARP inhibitors are now validated treatments for patients with ovarian, prostate, breast, and pancreatic cancers. Targeting DNA damage response (DDR) mutations, which have an important role in tumorigenesis, PARP inhibitors are now being studied in other cancers, as well as in combination with immunotherapies and other agents. Approvals of PARP inhibitors have, in some cases, brought with them approvals of companion diagnostics or complementary diagnostic tests. Join a panel of oncology experts for a PeerView MasterClass providing in-depth education on PARP inhibitors, including the rationale for their use, the latest efficacy and safety data in a variety of tumor types, and investigational uses of these agents. Didactic presentations will be supplemented with a practicum session featuring guidance and clinical perspectives on diagnostic testing, dosing considerations, managing AEs associated with PARP inhibitors, and selecting patients for clinical trial enrollment. Upon completion of this accredited CE activity, participants should be better able to: Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including malignancies of the ovaries, prostate, breast, and pancreas, Describe the efficacy and safety profiles of PARP inhibitors and the role of diagnostic testing in guiding patient selection across a range of cancers, Implement appropriate strategies for integrating PARP inhibitors, either through approved indications or clinical trial enrollment, into treatment plans for patients with cancer, Formulate strategies to prevent and/or manage PARP inhibitor–associated AEs.
Go online to PeerView.com/DCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With several available treatment modalities, hepatocellular carcinoma (HCC) requires a multidisciplinary approach that is based on disease stage and patient factors. The role of the interventional radiologist, always vital in managing intermediate-stage disease via locoregional approaches, has become increasingly more important in the treatment of advanced-stage disease, as oncologists, interventional radiologists, and transplant hepatologists work together to improve patient outcomes. Join PeerView’s multidisciplinary team of liver cancer experts for an in-depth analysis of the latest data on approved and emerging systemic treatment options for HCC and recent evidence on locoregional and multimodal approaches in various treatment settings. Through an engaging “tumor board” discussion, the expert panel will draw upon their clinical experience to provide guidance on optimal selection and transition between locoregional and systemic therapies, with a focus on guideline recommendations, underlying liver disease, biomarker information, and other patient-related factors. Upon completion of this activity, participants should be better able to: Describe the safety and efficacy of available systemic treatment options, including multikinase inhibitors, anti-angiogenic agents, and checkpoint inhibitors alone and in combinations, across multiple lines of therapy for patients with advanced HCC, Review the latest evidence and ongoing trials on established and emerging combination approaches (eg, dual immune checkpoint blockade, immunotherapy plus targeted therapy, systemic agents plus locoregional therapy) for patients with intermediate- and advanced-stage HCC, Develop safe and effective multidisciplinary treatment plans for patients with intermediate- and advanced-stage HCC that are based on expert guidance, available evidence, underlying liver disease factors, biomarker information, and recommendations on timely transitions from locoregional to systemic options.
Go online to PeerView.com/FFU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern precision oncology practice relies on detecting molecular alterations that drive specific cancers to target them with matched therapies that yield the best possible outcomes for patients. HER2 alterations are key therapeutic targets in breast cancer, as well as in gastric, colorectal, and non–small cell lung cancers, among other solid tumors. In addition to established HER2-targeted therapies, a number of new agents with unique mechanisms of action have recently received regulatory approval, and further investigations are ongoing. HER3 and TROP2 are also emerging therapeutic targets in several cancers for which novel therapeutics are being developed. This PeerView educational activity based on a recent web broadcast reviews relevant HER2 alterations along with HER3 and TROP2 as targets of interest in different tumors, assesses recent therapeutic advances, and provides practical guidance for optimal testing and interpretation of results to guide therapeutic decisions. Upon completion of this activity, participants should be better able to: Describe HER2, HER3, and other emerging therapeutically targetable alterations relevant in different cancers, and evolving testing approaches to identify these alterations, Discuss the characteristics, mechanisms of action, and clinical evidence on approved and emerging HER2-targeted therapeutic agents for the treatment of patients with HER2-altered solid tumors, as well as available data on emerging therapies targeting HER3 and other novel targets, Implement relevant methods and best practices for predictive testing to facilitate effective integration of the latest HER2-targeted and other promising therapies into personalized management plans for appropriate patients with solid tumors either in the context of clinical practice or clinical trials.
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.
Go online to PeerView.com/KQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with non–small cell lung cancer (NSCLC) is exemplary of precision medicine. Extensive and nuanced genomic profiling of NSCLC is essential to inform individualized treatment plans to optimize patient outcomes. Currently, there are seven different molecular alterations for which FDA-approved targeted therapies are available: EGFR, ALK, ROS1, BRAF V600E, NTRK, MET exon 14, and RET. With the growing complexity of the targeted therapeutic landscape of lung cancer, it is imperative that members of the multidisciplinary care team maintain best practices regarding genomic testing to effectively incorporate targeted therapies into clinical practice. This PeerView educational activity based on a recent web broadcast provides practical guidance for navigating the continuing wave of predictive genomic alterations and related matched therapies, uniting pathologists with oncologists and other multidisciplinary specialists to ensure that patients with genomically altered NSCLC receive appropriate testing and therapy. Upon completion of this activity, participants should be better able to: Discuss the expanding role and increasing importance of broad molecular testing for identifying patients with NSCLC who have therapeutically targetable molecular alterations, Describe the molecular alterations that are clinically relevant and therapeutically targetable in NSCLC, and the latest testing methods for identifying these alterations, Analyze data from clinical trials of precision therapies that target key molecular alterations in NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing to ensure that patients with NSCLC receive the most appropriate therapies in the context of clinical practice or clinical trials.
Go online to PeerView.com/BFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC/CC/NCPD-accredited activity, a hematologist-oncologist, a pathologist, and a physician assistant team up to discuss a collaborative approach to managing their patients with high-risk myeloid cancers, such as acute myeloid leukemia and myelodysplastic syndrome. Hear how Naval Daver, MD, Sanam Loghavi, MD, and Megan Wiese, PA-C, from the MD Anderson Cancer Center, collaborate on diagnosis, treatment decision-making, safety management, and patient education, with the ultimate goal of providing the best care for their patients. Upon completion of this activity, participants will be able to: Discuss the clinical signs and diagnostic principles of high-risk myeloid cancers, including TP53-mutant disease, Summarize current evidence related to the efficacy and safety of novel strategies for the management of high-risk acute myeloid leukemia or myelodysplastic syndromes, Develop team-based diagnostic, treatment, and safety management plans for patients presenting with high-risk myeloid cancers, Apply team-based educational interventions detailing prognostic and therapeutic expectations for patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.
Go online to PeerView.com/KNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading melanoma experts discuss the role of immunotherapy as a standard adjuvant option in stage III/IV—and potentially stage II—disease and the potential of neoadjuvant checkpoint blockade in certain resectable settings (eg, macroscopic stage III disease). Real-world examples of immunotherapy treatment in resectable disease and the foundational and emerging science that continues to inform surgical oncology care are also presented. Upon completion of this activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma, Describe efficacy and safety data surrounding the use of immunotherapy as adjuvant or neoadjuvant therapy in resectable melanoma, including in stage II or stage III macroscopic disease, respectively, Integrate adjuvant or neoadjuvant immunotherapy into the management of patients with resectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.
Go online to PeerView.com/BZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in renal cell carcinoma discusses the latest efficacy and safety data on new treatment approaches, including tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches; applying new clinical trial evidence to the selection and sequencing of combination therapies; and mitigating and managing adverse events related to targeted and immune-based therapies to optimize outcomes. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced renal cell carcinoma (RCC), including tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Apply new clinical trial evidence to the selection and sequencing of combination therapies for individual patients with advanced RCC across lines of therapy, taking into account patient- and disease-related factors, patient values and preferences, and other considerations, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC in order to optimize outcomes.
Go online to PeerView.com/ZEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies and immunotherapy-based combinations have become key components in the cancer treatment arsenal, and testing for predictive biomarkers to refine patient selection is of increasing importance. Assessment of PD-L1 expression plays an essential role in a number of tumor types, determination of MSI/MMR and TMB status has a place in current practice as well, and many other putative biomarkers are undergoing evaluation. To realize the potential of precision immuno-oncology, pathologists and oncologists must come together and establish effective communication and workflows for immunotherapy biomarker testing and interpretation of results to accurately guide clinical decisions. This PeerView educational activity based on a recent web broadcast highlights important recent advances with immune checkpoint inhibitors and combinations in lung, gastrointestinal, and other cancers, and provides practical guidance for implementing biomarker testing in modern pathology and oncology practice. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established and emerging biomarkers and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cut-points, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.
Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.
Go online to PeerView.com/URQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs). Upon completion of this activity, participants will be able to: Explain the role of RWE and the impact it may have on improving care and outcomes in patients with VTE, Assess the quality and validity of the evidence collected as part of real-world studies comparing the DOACs with warfarin in patients with VTE (eg, efficacy, safety, cost-effectiveness, quality of life), Incorporate RWE into clinical decision-making for patients with VTE to design individualized treatment plans, especially for patients who may not be well represented in randomized clinical trials.
Go online to PeerView.com/KXM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, experts in oncology and primary care examine how to best integrate future blood-based cancer screening tools into clinical practice in order to reduce cancer-related morbidity and mortality. Upon completion of this activity, participants should be better able to: Explain the scientific principles behind cfDNA-based liquid biopsy as a tool for early cancer screening, including the strengths and limitations of liquid biopsy compared with those of conventional screening methods, Identify the diagnostic/screening role of novel cfDNA-based screening assays for early cancer detection in the primary care setting, Adapt current cancer screening protocols based on recent evidence on emerging cfDNA-based multicancer screening assays in order to improve sensitivity, specificity, and tumor localization accuracy, Employ patient-centered strategies to integrate novel cancer screening methodologies in the primary care setting, including as part of educational and screening protocols.
Go online to PeerView.com/ZKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.Upon completion of this activity, participants will be able to: Review the scientific principles of liquid biopsy as a tool for cancer diagnosis, including relevant biomarkers, as well as strengths and limitations compared with conventional diagnostic techniques, Describe the role and clinical implications of emerging blood-based diagnostic aids for cancer in secondary and tertiary care settings, Adapt current diagnostic workflows for cancer based on recent evidence on emerging blood-based diagnostic tests in an effort to expedite cancer discovery and subsequent treatment, Apply a patient-centered approach to the diagnosis and transition of care for patients with cancer, including educating patients on potential blood-based testing options.
Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.
Go online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC. Oncologists and other healthcare professionals who manage patients with RCC are being called upon to apply these novel immune and targeted strategies in a patient-centric manner. During this PeerView CME/MOC-certified activity, an expert faculty panel will share the clinical science and current evidence on novel targeted and immunotherapeutic strategies in the upfront and previously treated advanced RCC settings. Upon completion of this activity, participants should be better able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced and/or resectable renal cell carcinoma (RCC), including targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest clinical evidence and relevant patient- and disease-related factors, Apply new clinical trial evidence to the selection and sequencing of novel agents and combination therapies for individual patients with advanced RCC that have progressed after one or more previous lines of therapy, taking into account patient treatment history and comorbidities, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.
Go online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Cite the latest safety and efficacy data on newer therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates and gene therapy across the spectrum of bladder cancer settings, Select novel therapeutics for the management of bladder cancer based on patient-related factors and preferences, Develop appropriate management plans that take into account unique adverse events associated with new immune-, targeted-, and antibody-, and gene therapy-based treatments for bladder cancer.
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/BCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A new, expert-led MasterClass from PeerView and the Us TOO International Prostate Cancer Education & Support Network will provide guidance on individualizing treatment regimens for patients with prostate cancer and will address the latest clinical evidence and guidelines/expert consensus recommendations. The program will also offer information on relevant patient-, tumor-, and treatment-related factors, as well as how to handle patients’ specific needs and preferences. Upon completion of this activity, participants should be better able to: Review recent safety and efficacy data of emerging and available agents across the prostate cancer disease continuum (nmCRPC, mCSPC, mCRPC), including the latest evidence and expert recommendations for selection and sequencing of approved hormonal and chemotherapy options, Outline the latest clinical evidence for appropriate use of novel therapies (eg, PARP inhibitors and immunotherapy) in mCRPC, including monotherapy and combination approaches, Evaluate the latest genetic testing guidelines to better direct treatment decision-making throughout the prostate cancer disease continuum, Develop evidence-based, tailored treatment plans, including the option of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.
Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.
Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decisions, including the timing of HCT, and newer evidence suggests that next-generation JAK inhibitors may also play a role in challenging treatment settings defined by failure of upfront JAK inhibitor therapy. Clinicians therefore should be prepared to develop truly personalized, newer therapeutic strategies for MF management that consider all available options—from targeted agents to supportive care, as well as HCT—and address the role of JAK inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation. In this activity based on a recent live web broadcast, a panel of experts describes the current therapeutic landscape of MF, including JAK inhibitors and HCT. They also review evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in MF. Upon completion of this activity, participants should be better able to: Describe modern diagnostic and prognostic models, as well as molecular and clinical features that are useful for capturing myelofibrosis (MF) presentations, including primary MF and post-PV/ET MF, Review the current therapeutic role of JAK inhibitors and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity transplant, in the management of MF, Cite recent safety and efficacy evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in the management of MF, Integrate modern JAK inhibitor-based regimens into risk-adapted treatment plans for patients with symptomatic MF, including those who are eligible for allogeneic transplantation or as sequential options in the non-HCT setting.
Go online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or ongoing studies. Upon completion of this activity, participants should be better able to: Summarize the benefits and limitations of available immune checkpoint inhibitors and the need for novel immunotherapies and combinations to optimize outcomes for patients with cancer, Discuss investigational immunotherapies and rational combinations that may be able to expand on the current therapies or overcome immune evasion and resistance, Integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or clinical trials.
Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.
Go online to PeerView.com/MSE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts are continuing to refine and expand the role of immunotherapies in SCLC. To make the most of this novel therapeutic approach, it is essential for oncology professionals as well as the broader multidisciplinary team of professionals to keep up with the latest therapeutic advances and collaborate effectively to establish the diagnosis, ensure a rapid initiation of therapy, and appropriately manage potential immune-related adverse events. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. Leading experts provide an engaging educational session on the latest science, best practices, and multidisciplinary implications related to integrating cancer immunotherapies into the management plans for patients with ES-SCLC. Upon completion of this activity, participants will be able to: Describe the epidemiology, clinical features, and current treatment of extensive-stage small cell lung cancer (ES-SCLC), including immunotherapies that can improve long-term outcomes, Examine the latest efficacy, safety, and biomarker data from clinical trials evaluating available and emerging immunotherapies and immune-based combinations for ES-SCLC, Implement optimal strategies for screening, diagnosing, and staging of patients with lung cancer to ensure timely and accurate diagnosis, prompt oncology referral, and rapid treatment initiation for patients with ES-SCLC, Apply best practices for collaboration and coordination of care with oncologists and other members of the multidisciplinary lung cancer team to provide optimal care to patients with ES-SCLC, including the integration of immunotherapies into treatment plans and recognition/management of irAEs, and improve outcomes.
Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovative treatment options—including CAR-T cell therapy, proteasome inhibitors, immunomodulators, and antibodies such as, CD38 antibodies, BCMA-targeting antibody-drug conjugates, and bispecific antibodies—can substantially improve outcomes. These improvements have been observed across the continuum of care, from primary therapy to the management of relapsed/refractory disease (post-ASCT), as well as in the setting of minimal residual disease eradication. Hear our expert panel as they highlight these improvements and discuss the integration of approved and emerging novel therapies in MM. Upon completion of this activity, participants should be better able to: List current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in various multiple myeloma treatment settings, Describe efficacy and safety data surrounding novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new targeted agent classes in the management of ASCT-eligible patients with multiple myeloma, Develop regimens with novel components for ASCT-eligible patients with multiple myeloma, including as induction/consolidation or maintenance therapy, or in the setting of early relapse or refractory myeloma.
Go online to PeerView.com/XXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a biliary cancer expert discusses the latest data on targeted treatments for biliary cancers and gives guidance on integrating precision medicine with new and emerging strategies. Upon completion of this activity, participants should be better able to: Describe the scientific rationale for therapeutic targeting in biliary cancers, including mechanisms involved with FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Evaluate the latest clinical evidence of newly validated and emerging therapeutic strategies, such as FGFR, IDH, TRK, multikinase, HER2, and checkpoint inhibitors, in patients with advanced biliary cancers, Review ongoing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, that are recruiting patients with biliary cancers, Develop tailored treatment plans for patients with advanced biliary cancer, utilizing molecular testing and established and emerging targeted therapeutic strategies based on individual tumor characteristics.
Go online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.
Go online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice. Upon completion of this activity, participants should be better able to: Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers, Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers, Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers, Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers.
Go online to PeerView.com/JCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in small cell lung cancer provides an overview of the features and challenges associated with the condition, as well as the current treatment landscape. Upon completion of this activity, participants should be better able to: Describe the current recommendations for diagnosis, staging, and appropriate evaluation of patients with SCLC throughout the disease course, Characterize the mechanisms of action and rationale for use of new/emerging therapies, including novel transcription inhibitors, for SCLC, Analyze the efficacy and safety data from the latest clinical trials evaluating standard, new, and emerging systemic therapies for SCLC, Integrate latest therapies into individualized treatment plans for appropriate patients with SCLC in the setting of clinical practice or clinical trial participation.
Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.
Go online to PeerView.com/CWE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in thoracic oncology and pathology discuss the latest advances in the management of patients with EGFR-mutated NSCLC, including foundational knowledge of oncogenic drivers, such as EGFR mutations, best practice guidance for molecular testing in advanced and early-stage NSCLC, new therapeutic options, and optimal multidisciplinary collaboration to identify actionable targets and individualize treatment to improve outcomes in patients with NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Discuss the latest recommendations and best practices for molecular testing in lung cancer, including the use of tissue- and blood-based testing, for detection of common and less common EGFR mutations in advanced NSCLC as well as the emerging role of EGFR testing in early-stage NSCLC, Describe the established, new, and investigational options for treatment of EGFR-mutated NSCLC, Implement current guidelines, best practices, and multidisciplinary strategies for molecular testing to identify EGFR mutations and other actionable targets and individualize treatment selection throughout the NSCLC disease continuum.
Go online to PeerView.com/MHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in anticoagulation and bleeding mitigation discuss evidence-based strategies for safe reversal of direct oral anticoagulant (DOAC) therapy.Upon completion of this activity, participants should be better able to: Review current guidance regarding appropriate and safe reversal of DOACs, Explain the mechanisms of action of current and emerging DOAC reversal agents and universal antidotes to factor Xa inhibitors, Critically evaluate recent clinical evidence regarding the efficacy and safety data pertaining to the use of current and emerging DOAC reversal agents.
Go online to PeerView.com/ZAW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) are a group of clonal myeloid neoplasms characterized by reduced and/or defective production of red blood cells, platelets, and mature granulocytes, often resulting in anemia, bleeding, increased risk of infection, and risk of transformation to AML. For many years, supportive therapy, blood transfusion, erythropoiesis-stimulating agents, and treatment of infections were the only therapies available. Subsequently, DNA methyltransferase inhibitors and immunomodulators showed survival benefits in MDS, leading to additional research on the efficacy of novel erythroid maturation agents in the setting of MDS-related anemia. Currently, multiple innovative therapies—including multikinase inhibitors, NEDD8-activating enzyme inhibitors, isocitrate dehydrogenase 1/2 inhibitors, BCL-2 inhibitors, and CD47 antibodies—are being investigated to improve care across different MDS populations, including low-, intermediate-, or high-risk patients, elderly individuals with comorbid conditions, and those ineligible for intensive treatment. At a recent CME web broadcast, an expert panel discussed the diagnosis and management of MDS. The panelists reviewed innovative treatment strategies, prognostic scoring systems for risk stratification, and how hematologist-oncologists can recommend appropriate therapeutic options for patients with MDS. Upon completion of this activity, participants should be better able to: Recognize the pathophysiology, clinical features, and modern prognostic scoring system for risk stratification in myelodysplastic syndromes (MDS), Identify mechanisms of action and safety-efficacy data of currently available and novel investigational agents in the settings of low-, intermediate-, and high-risk groups as well as MDS with adverse or targetable genetic features, Select risk-adapted therapeutic strategies for patients with MDS, based on the prognostic scoring systems and baseline factors such as patient age and comorbid conditions, Develop individualized treatment plans based on the potential use of novel and emerging combination therapies for managing high-risk MDS with targetable genetic mutations.
Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.
Go online to PeerView.com/QUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologists, oncologists, and a patient advocate discuss compelling, real-world case scenarios and the practice-changing evidence that continues to support the increasing role of novel therapeutics in CLL. This event also explores the future of CLL care and illustrates how novel combinations and cellular therapy may lead to deep, durable, and minimal residual disease-negative responses. Upon completion of this activity, participants should be better able to: Cite genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence and practice guideline recommendations related to the use of novel therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel components for patients with treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with the use of novel therapies in patients with CLL, Educate patients with CLL about treatment expectations, unique toxicity profiles, and dosing/adherence considerations with novel therapeutics.
Go online to PeerView.com/FSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As precision medicine has taken a varying course in the setting of hematologic cancers, safely integrating effective, novel therapeutics into the management of patients whose cancers express markers such as CD30 and CD123 is more important than ever. In this activity, our experts discuss the diagnostic and treatment implications of these markers in various hematologic disease settings and use workshop-style educational segments with patient cases and clinical scenarios to illustrate the medical benefits of precision medicine for hematologic cancers defined by CD30 and CD123 expressions. Upon completion of this activity, participants should be better able to: Describe the significance of CD30 and CD123 in a range of hematologic cancers, including implications for diagnosis, immunophenotypic/molecular testing, and prognosis, Cite current efficacy and safety evidence on the use of novel therapeutics in CD30-expressing lymphoma, including in patients with newly diagnosed or relapsed disease, Discuss current evidence on the use of CD123-targeting agents in a range of hematologic cancers characterized by CD123 expression, Integrate novel therapeutics into the management of patients with newly diagnosed or relapsed/refractory Hodgkin or T-cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, and chronic myelomonocytic leukemia, Manage safety considerations associated with the use of novel therapeutics in patients with CD30- or CD123-expressing malignancies.
Go online to PeerView.com/QAT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in urologic oncology discusses hormonal therapy in prostate cancer. Upon completion of this activity, participants should be better able to: Summarize the recent safety and efficacy data on novel hormonal therapy for metastatic castration-sensitive prostate cancer (mCSPC), as well as for other prostate cancer settings including castration-resistant (nmCRPC and mCRPC) disease, Counsel patients on current hormonal therapy standards for personalized management of prostate cancer, including for treatment selection based on disease progression, prior therapy, and patient characteristics, Design individualized, evidence-based treatment plans for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors, Manage the spectrum of adverse events associated with novel hormonal therapies in patients with prostate cancer.
Go online to PeerView.com/KTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in managing patients with thyroid cancer discusses the scientific background and rationale for molecular testing and targeted treatment of RET fusion/mutation–positive thyroid cancers, new data on novel targeted approaches, the importance of multidisciplinary collaboration, and how to effectively communicate with patients to promote shared decision-making and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the heterogeneity of thyroid cancers and the rationale for integrating molecular testing into practice to inform treatment decisions, Discuss the evolving evidence on molecular testing for RET fusions/mutations in thyroid cancer and best practices for its use to guide therapy selection, Evaluate clinical trial data on novel, targeted therapies for patients with thyroid cancers that harbor genomic abnormalities, such as RET fusions/mutations, Implement collaborative strategies among endocrinologists, pathologists, and oncologists to ensure widespread genomic testing to identify appropriate patients for RET-targeted therapy in the context of clinical practice or clinical trials, Communicate effectively with patients with thyroid cancer to address their concerns and questions about their disease, treatment options, and prognosis and promote shared decision-making.
Go online to PeerView.com/DMW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts, an oncologist and ophthalmologist, discuss the intricacies of ocular toxicities associated with multiple myeloma and explore the importance of collaborating when managing patients who are being treated with novel therapeutics. Upon completion of this activity, participants should be better able to: Identify ocular complications associated with the use of novel therapeutic options in the myeloma treatment setting, Utilize management tools such as dry eye prophylaxis, routine eye examinations, and therapeutic dose adjustment to address ocular toxicity in patients with myeloma, Develop strategies for oncology-ophthalmology collaboration in monitoring for and managing ocular toxicity in myeloma patients.
Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.
Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.
Go online to PeerView.com/JZZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an infectious diseases specialist provides guidance on improving the diagnosis and treatment of invasive fungal infections. Upon completion of this activity, participants will be able to: Describe the epidemiology and risk factors for invasive fungal infections in patients who are immunocompromised and/or immunosuppressed, Promptly evaluate high-risk patients with signs or symptoms that are suggestive of systemic fungal infection to mitigate the impact of delayed recognition and initiation of antifungal therapy, Discuss available diagnostic tests and emerging technologies to ensure early detection of invasive fungal infections, Outline the role of antifungal susceptibility testing in guiding therapeutic decision-making for invasive fungal infections, Optimize the efficacy, tolerability, and cost-effectiveness of antifungal therapy in individual patients with invasive fungal infections through targeted application of kinetic and dynamic principles.
Go online to PeerView.com/PFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, cardiologists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with or at risk for NVAF. Upon completion of this activity, participants should be better able to: Employ various evidence-based screening methods to identify patients with undiagnosed NVAF, Engage in shared decision-making with patients with NVAF about the benefits and limitations of anticoagulant therapies to reduce the risk of stroke in the context of anticoagulation stewardship.
Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.
Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this activity, participants should be better able to: Discuss current practice guidelines illustrating the role of antibody therapy in the management of newly diagnosed or relapsed/refractory ALL, including in Ph-negative or -positive disease, as a pretransplant strategy, or in patients with residual disease, Cite current evidence surrounding innovative antibody-based approaches, including antibody–drug conjugates and bispecific antibodies, in the management of ALL, Select evidence-based regimens with antibody components for the management of patients with ALL, Manage safety considerations related to the use of antibody therapy in patients with Ph-negative or -positive ALL.
Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to: Describe the prevalence of ID in patients with HF and its impact on patient outcomes and quality of life, Interpret laboratory results for diagnosing and monitoring iron status in patients with HF, Apply current clinical guidelines and clinical trial results for iron therapies to improve outcomes in patients with ID and HF.
Go online to PeerView.com/NDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts provides effective and practical guidance on strategies and techniques for triaging, diagnosing, monitoring, and managing patients who present to the emergency department with immune-related adverse events, as well as special considerations for optimizing the management of oncologic emergencies during the COVID-19 pandemic. Upon completion of this activity, participants will be able to: Interpret the underlying principles of leveraging the immune system in the treatment of cancer and the profiles of immune checkpoint inhibitors, including their characteristics, mechanistic aspects, and regulatory status, Review the biologic reasons and mechanisms that drive the development of immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Describe the spectrum of irAEs associated with the immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency medicine (EM) professionals in the emergency department (ED), Provide an overview of overarching and organ/site-specific recommendations for the identification, assessment, diagnosis/differential diagnosis, and management of irAEs in EM settings, Integrate recommended approaches to triage, evaluation, diagnosis, and management of pertinent irAEs in the ED in collaboration with oncology professionals.
Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and symptoms of localized and diffuse TGCT, including recurrent disease, Summarize the range of challenging clinical presentations of TGCT, including settings in which surgical resection is likely not a therapeutic option, Develop strategies for accurate diagnostic assessment of TGCT, including for localized and diffuse disease, Select patient-appropriate multimodal management strategies for TGCT in collaboration with the multidisciplinary team.
Go online to PeerView.com/CWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of hepatocellular carcinoma (HCC) is in the midst of a therapeutic paradigm shift. Partial hepatectomy, liver transplantation, ablation, radiation therapy, and embolization procedures remain important interventions for localized HCC, whereas sorafenib, a multikinase inhibitor, was the cornerstone of therapy for patients with extrahepatic disease. Recently, several single and combination agents (eg, atezolizumab with bevacizumab, cabozantinib, lenvatinib, nivolumab with and without ipilimumab, pembrolizumab, ramucirumab, regorafenib) have been approved and validated for treating patients with advanced HCC. Moreover, several emerging trials (eg, CheckMate -9DW, HIMALAYA, LEAP-002, and COSMIC-312) indicate that therapeutic advances for this malignancy are increasingly centered around exploiting the benefits of combination regimens with immunotherapy, as well as investigating innovative strategies such as adjuvant immunotherapy, tumor-treating fields, and combinations of systemic agents with locoregional therapies like TACE and TARE. This MasterClass and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each Tumor Board discussion will feature reflective case-centered discussion on the increasingly important role that hepatology professionals play for patients across the HCC continuum. This activity features an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients. Upon completion of this activity, participants should be better able to: Review the key clinical evidence on available systemic treatments, including multikinase, immune checkpoint, and anti-angiogenic inhibitors, for advanced HCC, Assess available and emerging combination strategies, such as targeted therapies with immunotherapy, dual checkpoint inhibition, and systemic agents with locoregional modalities across the disease spectrum of HCC, Develop personalized therapeutic plans in the first and subsequent lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the optimal management of patients with HCC, including those along the intermediate-to-advanced stage disease continuum.
Go online to PeerView.com/QRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel targeted, immune-based, and tyrosine kinase inhibitors (TKIs) to the treatment armamentarium. Most recently, these advances have included the validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents (which have led to FDA approvals). Oncology professionals are increasingly challenged to adopt a more nuanced and personalized approach to selecting and sequencing the available treatment options throughout the advanced RCC continuum while taking relevant patient-, disease-, and treatment-related factors into account. During this PeerView Live CME/MOC-certified web broadcast, an expert faculty panel in RCC will share insights on recent clinical trends and how to effectively navigate a complex therapeutic landscape to leverage the potency of newer agents across different disease settings. Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence on the use of multi-targeted tyrosine kinase inhibitors/anti-VEGF agents, immune checkpoint inhibitors, and novel combination approaches in the management of advanced and/or resectable renal cell carcinoma (RCC), Select individualized frontline treatment regimens utilizing targeted and immune-based options for patients with advanced RCC based on relevant patient- and disease-related characteristics, Develop regimens with novel components for patients with pretreated advanced RCC over multiple lines of therapy based on consideration of prior treatment history and patient comorbidities, Manage treatment-related complications with targeted agents and immunotherapy in patients with RCC.
Go online to PeerView.com/MER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Our understanding of the pathogenesis of GISTs was revolutionized by the discovery of KIT and PDGFRα mutations, which provided a diagnostic criteria and expanded treatment options. Tyrosine kinase inhibitors (TKIs), imatinib, sunitinib, and regorafenib are the recommended first three lines of therapy for most patients; however, tumor responses remain suboptimal, in part, because of resistance mutations associated with TKI therapy. With the goal to overcome treatment resistance and prolong life, research on modern TKIs has led to the approvals of avapritinib and ripretinib. Modern TKIs are also transforming the therapeutic algorithm for patients with unresectable/metastatic GISTs. In this video-based activity, leading experts on GISTs will dive into the pathobiology of this malignancy and discuss the latest data for newly approved and emerging agents to offer guidance on adopting modern targeted strategies to improve outcomes across multiple lines of therapy. Case vignettes and patient stories will help illustrate the practical aspects of multidisciplinary care throughout the treatment journey. Upon completion of this activity, participants should be better able to: Describe the pathobiology, including recurrence patterns and molecular/mutational features, of unresectable/metastatic GIST, Assess emerging and newly validated evidence on targeted TKI options for patients with GIST along multiple lines of treatment, Develop safe and effective therapeutic algorithms with modern TKIs based on molecular status, prior treatment history, and patient-centered factors, Plan management strategies associated with the use of modern TKIs in the GIST setting.
Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.
Go online to PeerView.com/QQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PARP inhibitors have transformed the treatment of multiple cancers in recent years. Indeed, many agents have yielded promising clinical data and received regulatory approval for a number of solid tumors, providing newer alternatives for cancer patients, especially those with limited therapeutic options. Key clinical aspects associated with maximizing the potential of PARP inhibitors in cancer care include application of recommended testing strategies to guide patient selection, individualized treatment planning, and management of treatment-related toxicities. In this web broadcast, oncology and pharmacy experts review the latest evidence on the use of PARP inhibitors in the treatment of different tumors, including breast, ovarian, pancreatic, and prostate cancers, as well as oncology value assessment frameworks and strategies for assessing the benefits, risks, and costs to guide decisions regarding the use of this class of agents. Additionally, practical guidance is provided for optimizing outcomes for cancer patients who may benefit from PARP inhibitor therapy in managed care settings. Upon completion of this activity, participants should be better able to: Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including ovarian, breast, pancreatic, prostate, and other malignancies, Assess the PARP inhibitors in terms of their mechanisms of action, efficacy and safety profiles, requirements for predictive testing to guide patient selection, nuances of administration and use, and other factors relevant to their value assessment in managed care settings, Implement appropriate decisions regarding the integration and use of PARP inhibitors in cancer care in managed care settings based on balanced assessments of all the evidence and unique characteristics of this class of agents.
Go online to PeerView.com/QBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC-accredited video activity, Josep Tabernero, MD, PhD, gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer. Hear about recent data presented on gastric cancer and how precision medicine may improve gastric cancer patient care. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.
Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.
Go online to PeerView.com/PDK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care. Upon completion of this activity, participants should be better able to: Identify specific molecular and histopathologic features that can inform the diagnosis of different AML subtypes, including secondary AML/AML-MRC or FLT3- or IDH-mutant AML, Select appropriate evidence-based molecular/pathology tests to confirm a diagnosis of AML, Develop molecular testing strategies to collect relevant information over the course of the AML treatment continuum, Recommend appropriate, safe management options for patients with diverse AML subtypes in collaboration with the wider oncology management team.
Go online to PeerView.com/ZJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologist-oncologists offers guidance on best practices for integrating Bruton’s tyrosine kinase (BTK) inhibitor options into chronic lymphocytic leukemia (CLL) treatment by presenting real-world clinical scenarios designed to illustrate cutting-edge treatment selection and sequencing strategies across the spectrum of CLL care, from treatment-naïve to relapsed disease. Upon completion of this activity, participants should be better able to: Discuss the implications of mechanistic and selectivity differences among first- and second-generation BTK inhibitors in the context of CLL care, Summarize updated clinical evidence and practice guideline recommendations for the use of BTK inhibitors in treatment-naïve and relapsed CLL, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, or in patients unable to tolerate BTK inhibitor therapy, Develop a management plan to address unique adverse events associated with the use of BTK inhibitors in patients with CLL.
Go online to PeerView.com/JAR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management of solid tumors. This activity will feature a review of the cutting-edge advancements in cancer devices, as well as expert insights and case discussions on the appropriate care strategies for patients being treated with new modalities like TTFields therapy. And, the interdisciplinary panel of experts will review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, NSCLC, pancreatic cancer, and other GU and GI tumors. Upon completion of this activity, participants will be able to: Describe the mechanism of action and rationale for novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Review key safety and efficacy evidence on innovative and emerging multimodal strategies for the treatment of GBM, MPM, and other solid tumors, Apply team-based strategies to minimize and manage the unique AEs associated with novel therapeutic platforms, such as TTFields therapy, for solid tumors, Provide guidance to patients on new cancer treatment modalities, such as TTFields therapy, to improve adherence and optimize cancer treatment outcomes.
Go online to PeerView.com/BUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView “How I Think, How I Treat” CME video activity, multiple myeloma (MM) experts explore the era of antibody-based therapy and the implications of new science for treatment decisions from early disease settings through the management of relapsed/refractory MM. By sharing their personal insights and intra-institutional experiences, and combining these reflections with in-depth analysis of recent evidence on anti-CD38, SLAMF7, and BCMA-targeting antibodies, Drs. Sagar Lonial and Robert Z. Orlowski recommend ways to improve clinical outcomes related to the integration of antibody therapy into modern MM management. Don’t miss this opportunity to get informed on the unique anticancer mechanisms of antibody-based therapy, as well as the safety and efficacy evidence supporting its use across the wide spectrum of MM presentations. Upon completion of this activity, participants should be better able to: Summarize the therapeutic targets and mechanisms associated with novel antibodies in multiple myeloma, including CD38, SLAMF7, and BCMA, among others, Discuss current efficacy and safety evidence surrounding the use of novel and next-generation antibodies in patients with newly diagnosed or relapsed/refractory multiple myeloma, Develop personalized treatment regimens with novel antibody components for patients with newly diagnosed or relapsed/refractory multiple myeloma, Manage practical considerations related to the use of antibody-based regimens in multiple myeloma, including unique adverse events, dosing considerations, and interference with blood compatibility testing, among others.
Go online to PeerView.com/BYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity Professor David I. Marks, Farhad Ravandi, MD, and Matthias Stelljes, MD, give insights on the evidence behind the emergence of antibody therapy and its use in conjunction with HSCT in AML and ALL. These scientific MasterClass sessions are paired with a case-centered segment that illustrates therapeutic nuances such as the identification of transplant-eligible patients who may benefit from antibody-enhanced treatment protocols and the management of safety considerations unique to the use of antibodies in HSCT populations. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction/consolidation, pretransplant conditioning, or other roles in conjunction with transplant in the acute leukemia setting, Summarize updated evidence surrounding innovative antibody-based approaches to induction/consolidation, conditioning, or post-HSCT therapy in patients with AML or ALL, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HSCT for patients with AML or ALL, Manage safety considerations related to the use of antibody therapy in transplant-eligible populations with acute leukemia.
Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/JBC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy has become a new pillar in the treatment arsenal for advanced triple-negative breast cancer (TNBC), and accumulating evidence is supporting its expansion into earlier disease stages as well. To make the most of this therapeutic approach as a component of multimodal management of patients, especially in curative intent settings, it is increasingly important for breast surgeons, medical oncologists, radiation oncologists, pathologists, and other healthcare professionals to collaborate and coordinate the care of patients with TNBC. This educational on-demand activity based on a recent live web broadcast provides up-to-date information and multidisciplinary perspectives on the current and emerging roles of immune checkpoint inhibitors and combinations throughout the disease continuum of TNBC, as well as practical guidance for optimal integration of these therapies into clinical practice, focusing on the most important implications for breast surgeons. Upon completion of this activity, participants will be able to: Discuss the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC), including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies that may enhance immunogenicity and improve outcomes, Assess the efficacy, safety, biomarker, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including early-stage (neoadjuvant/adjuvant settings) and advanced/metastatic disease, Incorporate immunotherapies into treatment plans for patients with TNBC based on the latest evidence, indications, recommendations, disease stage/treatment setting, patient and tumor characteristics, and other relevant factors in the context of effective multidisciplinary collaboration.
Go online to PeerView.com/GKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapies are addressing a big unmet need in triple-negative breast cancer (TNBC) due to limited treatment options, the aggressive nature of the disease, and poor patient outcomes. This PeerView Live MasterClass and Practicum provides a comprehensive overview of the evolving role of immune checkpoint inhibitors in TNBC, specifically directed to surgeons. Experts explain the biologic rationale for the use of cancer immunotherapies in TNBC and explore the clinical evidence supporting their use in advanced/metastatic TNBC, as well as neoadjuvant/adjuvant settings of early-stage TNBC. Additionally, the faculty provides guidance on the practicalities of patient/tumor evaluation and candidate selection for immunotherapies, including their use in the context of other treatment modalities, and detection and management of immune-related adverse events. Strategies for effective collaboration and coordination of care among surgeons, oncologists, and other specialists in the era of immuno-oncology are also shared. Upon completion of this activity, participants should be better able to: Review the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC), including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies that may enhance immunogenicity and improve outcomes, Evaluate the efficacy, safety, biomarker, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including early-stage (neoadjuvant/adjuvant settings) and advanced/metastatic disease, Integrate immunotherapies into treatment plans for patients with TNBC based on the latest evidence, indications, recommendations, disease stage/treatment setting, patient and tumor characteristics, and other relevant factors in the context of effective multidisciplinary collaboration.
Go online to PeerView.com/JTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts review the latest findings from randomized clinical trials as well as real-world studies assessing CDK 4/6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer, and discuss the complementary nature of clinical and real-world research and how data from both sources add to the body of evidence on this therapeutic class that helps inform clinical practice. Upon completion of this activity, participants should be better able to: Discuss real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in metastatic breast cancer, Establish best practices for analyzing and interpreting real-world data in addition to data collected from clinical trials related to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design, validity, data sources, and implications for everyday oncology practice, Implement appropriate clinical decisions regarding the selection and use of CDK 4/6 inhibitors in the treatment of patients with metastatic breast cancer informed by the latest real-world and clinical trial evidence.
Go online to PeerView.com/CEV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the use of extended half-life replacement factor VIII products for the treatment of patients with hemophilia A. Upon completion of this activity, participants will be able to: Describe the benefits and limitations of conventional replacement factor VIII regimens for the management of hemophilia A, Assess the latest clinical data regarding efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A, Incorporate extended half-life replacement FVIII regimens into the management of patients with hemophilia A, Discuss the importance of a collaborative approach among physicians, pharmacists, and other clinicians in the management of patients with hemophilia A.
Go online to PeerView.com/BUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss therapeutic innovations in a range of B-cell cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), and how community-based professionals can address the challenges of an increasingly complex B-cell cancer treatment landscape. The panel shares a series of practical insights on the continued validation and emergence of targeted therapy (such as BTK, BCL-2, PI3K, and EZH2 inhibitors) and other innovative options in diseases as diverse as CLL, MCL, FL, and DLBCL. Upon completion of this activity, participants should be better able to: Summarize the current treatment role of targeted therapies and other innovative agents across a range of B-cell cancer settings and patient populations, Cite updated safety and efficacy evidence on novel therapeutics, including single-agent and combination regimens, in patients with cancers such as CLL, FL, MCL, and DLBCL, Select personalized therapy with novel therapeutics for patients with treatment-naïve or relapsed/refractory B-cell cancers, Develop appropriate adverse event management strategies for patients with B-cell cancers who are experiencing toxicity while on therapy with newer therapeutics.
Go online to PeerView.com/NUB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in melanoma explore evidence and practical lessons from major studies of adjuvant immunotherapy in melanoma, and provide insights on the future of immune checkpoint blockade in resectable disease. The panel also discusses real-world cases that illustrate how surgeons and oncologists can work together to identify ideal candidates for checkpoint inhibitor therapy and safely integrate immunotherapy into the surgical management of melanoma. Upon completion of this activity, participants should be better able to: Cite current guideline recommendations for the use of adjuvant immunotherapy in resectable melanoma, Summarize updated efficacy findings on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable melanoma, including high-risk stage III disease, Integrate adjuvant immunotherapy into treatment protocols for eligible patients with resectable stage III melanoma, Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection.
Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView in collaboration with Let’s Win, an affiliate of the Lustgarten Foundation, will focus on effective management strategies with novel chemotherapy platforms, personalizing care with PARP and checkpoint inhibitors, and preparing for emerging multimodal approaches, such as tumor-treating fields (TTFields) therapy. Pancreatic cancer nurse expert, Gayle Jameson, will provide practical guidance on recognizing and managing adverse events associated with established and emerging treatments, counseling patients and their families on personalizing treatment plans, and addressing issues related to clinical trial enrollment. Upon completion of this activity, participants will be able to: Review the latest efficacy and safety data on available and emerging treatments for pancreatic cancer, including novel chemotherapy platforms, PARP inhibitors, targeted agents directed against molecular features/mutations, among others, Counsel patients on the clinical and potential use of novel treatments for pancreatic cancer, such as chemotherapy platforms for the metastatic setting, PARP inhibitors for the front-line maintenance setting, and the option of enrolling in clinical trials, Plan effective strategies to manage adverse events associated with established and emerging therapies for pancreatic cancer.
Go online to PeerView.com/TZV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology nurse experts discuss evidence on the safety and efficacy of novel therapeutics for the treatment of acute myeloid leukemia (AML) and, using a series of case scenarios, provide guidance on how to integrate innovative treatment options into the care of different AML populations. Upon completion of this activity, participants will be able to: Cite updated evidence about the efficacy and safety of newer cytotoxic, targeted, and epigenetic strategies for the management of AML, Manage safety considerations in patients with AML who are receiving novel cytotoxic or targeted therapeutics, Address psychosocial, longer-term care, dosing, and adherence considerations in patients with AML who are receiving novel therapeutics, Educate patients about the clinical benefits of novel therapies, relevant prognostic factors, and potential safety issues associated with newly approved treatments for AML.
Go online to PeerView.com/QUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss available and emerging therapeutic approaches for the treatment of patients with hemophilia, as well as current guidelines and treatment protocols for patients with hemophilia presenting to the emergency department. Upon completion of this activity, participants will be able to: Assess current data on available and emerging therapeutic approaches for the treatment of patients with hemophilia, Apply current guidelines for the management of patients with hemophilia in the emergency department, Develop treatment protocols for suspected bleeding episodes in patients with hemophilia who present to the emergency department that incorporate shared decision-making.
Go online to PeerView.com/MWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in thoracic oncology discuss the latest options for treatment of EGFR-mutated advanced NSCLC, including the rationale for and evidence supporting dual targeting of VEGF and EGFR pathways as well as the role of the first FDA approved combination of VEGF and EGFR inhibitors for newly diagnosed patients. Additionally, the experts explore the nuances and practicalities of individualized treatment selection and sequencing throughout the continuum of advanced disease to maximally extend the benefits patients with EGFR-mutated NSCLC can derive from targeted therapies. Upon completion of this activity, participants will be able to: Discuss the current understanding of the underlying biology of EGFR mutations in NSCLC, including exon 19 and 21 mutations, and mechanisms of acquired resistance, such as T790M, and their implications for treatment selection in first-line and later lines of therapy in advanced EGFR mutation–positive NSCLC, Assess the mechanistic rationale for targeting the VEGFR and EGFR pathways through combination therapy, Cite updated evidence on validated treatment options and emerging evidence on the use of novel regimens in the management of EGFR-mutated NSCLC, including newer antiangiogenic and TKI combinations or agents, Implement evidence-based, individualized, precision treatment plans for patients with advanced EGFR-mutant NSCLC, including for those patients who acquire resistance on prior lines of treatment.
Go online to PeerView.com/VJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts explore the potential of the next wave of novel HER2-targeting therapies in various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. Watch as the panel share their insights into the data that support therapeutic targeting of HER2 and consider other critical research questions and future directions. Upon completion of this activity, participants should be better able to: Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, and non–small cell lung cancers, Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or ERBB2-mutant cancers, Identify novel approaches to overcome mechanisms of resistance to HER2-targeted therapies, Integrate the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or ERBB2-mutant breast, gastric, colorectal, and non–small cell lung cancers, either in the context of clinical practice or through clinical trial participation.
Go online to PeerView.com/PHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of triple-negative breast cancer (TNBC) has remained challenging for many years, with limited effective options and poor outcomes for most patients. But the tide is turning, as new therapies are emerging for this patient population, with immunotherapy representing a new pillar of care in the treatment of TNBC. TNBC is known to be more immunogenic compared with other breast cancer subtypes, and thus, immunotherapy has been and continues to be extensively explored in TNBC. Clinical trials have started to show promising results in both advanced and early-stage TNBC; the first combination of an immune checkpoint inhibitor and chemotherapy has been approved by the FDA for the first-line treatment of PD-L1+ TNBC, and it is likely that the treatment landscape will continue to expand. In this educational on-demand activity based on a recent live web broadcast, a panel of leading experts discusses the current and emerging roles of immunotherapy in TNBC as well as the clinical trial data assessing immunotherapies and immune-based combinations throughout the continuum of TNBC. The practical nuances of patient selection, treatment integration, biomarker testing, and immune-related adverse event management are also explored. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.
Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.
Go online to PeerView.com/KFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Dr. Heather McArthur provides a brief recap of how the emergence of checkpoint inhibitor therapy in TNBC has changed the management of this challenging subtype of breast cancer, and what some of the unanswered questions and controversies are that ongoing research is aiming to answer. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.
Go online to PeerView.com/MMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody–drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.
Go online to PeerView.com/QYX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of PARP inhibitors and precise selection of patients using companion diagnostics have improved outcomes for patients with advanced ovarian cancer and provided new opportunities for oncologists to individualize care. In this activity, based on a recent live webcast, a panel of leading experts discuss the rationale behind the use of PARP inhibition in ovarian cancer and how these agents and their companion diagnostics can be used in clinical practice in a variety of settings. Using case vignettes, the experts address real-world applications of the latest research, including how to prevent and manage adverse events associated with the use of PARP inhibitors and determine which patients may benefit from enrollment in clinical trials testing these agents alone or in combination with other treatments. Upon completion of this activity, participants should be better able to: Review the rationale of PARP inhibitors targeting DNA repair pathway mutations as well as their validated clinical evidence in ovarian cancer, Employ PARP inhibitor therapy and their companion diagnostics, when appropriate, for patients with ovarian cancer in frontline maintenance, pretreated platinum-sensitive, pretreated platinum-refractory, and other settings, Plan strategies to prevent and/or manage the PARP inhibitor-associated adverse events, particularly in long-term use (eg, maintenance settings), in patients with ovarian cancer, Identify patients eligible for enrollment into clinical trials testing PARP inhibitors, including as combination approaches, in different treatment settings for ovarian cancer.
Go online to PeerView.com/VBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into sound, evidence-based management strategies to improve outcomes for patients with gastric cancer. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.
Go online to PeerView.com/JEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy and explores using PARP inhibitors in the urology clinic. Upon completion of this activity, participants should be better able to: Describe the rationale for therapeutic targeting of DNA repair defects and the mechanism of PARP inhibition in managing BRCA-mutant prostate cancer, Review companion diagnostic tests that detect germline and somatic mutations within the DNA repair pathways, Discuss the latest evidence with PARP inhibitors in advanced prostate cancer harboring DNA repair defects, Identify patients with prostate cancer who may be candidates for clinical trial based therapeutic approaches, including studies testing combination regimens with PARP inhibitor components.
Go online to PeerView.com/BTK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A panel of gynecologic oncology experts reviews the clinical evidence supporting the use of novel targeted, immunotherapeutic, and antibody-based strategies in gynecologic cancers. Learn the practical aspects of managing patients with advanced endometrial and cervical cancers and gain insight into experts’ in-clinic strategies for selecting the right treatment for the right patient. Upon completion of this activity, participants should be better able to: Summarize the current treatment role of novel therapeutics, including in conjunction with modern molecular diagnostic testing, in gynecologic cancers, Describe updated evidence on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancers, Integrate approved and emerging options in the management of endometrial and cervical cancer, including in the context of clinical trials, based on disease characteristics and latest recommendations, Discuss the spectrum of unique safety considerations with novel targeted, antibody-based, and immunotherapy regimens in patients with gynecologic cancers.
Go online to PeerView.com/GVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent approval of newer JAK inhibitors and new evidence on emerging JAK-targeting strategies have raised additional questions over optimized treatment selection in myelofibrosis (MF) and awareness of clinical factors that can influence therapeutic selection. Additionally, newer dynamic risk-assessment models have allowed for more precise characterization of this disease at diagnosis and during the treatment course. In the wake of these advances, understanding how to effectively personalize therapeutic management based on the modern diagnostic and risk-assessment tools while ensuring safe usage of JAK inhibitors is crucial to maximizing beneficial patient outcomes in MF. In a recent live webcast, our panel of experts used the latest real-world evidence to confirm the core therapeutic role for JAK inhibitor–based strategies in MF, highlighting modern diagnostic and risk-assessment strategies that have informed an individualized treatment approach. During a unique practicum session, the panel offered practice strategies using real-world case scenarios, walking through selection of JAK inhibitor–based options across the MF disease continuum to improve patient outcomes. Upon completion of this activity, participants should be better able to: Recognize clinical and molecular/mutational features that can be used for diagnosis and risk stratification in myelofibrosis, Review the latest efficacy and safety evidence about approved and emerging JAK inhibitors as well as other targeted therapies in the management of myelofibrosis, Design safe, risk-adapted treatment regimens for patients with symptomatic and asymptomatic myelofibrosis, including those refractory to front-line JAK inhibitor therapy.
Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.
Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.
Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don’t miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients’ needs.
Go online to PeerView.com/JQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The ability to personalize treatment for patients with gastric cancer has grown along with the improved understanding of the biologic rationale for therapeutic targeting. In this activity, based on a recent live webcast, an expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses practical strategies for choosing treatments based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric cancer. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for therapeutic targeting of gastric cancer, such as HER2 or PD-L1 overexpression, Summarize expert and guideline-based recommendations to accurately test for biomarkers in gastric cancer that can guide appropriate treatment selection, Appraise the latest safety and efficacy data of established and emerging therapeutics for gastric cancer, such as checkpoint inhibitors, novel cytotoxic agents, and HER2-directed antibody-drug conjugates, Select appropriate validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.
Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.
Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.
Go online to PeerView.com/XDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A panel of hematology-oncology experts use the latest guidelines and real-world evidence to explore how the data have influenced clinical decision-making in cancer-associated VTE in different cancer settings. Using clinical scenarios and cases designed to build consensus, the experts illustrate how DOACs can be used to optimally integrate and implement evidence-based strategies for the prevention and treatment of cancer-associated VTE. Upon completion of this activity, participants will be able to: Review major patient- and treatment-related risk factors for cancer-associated VTE using established diagnostic tools to identify patients for initial treatment or thromboprophylaxis, Evaluate current evidence and guidelines for prevention and treatment of cancer-associated VTE in routine clinical practice, Select a safe and effective anticoagulation regimen including DOACs as initial VTE therapy and/or thromboprophylaxis for managing VTE in patients with gastrointestinal, hematologic, and other malignancies.
Go online to PeerView.com/BBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Targeted therapies have had a beneficial role in the advanced gastric or GEJ cancer setting, and several novel strategies of combining targeted therapy with immunotherapy are evolving the treatment landscape. While medicine continues to scientifically advance, the holistic care of patients with gastric/GEJ cancers is becoming more complex, and factors such as symptom management, psychological support, and nutritional considerations, in addition to effective treatment selection, need to be considered to offer the best clinical and quality of life outcomes to patients. This three-part educational activity offers learners an exclusive look at how science and care merge in the clinic to enhance the multidisciplinary, multidirectional management of patients with gastric/GEJ cancers. Upon completion of this activity, participants will be able to: Summarize clinical evidence on established targeted therapies, such as antiangiogenic agents, and emerging combination strategies, such as with checkpoint inhibitors, for advanced gastric or gastroesophageal junction (GEJ) cancers, Select appropriate second-line targeted therapies based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric/GEJ cancers who have progressed following first-line chemotherapy, Develop a holistic treatment plan that addresses nutrition/diet concerns, emotional distress, treatment-related adverse events, and risk of disease progression, among other issues, with a multidisciplinary and interprofessional team of clinicians who care for patients with advanced gastric/GEJ cancers.
Go online to PeerView.com/NEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored. Upon completion of this activity, participants will be able to: Discuss the expanding role and increasing importance of broad genomic testing to identify molecular alterations that can guide the selection of matched targeted therapies for patients with NSCLC in the era of precision oncology, Describe new, emerging, and/or rare molecular alterations (eg, fusions, mutations, etc.) that are clinically relevant and therapeutically targetable in NSCLC, including NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others, and the latest testing methods/tools for identifying these alterations, Analyze data from clinical trials of precision therapies that target molecular alterations such as NTRK, RET, ROS1, and NRG1 fusions, MET and KRAS G12C mutations, HER2 mutations or overexpression, EGFR exon 20 insertions, and others in advanced NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing and interpretation of results into oncology and pathology workflows in community and academic settings to ensure that appropriate patients with NSCLC with genomic alterations are identified and receive the most appropriate therapies in the context of clinical practice or clinical trials.
Go online to PeerView.com/DWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therapy in the realm of advanced-stage disease. However, an improved understanding of HCC pathology has led to the realization that optimal approaches to selecting, combining, sequencing, and transitioning between different modalities has the potential to improve outcomes across disease settings, underscoring the importance of a multidisciplinary team-based approach to HCC management. As approvals for new drugs (eg, TKIs, antiangiogenic agents, immunotherapy, combinations) and positive clinical trial outcomes with novel multimodal strategies continue to impact the HCC treatment paradigm, clinical decision-making has become complicated, with many questions arising about optimal approaches to administering various therapies to the appropriate patient in a timely manner within a team-based care model. In this CME-certified online activity, a multidisciplinary panel of interventional radiology, hepatology, and oncology experts offers insights on how to navigate the intermediate- to advanced-stage HCC landscape in an era of evolving treatment—from use of modern IR approaches to newer systemic therapies and combination strategies—to provide the most benefit for patients with HCC. Upon completion of this activity, participants should be better able to: Review pivotal clinical evidence on newly available systemic treatment options, including multikinase inhibitors, antiangiogenic agents, and checkpoint inhibitors, for newly diagnosed and previously treated patients with advanced HCC, Examine the potential role of combination systemic therapy approaches (eg, dual immune checkpoint blockade, immunotherapy plus targeted therapy) for advanced HCC, Assess emerging evidence on novel multimodal approaches for intermediate- and advanced-stage HCC, Develop optimal multidisciplinary treatment plans based on available evidence, patient- and disease-related factors, and recommendations on timely transitions from locoregional to systemic options for patients with intermediate or advanced HCC.
Go online to PeerView.com/BKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary and analysis of the current state of the science. Practicalities of clinical integration of the CDK4 and 6 inhibitors are also explored, with a focus on navigating the current treatment landscape and making individualized clinical decisions. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanism of action, and characteristics (including similarities/differences) of the CDK4 and 6 inhibitors in breast cancer, Analyze the latest efficacy (including OS), safety, and other key data from clinical trials assessing CDK4 and 6 inhibitors in breast cancer, and relevant implications for clinical practice, Discuss the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive biomarkers that could be used to guide selection of patients who would benefit from CDK4 and 6 inhibitors, Incorporate CDK4 and 6 inhibitors alone or in combination into treatment plans for appropriate patients with hormone receptor–positive, HER2-negative advanced breast cancer according to relevant evidence, clinical guidelines, predictive factors, and patient needs and preferences, Manage treatment-related toxicities in patients with breast cancer undergoing treatment with CDK4 and 6 inhibitors to maintain optimal adherence and promote favorable outcomes.
Go online to PeerView.com/FDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CNE activity, a family nurse practitioner brings the nurse’s perspective to patient care in endometrial and cervical cancer. Kimberly Halla, MSN, FNP-C, discusses modern management techniques for patient’s receiving targeted therapy and immunotherapy, as well as combination therapies, and gives her take on how to approach the unique safety profiles associated with these treatment options. Upon completion of this activity, participants will be able to: Summarize the current treatment and regulatory landscape in the management of gynecologic cancers, including the role of novel targeted, immunotherapeutic, and combination approaches in cervical and endometrial cancers, Describe safety and efficacy evidence surrounding targeted, immune checkpoint inhibitor, and combination strategies for the management of gynecologic cancers, Educate patients about therapeutic and safety considerations associated with recently approved and emerging options for endometrial and cervical cancers, Manage the unique spectrum of adverse events associated with targeted and immunotherapy used to treat endometrial and cervical cancers.
Go online to PeerView.com/XBQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel charts progress in myeloma care by discussing their personal experiences and insights, including analyses of how current evidence has informed the experts’ own practice along the disease continuum, from newly diagnosed to relapsed disease. This unique activity provides a link that connects novel agents to their applications in daily practice and clearly shows how novel antibodies, immunotherapy, and other innovative strategies have shaped a new model for myeloma care. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma, including for patients with smoldering disease or those with symptomatic disease regardless of transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.
Go online to PeerView.com/YFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led bladder cancer program, Dr. Arjun Balar discusses recent updates from the 2020 American Society of Clinical Oncology Annual Meeting and reviews new evidence on the continuing integration of novel therapeutics, including immunotherapy, targeted agents, and antibody-based approaches, across a wide range of bladder cancer treatment settings. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.
Go online to PeerView.com/CSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting; the expert focuses on important questions related to primary therapy in myeloma, including triplet and quadruplet therapy, as well as advances with antibody platforms, cellular therapy, and targeted agents in relapsed disease. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma according to transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.
Go online to PeerView.com/WHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The evidence base for use of immunotherapy in lung cancer is expanding at a rapid pace, and immune checkpoint inhibition has become a new standard of care after chemoradiation in stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). The effectiveness of immunotherapy as a component of multimodal therapy has raised the possibility of further expanding this treatment approach to earlier stages of lung cancer, including as neoadjuvant or adjuvant therapy for patients with resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored, and results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapies in earlier stages of lung cancer remain. For example, which patients are most likely to benefit from immune-based therapies? What is the optimal way to individualize therapy and coordinate care among different specialists, including thoracic surgeons, radiation oncologists, and medical oncologists? How should the various adverse effects associated with these emerging treatment modalities be managed? This educational on-demand activity based on a recent live webcast features expert instruction and practical guidance for how to effectively navigate the rapidly changing and complex immunotherapy landscape in lung cancer, including in earlier disease settings as a component of multimodal therapy. Access the activity to learn more about this timely, important topic, and what the implications are for clinical practice. Upon completion of this activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier stages of lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.
Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.
Go online to PeerView.com/QHM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity features insights from leading clinicians on the evidence that links the underlying mechanistic principles of Bruton tyrosine kinase inhibition with lessons arising from major clinical studies of first- and second-generation BTK agents in the chronic lymphocytic leukemia (CLL) setting. Upon completion of this activity, participants should be better able to: Discuss the implications of mechanistic and selectivity difference among first- and second-generation BTK inhibitors in the context of CLL care, Summarize updated clinical evidence and practice guideline recommendations for the use of BTK inhibitors in treatment-naïve and relapsed CLL, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL and in patients unable to tolerate BTK inhibitor therapy, Manage the unique spectrum of toxicity associated with the use of BTK inhibitors in patients with CLL.
Go online to PeerView.com/VSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Watch Dr. Duska provide a brief recap of recent developments in endometrial and cervical cancer management, including evidence presented at the 2020 American Society of Clinical Oncology Annual Meeting. Dr. Duska comments on these findings and offers thoughts on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancer. Upon completion of this activity, participants should be better able to: Summarize the current treatment role of novel therapeutics, including in conjunction with modern molecular diagnostic testing, in gynecologic cancers, Describe updated evidence on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancers, Integrate approved and emerging options in the management of endometrial and cervical cancer, including in the context of clinical trials, based on disease characteristics and latest recommendations, Discuss the spectrum of unique safety considerations with novel targeted, antibody-based, and immunotherapy regimens in patients with gynecologic cancers.
Go online to PeerView.com/VSY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist discusses recent developments in the use of PARP inhibitors and their companion diagnostics in advanced ovarian cancer and shares insight on incorporating PARP inhibitors into individualized treatment plans to improve patient outcomes in a variety of ovarian cancer settings. Upon completion of this activity, participants should be better able to: Review the rationale of PARP inhibitors targeting DNA repair pathway mutations, as well as their validated clinical evidence in ovarian cancer, Employ PARP inhibitor therapy and their companion diagnostics, when appropriate, for patients with ovarian cancer in frontline maintenance, pretreated platinum-sensitive, pretreated platinum-refractory, and other settings, Plan strategies to prevent and/or manage the PARP inhibitor-associated adverse events, particularly in long-term use (eg, maintenance settings), in patients with ovarian cancer, Identify patients eligible for enrollment into clinical trials testing PARP inhibitors, including as combination approaches, in different treatment settings for ovarian cancer.
Go online to PeerView.com/GZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist reviews the latest evidence and recent developments in gastric cancer care, including innovative targeted therapeutics, and offers strategies to optimally navigate patient care and integrate novel therapeutics into treatment plans. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for therapeutic targeting of gastric cancer, such as HER2 or PD-L1 overexpression, Summarize expert and guideline-based recommendations to accurately test for biomarkers in gastric cancer that can guide appropriate treatment selection, Appraise the latest safety and efficacy data of established and emerging therapeutics for gastric cancer, such as checkpoint inhibitors, novel cytotoxic agents, and HER2-directed antibody-drug conjugates, Select appropriate validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.
Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.
Go online to PeerView.com/KAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology discusses the recognition, classification, and treatment of adult and pediatric patients with veno-occlusive disease and sinusoidal obstruction syndrome. Upon completion of this activity, participants should be better able to: Cite updated recommendations and evidence on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) risk factors, diagnostic criteria, and disease severity grading, Establish a diagnosis of VOD/SOS, including late-onset disease, and VOD/SOS with or without organ dysfunction in adult and pediatric populations, Recommend effective, timely treatment for patients with confirmed VOD/SOS, including those presenting with or without organ dysfunction.
Go online to PeerView.com/TYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Brendon Stiles, MD, provides a brief recap of the latest advances in the use of immunotherapy as a component of multimodal lung cancer care in locally advanced and earlier stages of NSCLC. He highlights some of the newest data from clinical trials and shares his perspective on the promise and implications of the transition of immune checkpoint inhibitor therapy into curative intent settings of lung cancer. Upon completion of this activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier stages of lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.
Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients’ needs.
Go online to PeerView.com/MWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Dr. Alok Khorana provide a brief recap of recent developments with DOACs in cancer-associated VTE, including evidence presented at the American Society of Clinical Oncology 2020 Annual Meeting. Dr. Khorana comments on these findings and offers thoughts on how to integrate novel oral anticoagulants for personalized management of patients with elevated-risk malignancies such as gastrointestinal and hematologic cancers, among others. Upon completion of this activity, participants will be able to: Review major patient- and treatment-related risk factors for cancer-associated VTE using established diagnostic tools to identify patients for initial treatment or thromboprophylaxis, Evaluate current evidence and guidelines for prevention and treatment of cancer-associated VTE in routine clinical practice, Select a safe and effective anticoagulation regimen including DOACs as initial VTE therapy and/or thromboprophylaxis for managing VTE in patients with gastrointestinal, hematologic, and other malignancies.
Go online to PeerView.com/NPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic visceral acid sphingomyelinase deficiency (ASMD), also referred to as Niemann-Pick disease type B, is a rare and progressive autosomal recessive lysosomal storage disorder that causes progressive accumulation of sphingomyelin and other lipids in tissues throughout the body and is associated with significant morbidity and reduced life expectancy. The diagnosis of chronic visceral ASMD is often delayed by months or years, because its complex signs and symptoms overlap with other diseases. In this activity, leading experts review current consensus recommendations for the diagnosis of ASMD in pediatric and adult patients. The faculty also review the latest safety, efficacy, and tolerability data on emerging therapies and explore patient cases to offer practical strategies on how to optimally manage patients with chronic visceral ASMD. Upon completion of this activity, participants should be better able to: Diagnose individuals with ASMD through the application of recent consensus recommendations, Cite available efficacy, safety, and tolerability data on emerging therapeutic modalities for the treatment of patients with ASMD, Examine the potential impact that ongoing clinical trials of emerging therapeutic approaches may have on the future treatment of patients with ASMD.
Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.
Go online to PeerView.com/KNT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the basic biology of how the immune system responds to tumor activity, reviews the pathophysiology of the tumor microenvironment, provides up-to-date data supporting the use of cancer immunotherapies, including immune checkpoint inhibitors, and discusses investigational immuno-oncology pathways, putative targets for novel therapies, and current and emerging prognostic biomarkers to inform clinical treatment decisions. Upon completion of this activity, participants will be able to: Describe the foundational aspects of the immune system’s response to tumor activity through innate and adaptive immunity mechanisms, Review the pathophysiology of the tumor microenvironment and its relationship to tumor evasion and resistance, Characterize the mechanisms of action of the immune checkpoint inhibitors (ie, CTLA-4 and PD-1/PD-L1 inhibitors) and how they differ in their activity and adverse effects from conventional anticancer therapies, Summarize the current FDA-approved indications and investigational approaches with the immune checkpoint inhibitors across different tumors, Discuss investigational immuno-oncology pathways and potential new therapies that may be able to expand on the current therapies or overcome immune evasion and resistance, Assess current and emerging immuno-oncology biomarkers and their potential roles/uses, Integrate the latest immunotherapies and biomarker approaches into cancer care in the context of clinical practice or trials.
Go online to PeerView.com/XUK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Exploiting the impact of mutations in DNA damage response (DDR) pathways on tumorigenesis has led to advances in the development of targeted therapies such as poly-ADP ribose polymerase (PARP) inhibitors for patients with relevant cancers. These agents are currently approved for several indications and are under investigation in a number of other tumor types. Increasingly, optimal care for patients with breast, ovarian, pancreatic, and other cancers must include genetic and other biomarker testing to inform risk, prognosis, and treatment selection. This PeerView inExchange features two leading experts who share the fundamentals of DDR pathway biology and their insights into current and emerging biomarkers, genetic testing guidelines, indications, and mechanisms, as well as the latest evidence on PARP inhibitors and other novel therapeutic approaches. The experts also provide guidance on how to incorporate molecular testing into current clinical practice to ensure that patients who have or are at risk for DDR-mutant cancers receive optimal care. Upon completion of this activity, participants should be better able to: Discuss key features of the DNA damage response (DDR) pathway and the rationale for therapeutic targeting of DDR mutations in patients with cancer, Compare current and emerging actionable mutations associated with DDR (eg, BRCA1/2) and the different testing methods used to identify these biomarkers, Evaluate recent clinical evidence on current and emerging agents and combinations targeting DNA repair mechanisms, including poly-ADP ribose polymerase (PARP) inhibitors, Describe the guidelines for genetic risk evaluation, genetic testing procedures, and pre- and post-test counseling for patients who may be at risk for a germline mutation in the DDR pathway, Apply guideline-based recommendations to identify patients who should receive genetic testing, provide effective genetic counseling, and tailor biomarker testing options to the individual patient’s needs.
Go online to PeerView.com/BBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert discusses key concepts in oncology and supportive care biosimilars, including how they are defined, the regulatory approval process for these agents, and an overview of data for biosimilars in the treatment and supportive care of cancer patients. Upon completion of this activity, participants will be able to: Describe the biosimilar manufacturing process and differences between biosimilars and originator biologics used in the oncology setting, Discuss the concepts of biosimilar interchangeability, therapeutic equivalence, and safety in the context of the regulatory process, Cite efficacy evidence on the use of biosimilars in the management of solid tumors, including breast cancer, lung cancer, GI cancers, and others, Integrate biosimilars into oncology management plans in order to increase patient access to effective medications and improve health system efficiency.
Go online to PeerView.com/BBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss current evidence and clinical insights on the evolving role of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in the frontline and recurrent maintenance settings in patients with ovarian cancer. Upon completion of this activity, participants should be better able to: Review the benefits of maintenance therapy on overall patient outcomes in ovarian cancer management, Summarize new evidence on and recent indications for PARP inhibitors as maintenance therapy in the frontline and recurrent advanced ovarian cancer settings, Select appropriate maintenance interventions based on patient and disease characteristics and response to prior therapy in patients with advanced ovarian cancer.
Go online to PeerView.com/SMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the evolving era of precision cancer care, increasing emphasis is placed on detecting molecular alterations driving the development of specific cancers and targeting them with matched therapies or combinations that can yield the best outcomes for patients. Such is the case with HER2—and, more recently, also HER3 and TROP2—which are gaining growing interest as relevant targets in different malignancies. This is particularly important now, as a number of new targeted therapies have started to reach the clinic and are expected to change practice, and many others are showing great promise in clinical trials in breast, gastrointestinal, lung, and other tumors. Pathology professionals play an essential role in realizing the potential of precision cancer care by carrying out optimal predictive testing. This PeerView on-demand activity, based on a recent symposium at the United States and Canadian Academy of Pathology (USCAP) 108th Annual Meeting, features a panel of leading pathology and oncology experts, who share their insights into recent advances in testing and treatment of various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. The emerging roles of HER3 and TROP2 as potential new targets are reviewed as well. In addition, they provide useful guidance to improve testing and best practices for interpretation, as well as interdisciplinary collaboration, all for the benefit of the patients. Upon completion of this activity, participants should be better able to: Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, non–small cell lung, and other cancers, Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or HER2-mutant cancers, Implement appropriate methods and best practices for HER2 testing and interpretation to guide integration of the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or HER2-mutant cancers either in the context of clinical practice or through clinical trial participation.
Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.
Go online to PeerView.com/QMH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this educational activity, based on a live event developed by PeerView and the Head and Neck Cancer Alliance and held at the 2020 Multidisciplinary Head and Neck Cancers Symposium, a panel of oncology and radiology professionals assess the latest evidence on immune checkpoint blockade as a part of a multipronged management approach to head and neck cancer (HNC). During this activity, the experts also explore several practical issues arising from the integration of immunotherapy into practice, including the selection of immunotherapy as upfront treatment, management of immune-related events, the use of immune-based multimodal therapy, and referral of patients with resectable or locally advanced disease for clinical trials. Upon completion of this activity, participants should be better able to: Cite updated evidence on immune checkpoint inhibitors in squamous cell carcinoma of the head and neck across treatment settings and patient populations, Select single-agent and immune-based combination regimens for the management of patients with recurrent/metastatic head and neck cancer, including as upfront treatment or after progression on platinum chemotherapy, Summarize the clinical potential of immunotherapy as part of multimodal care in the locally advanced or resectable head and neck cancer settings, including in the context of a clinical trial testing combinations of checkpoint inhibitors with surgery and/or radiation, Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities.
Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.
Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been paired with expert analysis of the clinical evidence on available therapeutic strategies and ongoing research on novel combinations in clinical trials. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence on available multikinase inhibitors for newly-diagnosed patients with HCC, Review the available treatment options, such as targeted and immune checkpoint therapies, and their associated clinical data for patients with advanced HCC who have progressed after first-line treatment, Describe ongoing clinical trials that are studying combination strategies, including immunotherapy with targeted therapy, dual checkpoint inhibitor therapy, or others for patients with HCC, Examine the potential use of systemic treatments, including multikinase and checkpoint inhibitors, in earlier HCC disease settings, Develop safe and effective treatment plans across multiple lines of therapy for patients with advanced HCC based on guideline recommendations and validated evidence.
Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.
Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.
Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.
Go online to PeerView.com/UQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in the management of myelofibrosis (MF) offers learners an update on the modern diagnostic and risk assessment strategies that have informed a more considered treatment approach to symptomatic disease. An emerging paradigm, in which potentially curative hematopoietic cell transplantation (HCT) is used in conjunction with Janus kinase (JAK) inhibitor therapy, is discussed, along with an expert-led assessment of JAK inhibitor options in development for MF and how these additions to the treatment arsenal will be used alongside standard approaches. For professionals who are looking to pair recent evidence on JAK inhibitors with HCT and other options in the management of MF, this educational event is an essential disease management resource. Upon completion of this activity, participants should be better able to: Identify clinical symptoms and molecular/mutational features that can be used to diagnose and risk-stratify myelofibrosis, Discuss the current treatment role of JAK inhibitors and allogeneic transplantation in the management of myelofibrosis, Cite recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of myelofibrosis, Develop risk-adapted treatment plans for patients with symptomatic myelofibrosis, including those who did not respond to previous JAK inhibitor therapy or are eligible for allogeneic transplantation.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
Go online to PeerView.com/AML20Live?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.
Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Tumor Board will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals in interpreting biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of current and emerging immunotherapies and combinations across different malignancies, along with relevant biomarker alignments, Evaluate the latest evidence supporting the use of PD-L1, MSI/MMR, TMB, and other emerging biomarkers and multiparametric approaches as predictors of benefit from cancer immunotherapies, Discuss the practical aspects of immunotherapy biomarker testing and interpretation in pathology practice, including companion diagnostic use requirements, benefits/limitations of different testing methodologies, assays, cutpoints, and other nuances, Implement best practices for cancer immunotherapy biomarker testing and interpretation in collaboration with oncologists and other relevant professionals to guide and refine the use of cancer immunotherapies in current practice
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don’t miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers
Go online to PeerView.com/MJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide decision-making in the clinic. The panel also provides guidance on how to manage several challenging patient types across the disease spectrum—from locally advanced metastatic to non-muscle–invasive bladder cancer. Upon completion of this activity, participants should be better able to: Review the rationale for the use of and latest evidence on approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, FGFR inhibitors, and gene therapy, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Optimally apply new and emerging treatment approaches for the management of bladder cancer while considering the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials that incorporate checkpoint blockade, novel targeted approaches, and gene therapy to eligible patients across disease settings in bladder cancer
Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let’s Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors
Go online to PeerView.com/YTB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rarity and heterogeneity of biliary cancers (eg, cholangiocarcinoma, gallbladder cancer) make this group of malignancies a clinical challenge in GI oncology. Fortunately, recent scientific developments on the genetic and molecular level have led to the clinical testing of several targeted agent classes, including FGFR, IDH, HER2, TRK, and multikinase inhibitors, in patients with biliary cancers. This educational activity, based on a recent PeerView “MasterClass” symposium presented in collaboration with the Cholangiocarcinoma Foundation, provides an in-depth examination of the latest science on the biologic rationale for targeting biliary cancers and the important evidence that is validating potent therapies in a setting where conventional chemotherapy often has limited efficacy and value for patients. Each segment will conclude with expert insights on patient-centric care and strategies for translating new evidence and data into clinical practice for the optimal management of biliary cancers. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale for targeting biliary cancers, including multikinase tumor pathways, NTRK gene fusions, IDH2 mutations, FGFR translocations, and immune checkpoint pathways, Examine the latest efficacy and safety evidence on the use of novel therapeutic strategies, such as multikinase, TRK, IDH, and FGFR inhibitors, in patients with biliary cancers, Describe ongoing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, that are recruiting patients with biliary cancers, Apply current and emerging therapeutic strategies into personalized treatment plans for patients with biliary cancers, including in the context of a clinical trial
Go online to PeerView.com/QXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in medical genetics and inborn metabolism errors discusses novel strategies and emerging evidence for the identification and management of patients with long-chain fatty acid oxidation disorders. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms associated with the clinical presentation of long-chain fatty acid oxidation disorders (LC-FAOD), Review current recommendations for screening, diagnosis, and treatment of patients with LC-FAODs, Summarize the mechanism of action and emerging evidence for novel agents designed to address unmet needs among patients with LC-FAODs
Go online to PeerView.com/WUA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an oncology nurse practitioner and expert in immuno-oncology provides a comprehensive overview of cancer immunotherapies, including how the immune checkpoint inhibitors work, their efficacy and safety profiles, and the latest approvals and indications. In addition, practical guidance for determining candidates for immune checkpoint inhibitor therapy, recognizing and managing immune-related adverse effects, and educating and counseling patients and survivors about this new class of agents and what to expect during and after treatment is offered. Upon completion of this activity, participants will be able to: Assess clinical data on the efficacy and safety of cancer immunotherapies and immune-based combinations across the oncologic spectrum, Describe indications for and roles of immunotherapies and combinations in the treatment of different cancers, Discuss factors that should be considered in determining best candidates for cancer immunotherapies, including patient-related factors and predictive biomarkers, Characterize potential immune-related adverse effects (irAEs) of cancer immunotherapies and how to recognize, diagnose, and manage them, Evaluate patients with cancer to help determine who would/would not be good candidates for cancer immunotherapy, Manage irAEs according to the latest recommendations and best practices, Educate patients with cancer and survivors about the basics of immuno-oncology, what to expect during and after treatment with cancer immunotherapies, and how they can collaborate with their nurses, nurse navigators, other members of the oncology team, and other providers to maximize the benefits and minimize the risks of these therapies
Go online to PeerView.com/NNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hospital and vascular medicine discusses how real-world data enhance the data from randomized clinical trials on direct oral anticoagulants (DOACs) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) and offers insight on applying evidence from both real-world studies and randomized clinical trials to improve patient care. Upon completion of this activity, participants will be able to: Identify the role of real-world data and evidence in augmenting the efficacy and safety data that have been collected as part of clinical trials for stroke prevention among patients with NVAF, Compare and contrast evidence collected to date from real-world studies with data reported from clinical trials of DOACs to prevent stroke among patients with NVAF, Apply evidence from real-world studies and clinical trials of DOACs in patients with NVAF
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/KWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment armamentarium for advanced renal cell carcinoma (RCC) has undergone rapid expansion with the validation of novel multitargeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. More recently, the emergence of dual checkpoint blockade and immunotherapy-TKI combinations in RCC has increased the number of treatment choices in the frontline setting, allowed for greater flexibility when selecting second-line agents, and sparked additional research into TKI and immune checkpoint inhibitor options in earlier disease settings. In the wake of these advances, understanding how to effectively select and sequence newer regimens through multiple lines of therapy while ensuring safe usage is crucial to maximize beneficial patient outcomes throughout the advanced RCC continuum. This unique “How I Think, How I Treat” educational on-demand activity, based on an event held adjunct to the 18th International Kidney Cancer Symposium, features personal insights from leading kidney cancer experts on how they are adapting their own practice based on the evidence supporting optimized care in advanced RCC in the context of patient-, disease-, and treatment-specific factors, as well as how the innovations fueling modern approaches to care are improving outcomes for patients with RCC. Upon completion of this activity, participants should be better able to: Assess the latest evidence and clinical implications of novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Apply validated targeted therapy and immunotherapy options effectively for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC
Go online to PeerView.com/FKM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the therapeutic landscape of several lymphoid cancers, including chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). The present and future management of these diseases will increasingly be defined by the integration of BTK inhibitors—along with other novel therapeutics—into management protocols that have previously been characterized by the use of immunochemotherapy-focused options. Several important practical issues arising from the use of BTK inhibitors, ranging from the initial therapy selection to therapeutic sequencing and use of active combinations, will continue to be a part of patient management for years to come. This PeerView Live “How I Think, How I Treat” on-demand activity, based on a satellite symposium preceding the 61st ASH Annual Meeting and Exposition, exposes learners to the personal insights of several experts in the field and includes in-depth analyses of the cutting-edge science on the present and future role of BTK inhibitors in CLL, MCL, and other lymphoid cancers. Key topics include BTK inhibitor sequencing, selecting patients for treatment, differentiating among first- and second-generation compounds, and safety management. Ultimately, this event provides a “virtual mentorship” experience on the use of BTK inhibitors in several different diseases. Upon completion of this activity, participants should be better able to: Describe updated evidence regarding the use of first- and second-generation BTK inhibitors in the management of B-cell NHL, including agent potency/selectivity, response data, survival outcomes, and activity in BTK inhibitor–intolerant or –resistant disease, Recommend personalized therapy with BTK inhibitors for patients across the spectrum of B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, among others, Manage unique safety considerations associated with BTK inhibitor therapy in patients with B-cell NHL
Go online to PeerView.com/GZS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gastrointestinal oncology provides an update on targeted therapies for patients with biliary tract cancers. Upon completion of this activity, participants should be better able to: Review the rationale of newly discovered targets, such as multikinase tumor pathways, NTRK gene fusions, and FGFR translocations, for biliary tract cancers, Appraise emerging efficacy and safety evidence on the use of novel targeted agents, including multikinase, TRK, and FGFR inhibitors, in patients with biliary tract cancers, Incorporate novel targeted agents safely and effectively into treatment plans for biliary tract cancers, including in the context of a clinical trial
Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials
Go online to PeerView.com/JYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity an expert in acute and chronic graft-versus-host disease (GVHD) discusses the underlying biologic features of GVHD and the latest evidence supporting the use of innovative therapeutics in this setting. The expert also provides guidance on clinical and practical experience with current treatment options for acute and chronic, previously untreated, and steroid-refractory GVHD, while also discussing new data and ongoing clinical trials in GVHD prophylaxis. Upon completion of this activity, participants should be better able to: Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD, Discuss the latest evidence on innovative therapies for management of acute or chronic, steroid-refractory GVHD, Apply the most optimal evidence-based strategies, including recently approved and investigational therapies in the context of clinical trials, for post-transplant GVHD care based on individual patient and disease characteristics
Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others
Go online to PeerView.com/PMD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that will bring the novel class of cancer immunotherapies to this population of patients. What is the most rational way and optimal setting to use cancer immunotherapies? How can we maximize their benefits so that more patients with TNBC would benefit from them? In this CME/MOC/CNE-accredited PeerView MasterClass on-demand activity, our expert panel discusses the biologic rationale for the use of cancer immunotherapies in breast cancer in general and TNBC specifically, as well as evolving evidence supporting the use of immune checkpoint inhibitors in advanced/metastatic and early-stage TNBC in neoadjuvant and adjuvant settings. Additionally, the panel focuses on patient/tumor evaluation and candidate selection for immunotherapies, using current and novel biomarkers to guide clinical decisions in early-stage and advanced disease, the importance of being aware of potential immune-related adverse events and how to diagnose/manage them, and the need for close collaboration among oncologists, breast surgeons, pathologists, and other professionals involved in the management of patients with breast cancer. Illustrative case studies and clinical scenarios discussed during the Practicum segment provide further guidance on best practices for the use and integration of immunotherapies into the treatment arsenal for patients with TNBC in real-world, clinical practice settings. Upon completion of this activity, participants will be able to: Describe the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC) specifically, and in breast cancer more broadly, including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies (eg, chemotherapies, other immunotherapies, PARP inhibitors and other targeted agents, surgery, radiation, etc) that may enhance immunogenicity and improve outcomes, Discuss biomarkers that may have utility in guiding and refining clinical decisions regarding the selection of appropriate candidates for immune-based and other therapies in TNBC, and the nuances of testing for these biomarkers in practice, Analyze efficacy, safety, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including metastatic, locally advanced, and early-stage resectable disease, Integrate immune checkpoint inhibitors and/or other effective treatment modalities into management plans of patients with TNBC based on the latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, biomarker testing results, and patient needs/preferences
Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView’s latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don’t miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders
Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology
Go online to PeerView.com/YCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium held in conjunction with the 2019 ASCP Annual Meeting in Phoenix, Arizona, pathology and hematology-oncology experts offer guidance on how to differentiate high-risk AML subtypes at diagnosis, determine useful prognostic features, and use the results of diagnostic testing to help guide the integration of newly validated treatment options into care. The expert panel also discusses the nuances of multidisciplinary collaboration between pathologists and hematologist-oncologists, including practical issues related to defining and establishing management protocols for high-risk and molecularly defined AML subtypes. Upon completion of this activity, participants should be better able to: Identify the molecular and histopathologic features of various AML subtypes, including secondary AML, AML-MRC, and FLT3- or IDH-mutant AML, Recommend appropriate evidence-based molecular/pathology testing for patients with a likely diagnosis of AML, Safely integrate novel treatment regimens into the management of patients with secondary AML/AML-MRC, Develop safe and effective management plans for patients with AML whose disease exhibits FLT3 or IDH mutations
Go online to PeerView.com/XKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is an aggressive, complex disease and is a leading cause of cancer-related deaths worldwide. Research endeavors to mitigate HCC mortality have led to rapid advances, especially in the past two years. Today, clinicians specializing in HCC have various treatment options to select for their patients across the spectrum of the disease, and the therapeutic landscape continues to evolve with promising results from ongoing clinical trials investigating novel approaches. This PeerView MasterClass and Tumor Board on-demand educational activity, based on a symposium held adjunct to the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019), features a panel of multidisciplinary HCC experts who review pivotal evidence on available TKI, antiangiogenic, and checkpoint inhibitor therapies and their optimal treatment sequencing strategies, as well as emerging data on novel combinations and innovative modalities for early- to advanced-stage disease. The experts weave the science into real-world case scenarios, helping to translate the data into practical experiences in the HCC clinic. Upon completion of this activity, participants should be better able to: Summarize recent safety and efficacy evidence of available targeted therapies, such as multikinase inhibitors and monoclonal antibodies, for HCC, Evaluate the significance of new data and ongoing clinical trials with checkpoint inhibitors as treatment options for HCC, Review the potential use of systemic treatments in novel multimodal strategies for intermediate HCC, Construct safe and effective treatment plans across multiple lines of therapy for patients with HCC based on multidisciplinary team–based strategies
Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials
Go online to PeerView.com/RZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView’s latest MasterClass and “Tumor Board” on demand activity is based on a live symposium at the 2019 hematologic malignancies meeting in Chicago and covers the ongoing integration of novel and next-generation therapeutics in the management of several B-cell malignancies, including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). This educational video activity combines scientific discussions with more practically focused case and tumor board-style elements in order to illustrate how innovative therapies, such as BTK, PI3K, and BCL-2 inhibitors, as well as IMiD-based regimens, are increasingly surpassing conventional options in the management of lymphoid cancers. Upon completion of this activity, participants should be better able to: Summarize recent efficacy and safety data associated with novel therapies, including BCR inhibitors, next-generation antibodies, BCL-2 inhibitors, and IMiDs, used to treat B-cell malignancies, Recommend novel agent classes for the treatment of newly diagnosed or relapsed/refractory B-cell malignancies, including for patients with CLL, FL, or MCL, Manage the unique spectrum of adverse events associated with the use of novel therapies in the management of B-cell malignancies
Go online to PeerView.com/CSQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hemophilia discuss the latest advances in the treatment of hemophilia and the importance of shared decision-making in optimizing the management of patients with hemophilia who present to the ED. Upon completion of this activity, participants should be better able to: Apply current data on the efficacy, safety, and tolerability of approved therapeutic approaches when managing patients with hemophilia in the emergency department, Cite available data on emerging treatment modalities for the management of hemophilia, Employ current guidelines for the management of hemophilia in the emergency department, Use shared decision-making when treating suspected bleeding episodes in patients who present to the emergency department
Go online to PeerView.com/PPF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Central nervous system (CNS) metastases occur commonly in patients with lung cancer, and those patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) are particularly prone to their development. Treatment of brain metastases is challenging, and there are varied perspectives among different specialists about the best approach—if, when, and how to use local therapies, systemic therapies, or different treatment modalities in combination or sequence, etc. Clinical trials are underway to try to answer some of these critical questions about which treatment strategies yield the best results for these patients. This PeerView Live MasterClass and Practicum on-demand educational activity features a panel of multidisciplinary experts in EGFR-mutant lung cancer and CNS metastases who discuss the evolving evidence, clinical challenges, and practicalities of patient care. Real cases are debated from multiple perspectives, with an emphasis on information and guidance relevant for radiation oncologists. Upon completion of this activity, participants should be better able to: Describe molecular pathways that drive malignancy in lung cancer and the oncogenic activation of tyrosine kinases, such as mutations in EGFR, and the epidemiology and presentation of CNS metastases in EGFR-mutant lung cancer, Discuss the mechanisms of action, characteristics, and safety/efficacy profiles of the various EGFR TKIs available for the treatment of EGFR-mutant NSCLC throughout the continuum of advanced disease, including in patients with CNS metastases, Summarize the efficacy and safety data of available and emerging treatment strategies used in the management of brain or leptomeningeal metastases in patients with EGFR-mutant NSCLC, including the use of local therapies such as radiation, systemic therapies such as EGFR TKIs, and sequential/combination treatment approaches, Implement individualized treatment plans for patients with EGFR-mutant lung cancer with CNS metastases, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care
Go online to PeerView.com/UJT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, and others. Testing for these biomarkers has significant implications for clinical practice. This activity provides participating professionals with updates on current and emerging immunotherapies and biomarkers as well as practical guidance for immuno-oncology biomarker testing in pathology practice. Upon completion of this activity, participants should be better able to: Describe the mechanistic underpinnings and current evidence supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, including thoracic, gastrointestinal, genitourinary, dermatologic, and other cancers, Evaluate the rationale for use and current/emerging roles of established and new cancer immunotherapy biomarkers (including PD-L1, MSI/MMR, TMB, LAG-3, and composite biomarkers) as predictors of benefit from cancer immunotherapies to guide precision treatment decisions, Discuss the practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cut-points, and other nuances, Establish best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding cancer biomarker testing and interpretation of results to guide clinical decisions in the precision immuno-oncology era
Go online to PeerView.com/AMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment of cancer has been transformed by the new immune checkpoint inhibitor class of agents that have shown remarkable benefit in many different types of tumors, but they can also cause unusual immune-related adverse effects (irAEs) that can affect any organ system. Expanding use of these immunotherapies in oncology means that emergency medicine professionals can expect to encounter an increasing number of patients experiencing various irAEs in emergency departments. Timely recognition, accurate diagnosis, and effective management of irAEs can ensure that patients derive maximum benefit from these therapies, and emergency nurses have an important role to play in evaluating and triaging these patients. This CNE educational on-demand activity combines lessons on everything emergency nurses need to know about cancer immunotherapies and irAEs with case discussions and practical guidance for keeping patients with cancer safe in the era of immuno-oncology. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-related adverse effects (irAEs), Characterize the presenting symptoms of the spectrum of irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency nurses and other professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for the recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology specialists
Go online to PeerView.com/YKQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the role of immunotherapy in multimodal management of locally advanced and early-stage lung cancer. Upon completion of this activity, participants should be better able to: Discuss how to harness the immune system in the treatment of cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced and earlier stages of lung cancer in the context of other treatment modalities, including chemotherapy, radiotherapy, and surgery, Evaluate key clinical trial data on the efficacy and safety of immune checkpoint inhibitor–based treatment in patients with unresectable stage III NSCLC whose cancer has not progressed following concurrent chemoradiation, Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer, and available evidence from these trials, Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease, Implement an optimal multimodal treatment plan inclusive of concurrent chemoradiotherapy and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences, Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation
Go online to PeerView.com/MDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView onDemand activity based on a nurse-led program at the SUNA 2019 uroLogic Conference, experts on modern RCC treatment (including immunotherapies and TKIs) offer valuable, practical insights on the current therapeutic and regulatory landscape in RCC, real-world application of evidence on novel targeted and immunotherapeutic regimens, the importance of counseling patients on therapeutic expectations with immune checkpoint inhibitors and TKIs, and the recognition and management of unique safety issues associated with newer agents in RCC. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety findings on novel regimens, including immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination approaches, for management of patients with renal cell carcinoma (RCC), Provide appropriate education and guidance to patients with RCC on available and emerging targeted- and immuno-therapeutic options in different disease settings, Counsel patients with RCC receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors on appropriate strategies to manage treatment-related complications
Go online to PeerView.com/ZVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist/oncologist and a nurse professional discuss the characteristics and management of secondary AML, with an emphasis on practical aspects of care and the use of novel therapy. This multidisciplinary panel also features commentary from a patient with secondary AML and discusses the patient’s experience of a secondary AML diagnosis and subsequent therapeutic journey. Upon completion of this activity, participants should be better able to: Cite the clinical features and therapeutic challenges associated with secondary AML, Recommend novel treatment strategies for patients with secondary AML who are able to receive intensive therapy and/or are eligible for HCT, Identify opportunities for multidisciplinary collaboration with other oncology team members when managing secondary AML, Educate patients about the risks and benefits of novel treatment strategies for secondary AML in the context of a collaborative oncology team.
Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current HCC landscape in order to provide the most benefit for their patients. This activity also features important insights on how to utilize newly approved TKIs and checkpoint inhibitors across disease and treatment settings, as well as provides expert thoughts on the next wave of emerging solutions that leverage the power of novel therapies across the continuum of HCC. Upon completion of this activity, participants should be better able to: Summarize emerging clinical evidence on the use of novel systemic treatments, including targeted and immunotherapeutic agents, in a range of HCC treatment settings and populations, Apply recent safety and efficacy data on targeted therapies into clinical practice to enhance aspects of HCC care, including treatment sequencing and managing treatment-related adverse events, Integrate immunotherapeutic strategies for the management of patients with advanced HCC, including through optimal treatment selection and via management of immune-related adverse events, Identify innovative treatment strategies currently being assessed in clinical trials across the spectrum of HCC, such as immunotherapy combinations, combinations of novel agents with locoregional therapies, and early transition to systemic treatment, among others.
Go online to PeerView.com/TXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the management of MM discusses the implications of recent efficacy and safety data that support the ongoing integration and use of several innovative treatments, such as antibody-based therapies, next-generation IMiDs and proteasome inhibitors, and novel therapies directed against intracellular targets. The expert also provides a review of the overall shape of MM therapy in newly diagnosed and relapsed disease, and discusses strategies to manage treatment-related adverse effects. Upon completion of this activity, participants will be able to: Summarize updated evidence on the use of novel agent classes and next-generation therapeutics in multiple myeloma (MM), including proteasome inhibitors, immunomodulators (IMiDs), novel antibodies, and targeted agents, Select appropriate therapy in patients with newly diagnosed MM, including those requiring eradication of MRD or treatment for high-risk disease, Recommend therapy with novel components for patients with early relapse or treatment-refractory MM, Manage treatment-related adverse events in patients with MM who are receiving novel therapeutics as part of their care.
Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019). Modeled after the format of a late-night talk show, this activity merges focused talks on defined topics with personal story-telling, candid interviews, and interactive debates/discussions among top experts. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies and combinations in the frontline setting and beyond in advanced/metastatic NSCLC, Assess the role of predictive biomarkers (PD-L1, TMB) and other tumor-, patient-, and treatment-related factors that should be taken into consideration as part of individualized treatment planning and selection for patients with NSCLC, Describe key new research directions and clinical trials with immunotherapies aiming to refine, expand, and maximize their use throughout the lung cancer continuum, including novel immune targets or combinations and biomarkers in advanced settings, as well as potentially curative approaches in earlier stages of NSCLC, Implement individualized, evidence-based, patient-centric treatment plans involving immunotherapies and/or combinations for patients with NSCLC.
Go online to PeerView.com/VGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in malignant pleural mesothelioma discuss tumor treating fields and novel systemic approaches to optimize patient outcomes. Upon completion of this activity, participants will be able to: Describe the rationale for use of tumor treating fields (TTFields), antiangiogenic strategies, and immunotherapeutic approaches in the management of malignant pleural mesothelioma (MPM), Discuss the latest efficacy and safety evidence on TTFields, angiokinase inhibitors, immune checkpoint inhibitors, and combination strategies in different MPM settings, Employ appropriate strategies to monitor for and manage treatment-emergent adverse events in patients with MPM receiving TTFields or other novel therapies, Recommend TTFields and other emerging systemic options appropriately, in the context of clinical trials or as they become available for daily practice, for eligible patients with MPM.
Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let’s Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let’s Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.
Go online to PeerView.com/TVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology reviews recent evidence for novel therapeutics for the management of mantle cell lymphoma and offers practical insight on integrating clinical evidence into patient care and management, including for patients who have progressed after upfront therapy and who are candidates for second-line treatment. Upon completion of this activity, participants should be better able to: Cite evidence on the use of newer therapeutics, including BTK inhibitors and immunomodulators, among others, for the management of relapsed/refractory and newly diagnosed MCL, Select regimens with novel components for the management of patients with MCL, Manage therapy-related toxicity in patients with MCL who are receiving treatment with novel therapeutics.
Go online to PeerView.com/NXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for prostate cancer has evolved rapidly in recent years, and research endeavors continue to expand treatment options, with significant implications for patients with early-stage and advanced disease. In addition to the approval of multiple second-generation anti-androgen therapies in nonmetastatic castration-resistant and metastatic hormone-sensitive prostate cancer, current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. When managing patients with prostate cancer, clinicians must consider established, newly approved, and emerging therapies throughout the disease continuum, as well as individual patient-, tumor-, and treatment-related factors. Questions that frequently arise include: What is the impact of using anti-androgen therapies earlier in the treatment plan? What is the ideal way to sequence therapies in different disease settings? How should therapy be personalized to ensure that each patient with prostate cancer receives the right treatment? Answers to these and other thought-provoking queries are provided by a panel of prostate cancer experts in this PeerView Talks CME-certified on-demand activity based on a recent live symposium at the American Society of Clinical Oncology Annual Meeting 2019 (ASCO 2019) in Chicago, Illinois. Utilizing an innovative educational design, the experts relate engaging patient stories and link them to practical clinical considerations, enabling learners to better connect evidence to everyday practice. Upon completion of this activity, participants should be better able to: Discuss the clinical evidence, latest guidelines, and expert recommendations for selection and sequencing of hormonal, anti-androgen, cytotoxic, bone-directed, molecularly targeted, and other therapies throughout the disease continuum for patients with hormone-naïve, hormone-sensitive, or castration-resistant, nonmetastatic, and metastatic prostate cancer, Develop personalized, evidence-based treatment plans for patients with early-stage and advanced prostate cancer with considerations of tumor-, patient-, and treatment-related factors, Summarize current and planned clinical trials assessing novel strategies with potential to improve outcomes in different prostate cancer settings.
Go online to PeerView.com/FPP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, recorded from a live event at the 2019 American Society of Clinical Oncology Annual Meeting, a panel of kidney cancer experts offers case-centric discussion of key evidence that supports clinical decision-making through multiple lines of therapy in advanced RCC, as well as practical instruction on how to effectively and safely integrate novel targeted and immunotherapeutic strategies in an increasingly complex RCC treatment landscape. Upon completion of this activity, participants should be better able to: Summarize the latest evidence and ongoing investigations with novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies, in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Recommend targeted agents and immune checkpoint inhibitors optimally to patients with pretreated advanced RCC through multiple lines of therapy, with considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC.
Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.
Go online to PeerView.com/XFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Already a cornerstone of care for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), immune checkpoint inhibitors are being explored in earlier treatment settings and in combination with other pillars of SCCHN care (such as surgery and radiotherapy). In this MasterClass activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 ASCO Annual Meeting, experts in head and neck (HNC) explore the evidence that is redefining the role of immunotherapy in HNC and offer insight on applications of new evidence on immunotherapy in HNC, as well as its future as a part of multimodal treatment plans. This activity also features a dedicated “Tumor Board” session designed to provide useful guidance on integrating checkpoint inhibitors into care—from the selection of upfront immunotherapy to the role of clinical trials as options for patients eligible for immune treatment. Upon completion of this activity, participants will be able to: Summarize evidence on the use of immune checkpoint inhibitors as single agents or in combination with other strategies in recurrent/metastatic, locally advanced, or resectable squamous cell carcinoma of the head and neck, Integrate immune checkpoint inhibitors into the treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck, including as upfront treatment or after progression on platinum chemotherapy, Identify patients with head and neck cancer who are eligible to receive immunotherapy as part of multimodal care across the disease spectrum, including in the context of a clinical trial, Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities.
Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.
Go online to PeerView.com/AWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology and oncology experts discuss the emergence of novel, orally administered therapeutics as management options for patients with B-cell lymphoma. This activity also features the perspectives of a patient with small lymphocytic lymphoma and his experience of oral therapy during the course of his therapeutic journey. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data on novel oral agent classes, including BTK and PI3K inhibitors, and immunomodulators, for B-cell non-Hodgkin lymphomas (NHLs) such as CLL, MCL, WM, and other indolent or aggressive B-cell malignancies, Apply optimal strategies to educate patients on therapeutic expectations, and adherence and safety issues regarding oral treatment regimens for B-cell NHL, Collaborate with other members of the hematology-oncology team to manage dosing and develop effective side effect prevention and management strategies in patients with B-cell NHL receiving oral therapies.
Go online to PeerView.com/TGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustrates how this development can lead to clinical improvements in the prevention and management of VTE in the cancer setting. Upon completion of this activity, participants will be able to: Use established clinical tools to assess the risk for VTE in patients preparing to receive anticancer therapy, Summarize current evidence and guidelines on VTE treatment and prophylaxis including the use of direct oral anticoagulation in patients with cancer, Apply updated evidence on the use of DOACs as initial VTE therapy and/or thromboprophylaxis in the cancer setting.
Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.
Go online to PeerView.com/CPZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New evidence from clinical trials assessing immunotherapies and combinations in lung cancer is emerging at a rapid pace. As a result, the treatment landscape is constantly evolving, and checkpoint inhibitor–based therapeutic approaches are establishing a foothold not only in advanced disease but in earlier stages of lung cancer as well. Immunotherapy has proven to be effective in the context of multimodal therapy in stage III locally advanced NSCLC. This has increased excitement about further expanding the role of this therapeutic approach in earlier stages of lung cancer, including resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored in studies in different settings and populations throughout the disease continuum, and the results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapy in stage III and earlier stages of lung cancer remain. In this activity, based on a recent satellite symposium, an expert panel of two surgeons and a medical oncologist offers practical guidance on how to navigate the rapidly changing and complex immuno-oncology landscape in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Review the present immunotherapy landscape and state of the science in lung cancer, including key approvals/indications in different settings from early-stage to more advanced disease, Discuss key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, including resectable disease, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.
Go online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life, Identify evidence-based guidelines and the latest clinical data on the efficacy and safety of currently available and emerging iron therapies for the management of ID in patients with HF, Apply evidence-based guidelines and the latest clinical data on available and emerging iron therapies to the treatment of ID in patients with HF.
Go online to PeerView.com/XNW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of advanced urothelial carcinoma of the bladder has undergone significant transformation in the last 2 years, with the emergence of immune checkpoint inhibitors as an essential component of the treatment armamentarium. Extensive research is also focused on newer approaches, such as antibody-drug conjugates and FGFR inhibitors, against actionable targets on urothelial cancer cells. This rapid expansion in the field poses several challenges for urologists and other healthcare professionals who are essential to the multidisciplinary team managing patients with urothelial cancer. In this PeerView activity, based on a recent live symposium, a panel of bladder cancer experts review the science and latest evidence on immunotherapeutic and targeted strategies for urothelial cancers combined with practical, interactive segments offering the urologist’s perspective on achieving optimal outcomes through appropriate counseling of patients and effective collaboration among different specialists, including urologists and oncologists. Upon completion of this activity, participants should be better able to: Describe the rationale for and mechanisms of action of novel immunotherapeutic and targeted strategies in clinical development for management of urothelial cancer, Discuss the latest evidence on and clinical roles of approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors throughout the urothelial cancer disease continuum, Employ effective strategies to ensure optimal and timely application of the latest treatment approaches for patients with urothelial cancer, including in the context of clinical trial enrollment, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with novel therapies for urothelial cancer.
Go online to PeerView.com/ZEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that now brings the novel class of cancer immunotherapies to this population of patients. In this activity, based on a recent live satellite symposium held in Dallas, Texas during the 20th Annual Meeting of The American Society of Breast Surgeons, our expert panel discusses the biologic rationale for the use of cancer immunotherapies in breast cancer in general and TNBC specifically, as well as the evolving evidence supporting the use of immune checkpoint inhibitors in advanced/metastatic and early-stage resectable TNBC. Additionally, the panel focuses on patient/tumor evaluation and candidate selection for immunotherapy, using current and novel biomarkers to guide clinical decisions in early-stage and advanced disease, the importance of being aware of potential immune-related adverse events and how to diagnose/manage them, and the need for close collaboration among breast surgeons, oncologists, pathologists, and other professionals involved in the management of patients with breast cancer. Upon completion of this activity, participants will be able to: Describe the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC) specifically, and in breast cancer more broadly, including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies (eg, chemotherapies, other immunotherapies, PARP inhibitors and other targeted agents, surgery, radiation, etc.) that may enhance immunogenicity and improve outcomes, Discuss biomarkers that may have utility in guiding and refining clinical decisions regarding the selection of appropriate candidates for immune-based and other therapies in TNBC, and the nuances of testing for these biomarkers in practice, Analyze efficacy, safety, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including metastatic, locally advanced, and early-stage resectable disease, Integrate immune checkpoint inhibitors and/or other effective treatment modalities into management plans of patients with TNBC based on the latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, biomarker testing results, and patient needs/preferences.
Go online to PeerView.com/UXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss various treatment options for small cell lung cancer (SCLC), including the rationale for using new therapies, key clinical trial data, and methods for integrating novel therapies into routine practice or through clinical trial participation. Upon completion of this activity, participants will be able to: Describe the mechanisms of action and rationale for use of novel therapies for SCLC, including immune checkpoint inhibitors, PARP inhibitors, transcription inhibitors, and other investigational agents and combinations, Discuss key clinical trials assessing different new therapies for SCLC, Evaluate the latest available clinical trial data regarding standard as well as novel/emerging therapeutic approaches for SCLC, Integrate novel therapies into treatment plans for patients with SCLC either in the context of routine clinical practice or clinical trial participation.
Go online to PeerView.com/MFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor (CAR)-T cell therapy has recently emerged as an effective strategy for the management of multiple hematologic malignancies and offers hope for patients in leukemia, lymphoma, and myeloma settings. Oncology nurse professionals have a central role within the hematology-oncology team in guiding patients through their treatment continuum with this innovative drug class. In this activity, based on a recent live symposium, an expert panel takes a deep dive into the science behind adoptive immunotherapy with CAR-T cells. They provide guidance on best nursing practices to effectively apply lymphodepletion regimens, safely administer CAR-T cell therapy, appropriately monitor for and manage unique CAR-T cell–related toxicities, educate and counsel patients on expectations from therapy throughout the treatment protocol, as well as collaborate and communicate with the team members to optimize benefit from this novel treatment approach in a diverse range of hematologic malignancies. Upon completion of this activity, participants will be able to: Discuss the latest science, including rationale, recent evidence, and ongoing clinical research, on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in a range of hematologic malignancies, Implement practical interventions for monitoring and managing the unique safety issues associated with the use of different CAR-T cell approaches, Employ effective strategies to educate, support, and counsel patients with leukemia, lymphoma, and myeloma receiving CAR-T cell therapy, including in the context of a clinical trial, to optimize benefit and overall care.
Oncology nurses are at the forefront of care for patients with pancreatic cancer, a much-feared disease whose management was for years characterized by modestly effective treatment options. The recent emergence of new cytotoxic platforms combined with rapid research on potent targeted therapies has made the role of the nurse as a caregiver and educator more important than ever, particularly because these new options differ greatly from conventional chemotherapy strategies. In this activity based on a recent live symposium held in Anaheim during the Oncology Nursing Society’s (ONS) 44th Annual Congress, expert nurse faculty use a patient-voice inclusive MasterClass designed to provide real-world guidance for effective translation of the latest evidence into clinical practice. In addition, the experts offer their perspectives on the unique needs and concerns of patients, and how engagement strategies can shape individualized, patient-centric management plans throughout the continuum of pancreatic cancer care. This activity also features perspectives from pancreatic cancer patients developed in collaboration with Let’s Win, an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on therapeutic strategies in pancreatic cancer, including cytotoxic platforms and chemotherapy sequencing approaches, targeted agents directed against molecular features/mutations, or tumor treating field therapy, among others, Educate patients on the clinical uses and potential of clinical trials investigating novel therapeutics alone and in combination with cytotoxic regimens in the pancreatic cancer setting, Provide guidance to patients on therapeutic sequencing with cytotoxic platforms in advanced pancreatic cancer based upon available evidence, guideline recommendations, and disease- and patient-specific characteristics, Manage adverse events associated with established and emerging therapies for pancreatic cancer.
Go online to PeerView.com/TTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent developments in B-cell lymphoma have increased the availability of novel, orally administered therapies. Nurse professionals managing patients with B-cell cancers play a central role in caring for patients who are eligible for treatment with oral therapeutics, including BTK, PI3K, and BCL-2 inhibitors, and immunomodulating agents. In this activity, based on a recent live symposium held at the ONS 44th Annual Congress, an expert nurse faculty panel offers an in-depth look at the integration of novel, orally administered therapies in the B-cell cancer setting and the therapeutic applications of these agents, as well as the practical issues that are central to oncology nursing practice. Upon completion of this activity, participants will be able to: Cite updated evidence about the use of novel, orally administered agent classes in B-cell cancers, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, and other oral therapies, Develop treatment plans in consultation with a wider oncology management team for patients with B-cell lymphoma who are candidates for oral therapies, Educate patients about practical issues surrounding the use of oral therapies for CLL, MCL, and FL, including adherence, safety, and therapeutic expectations, Manage dosing, adherence, and safety considerations in patients with B-cell lymphoma receiving oral agents as part of their therapy.
Go online to PeerView.com/KWE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView MasterClass, an expert panel of oncology nurse professionals presents the highlights of emerging science and clinical data on PARP inhibition in multiple solid tumors, assesses the role of companion diagnostic tests that identify patients with DDR mutations, as well as engage the audience in a stimulating discussion on the value of genetic testing and significance of enrollment in ongoing PARP inhibitor clinical trials. Going beyond the standard didactic lectures, our experts share their own perspectives on best practice strategies to effectively and safely use approved and emerging PARP inhibitors within the framework of challenging case scenarios. Upon completion of this activity, participants will be able to: Describe DNA-damage response (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors as a cancer therapeutic strategy, Assess the clinical role, efficacy, and safety of PARP inhibitors in multiple tumor types, including ovarian, breast, pancreatic, and prostate cancers, across different treatment settings, Counsel patients receiving PARP inhibitor therapy on strategies to prevent and/or manage treatment emergent adverse events, Provide appropriate education and guidance to patients on the safe and effective clinical use of novel PARP inhibitors, including dosing, the need for adherence to therapy, and enrollment into clinical trials.
Go online to PeerView.com/AKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses current and emerging interventions to reduce morbidity and mortality due to cerebral edema in patients with LHI. Upon completion of this activity, participants should be better able to: Apply evidence-based strategies for evaluation and management of large hemispheric infarction (LHI), Recognize the latest clinical trial data evaluating emerging therapy in the management of LHI and how this data applies to current practice
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.
Go online to PeerView.com/XAC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium held during the Oncology Nursing Society’s (ONS) 44th Annual Congress, a panel of expert nurse faculty use a MasterClass/case-forum design to offer an in-depth review of BTK inhibitors, their therapeutic applications in B-cell malignancies, and the core nurse-focused practice issues that are central to the further integration of BTK inhibitors into treatment plans for patients with cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), among other B-cell disorders. Upon completion of this activity, participants will be able to: Summarize updated safety and efficacy evidence about first- and second-generation BTK inhibitors in the management of B-cell cancer, Cite dosing considerations, administration strategies, and treatment schedules of BTK inhibitors for the management of newly diagnosed or refractory/relapsed B-cell cancer, Educate patients about the varying side effect profiles, efficacy outcomes, and potential for treatment resistance associated with the use of BTK inhibitors for B-cell cancer, Manage side effect and adherence considerations in patients with B-cell cancer treated with BTK inhibitors.
Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.
Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.
Go online to PeerView.com/FJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of solid tumors and hematologic malignancies. Reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit. Testing for programmed death-ligand 1 (PD-L1) expression and the presence of DNA mismatch repair deficiencies (dMMR) or high levels of microsatellite instability (MSI-H) should presently be routinely done in oncology and pathology practice in alignment with the latest recommendations and indications. Assessment of tumor mutational burden (TMB) is also showing great promise as a new and distinct predictor of benefit from cancer immunotherapies. Other novel biomarkers are undergoing investigations as well. How can pathologists ensure that immuno-oncology biomarker testing is carried out according to best practices, and collaborate with oncologists and other members of the cancer care team in interpreting the results to guide therapeutic decisions for patients with cancer? In this activity, based on a recent CME/MOC/CC-certified symposium held during the 2019 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) held in National Harbor, Maryland, a panel of experts discuss the latest clinical advances with cancer immunotherapies and the research underway to further refine biomarker testing and maximize the use of checkpoint inhibitors and combinations across a broad spectrum of malignancies. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations across the spectrum of solid and liquid cancers, Describe evidence supporting the use of PD-L1, MMR/MSI, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances, Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes, Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations, Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer.
In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.
Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.
Go online to PeerView.com/EWW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Melanoma was the first clinical setting in which the use of immune checkpoint inhibitors was validated, leading to their rapid integration into the management of advanced disease. More recently, checkpoint inhibitors, based on phase 3 evidence, have claimed a role in the adjuvant setting. The future of adjuvant therapy for high-risk resectable melanoma is bright, but achieving optimal care will depend on close collaboration between oncologists and surgeons, as well as the identification of patients who are excellent candidates for immune-based adjuvant therapy. In this activity, based on a recent live symposium, experts in oncology get to the heart of why immunotherapy is a rational and potent management strategy for patients with high-risk, resected melanoma, offer insights into the key studies that validated adjuvant immunotherapy in resectable disease, as well as clarify what the evidence from these trials means for the practice of surgical oncology. The panel of leading experts also synthesizes the clinical experience with adjuvant checkpoint inhibition and detail practical patient identification, dosing, and safety considerations that will make a difference in how you manage your patients. Upon completion of this activity, participants should be better able to: Describe the clinical role and rationale for use of immune-based therapy in stage III, resectable melanoma, Cite updated efficacy and safety findings regarding immune checkpoint inhibitors as an adjuvant option in surgically resected melanoma, including high-risk stage III disease, Recommend the use of adjuvant immunotherapy for eligible patients with resectable stage III melanoma, Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection.
Go online to PeerView.com/CXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The best practices for management of patients with EGFR-mutant NSCLC continue to evolve as a result of advances in molecular testing and targeted treatment. Understanding what, when, and how to test, as well as how to select therapy, throughout the continuum of advanced NSCLC is paramount. In this activity, based on a recent live symposium held in San Diego, California, experts in EGFR-mutant NSCLC provide a concise but comprehensive overview of all the recent key evidence and new research directions and provide practical guidance for how to navigate clinical decisions in EGFR-mutant NSCLC in different settings and patient populations. Upon completion of this activity, participants will be able to: Discuss the latest recommendations for tissue- and blood-based molecular testing to evaluate EGFR mutation status in patients with advanced/metastatic NSCLC, Assess the characteristics, safety/efficacy profiles, and indications of the different EGFR inhibitors available for the treatment of EGFR-positive NSCLC in different settings and patient populations, including those with brain or leptomeningeal metastases, Evaluate the current evidence related to the mechanisms of acquired resistance to the various EGFR TKIs used in the first line and subsequent therapy of advanced EGFR-mutant NSCLC, Implement best practices related to molecular testing for EGFR mutations through the continuum of advanced NSCLC, and interpret results to guide treatment selection, Implement evidence-based, individualized treatment plans for patients with EGFR-mutant NSCLC.
Go online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and address several ongoing clinical questions from the choice of novel induction and maintenance options to minimal residual disease monitoring and the use of newer therapeutic platforms for post-transplant relapsed disease. Upon completion of this activity, participants should be better able to: Summarize evidence regarding the safety, efficacy, and current clinical role of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma, Develop personalized induction and post-ASCT maintenance/consolidation regimens with novel components for eligible patients with multiple myeloma, Select novel therapeutics for the management of relapsed multiple myeloma post-ASCT.
Go online to PeerView.com/SXH860 to view the entire program with slides. In this activity, based on a live symposium held during the 2019 Transplantation and Cellular Therapy (TCT) Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in hematology-oncology explore new developments related to the changing clinical consensus for managing veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) as a post-transplant complication. In this program, the panelists will share their views on VOD pathophysiology and proposed revisions to diagnostic and severity grading criteria, while providing guidance on practical issues related to the selection and use of novel treatments for VOD. Ultimately, the experts present a picture of modern VOD management in which diagnoses can be accurately and rapidly made and where a diversity of disease presentations (including in adult and pediatric patients) can be effectively treated. Upon completion of this activity, participants should be better able to: Describe new evidence on VOD/SOS pathophysiology, risk factors, diagnostic criteria, and disease severity grading, Cite factors that may signal the development of multi-organ dysfunction in patients with VOD/SOS, Confirm a diagnosis of VOD/SOS throughout the clinical spectrum, including late-onset disease or disease presenting with or without organ dysfunction in adult and pediatric populations, Utilize effective, timely treatment for patients with confirmed VOD/SOS, including those exhibiting multi-organ dysfunction or failure.
Go online to PeerView.com/ZGE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hematologic malignancies, including in the context of hematopoietic stem cell transplantation (HCT). The expert panel also shares personal experiences from their practice or research on relevant patient cases to guide learners on how to effectively impact treatment care and improve outcomes for patients with leukemia and lymphoma. Upon completion of this activity, participants should be better able to: Summarize the anticancer mechanism and the latest evidence on the efficacy and safety of adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in various lymphoma and leukemia settings, Assess the clinical role and benefits of CAR-T cell therapy within the context of HCT in eligible patients with leukemia and lymphoma, Apply appropriate strategies to manage the unique safety issues associated with CAR-T cell therapy in leukemia and lymphoma.
Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they’re used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn’t have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.
Go online to PeerView.com/XYM860 to view the entire program with slides. This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative therapeutics while also obtaining expert perspectives on the practical application of these advancements as prophylaxis or for treatment of acute and chronic, steroid–nonresponsive, and previously untreated GVHD. Upon completion of this activity, participants should be better able to: Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD, Discuss the latest evidence on novel therapies, including JAK 1/2 inhibitors, BTK inhibitors, and T-cell costimulation modulators, for prophylaxis or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HSCT setting, Apply the most optimal evidence-based strategies, including enrollment in clinical trials, for post-transplant GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.
Go online to PeerView.com/XHP860 to view the entire program with slides. In this activity, experts in the management of patients with prostate cancer discuss recent advances that have rapidly expanded the therapeutic landscape, including treatments for both early-stage and advanced disease. Focusing on selection and sequencing of therapies based on patient and tumor characteristics, prior treatment history, and patient preferences, the expert panel provides an engaging MasterClass and Practicum that combines key clinical evidence and current guideline recommendations with practical guidance for personalizing application of approved and investigational therapies throughout the prostate cancer disease continuum, including nonmetastatic (M0), metastatic hormone-sensitive, and metastatic castration-resistant settings. Upon completion of this activity, participants should be better able to: Evaluate the efficacy, safety, and clinical role of approved and investigational therapies, including hormone, cytotoxic, immuno-oncology, bone-directed, and molecularly targeted therapies alone or in combination for localized, M0, and advanced prostate cancer, Assess current clinical trials evaluating agents with varying modalities alone or in combination and refer appropriate patients with prostate cancer for clinical trial enrollment, Recommend individualized treatment plans for patients with prostate cancer throughout the disease continuum in accordance with current clinical guidelines, expert recommendations, disease and patient characteristics, and patient needs/preferences.
Go online to PeerView.com/FEJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Genitourinary Cancers Symposium in San Francisco, experts in renal cell carcinoma (RCC) dip into their patient “CaseBook” to offer insights from their own practice on how best to bridge the divide between clinical research and daily care in the management of RCC. Pairing analysis of the latest evidence with application of key clinical concepts to decision-making in a complex therapeutic landscape, the expert panel explores how best to leverage the potency of newer agents across different RCC settings. Upon completion of this activity, participants should be better able to: Assess the latest evidence with and clinical implications of novel approaches, including new targeted agents, immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Apply recently validated immunotherapy and targeted therapy options effectively for patients with advanced RCC that reflect optimal patient-centric selection and sequencing through multiple lines of therapy, Employ effective strategies to prevent and/or manage treatment-related complications with multi-targeted TKIs and immune checkpoint inhibitor therapy in patients with RCC, Recommend ongoing clinical trials assessing the latest therapies and/or combination approaches for advanced RCC patients in different disease settings.
Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings and how to manage treatment-related adverse effects associated with emerging agent classes. Upon completion of this activity, participants should be better able to: Cite updated data about the efficacy and safety of novel agent classes and next-generation therapeutics in multiple myeloma, including proteasome inhibitors, IMiDs, novel antibodies, immunotherapies, and epigenetic agents, among others, Develop customized therapy for patients with newly diagnosed multiple myeloma, including elderly patients, individuals eligible or ineligible for stem-cell transplant, and those requiring maintenance therapy post-transplant, Select regimens adapted to the needs of patients with previously treated multiple myeloma, including those with early relapse or relapsed/refractory multiple myeloma, Manage treatment-related adverse events in patients with multiple myeloma receiving therapy with novel or next-generation agent classes.
Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes
Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists
Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to the Clinical Role of TRK Fusions in Personalizing Cancer Therapy
Defining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A
Beyond Clinical Trials: Can Real-World Evidence Provide a Roadmap for Long-Term Treatment Planning in EGFRMutation-Positive NSCLC?
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and Updated Guidelines: What Pathologists Need to Know and Do
Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes
Progress in Developing Novel Treatment Options for PTCL: Expert Views on Integrating Innovative Therapeutics Into Care
The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies
The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care
Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond
Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes
Transforming Glioblastoma Management: A MasterClass on Evaluating Newer and Emerging Options in the Precision Medicine and Person-Centered Care Era
Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management
The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do
The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care
Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution
Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists
Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice
Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department
Treatment Innovation in hemophilia A: Integrating Extended Half-Life Replacement Clotting Factors Into Clinical Practice
Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?
Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL
Unraveling the Complex Treatment Landscape of Prostate Cancer: Guidance for Delivering Evidence-Based, Patient-Centered Care